drug formulary hbuk - Laman Utama Hospital Bahagia Ulu Kinta

4th EDITION
JULAI 2015
DRUG FORMULARY
HOSPITAL BAHAGIA ULU KINTA
HBUK
DRUG FORMULARY
HOSPITAL BAHAGIA ULU KINTA
4th EDITION
JULAI 2015
DRUG FORMULARY HOSPITAL BAHAGIA ULU KINTA
4th EDITION
JULAI 2015
All Rights Reserved
Permission is hereby granted to reproduce information contained herein provided that such reproduction be given due to
acknowledgement and shall not modify the text.
This publication of the Pharmacy Unit, Hospital Bahagia Ulu Kinta. Enquiries are to be directed the address below.
Drug Information Service (DIS),
Pharmacy Unit,
Hospital Bahagia Ulu Kinta,
31250, Tanjung Rambutan,
Perak Darul Ridzuan
Tel : 605-5332333 (Ext: 5609/6083)
Faks : 605-5333195
Website : http://hbuk.moh.gov.my
TABLE OF CONTENTS
MESSAGE FROM DIRECTOR
MESSAGE FROM CHIEF PHARMACIST
FORMULARY COMMITTEE
PHARMACY SERVICES CONTACT NUMBER
PHARMACY OPERATIONAL HOUR
GUIDANCE ON PRESCRIBING
PRESCRIPTION WRITING
THERAPEUTIC DRUG MONITORING (TDM) INFORMATION
FORMULA
1.Emergency
2.Anaesthesia
3.Analgesics
4.Antiinfectives
5.Cardiovascular
6.Dermatology
7.Ear, Nose and Oropharynx
8.Endocrine
9.Gastrointestinal
10.Genitourinary
i
ii
iii
iv
iv
v
vi
vii
x
11.Immunological Products & Vaccines
12.Neurology
13.Nutrition and Blood Disorder
14.Obstetrics and Gynaecology
15.Ophthalmology
16.Psychiatry
17.Respiratory
18.Rheumatology
19.Diagnostic
20.Miscellaneous
INDEX
Generic Names
MESSAGE FROM HOSPITAL DIRECTOR
Hospital Bahagia Ulu Kinta is the first and largest psychiatric institution in Malaysia. Thus as a specialized psychiatric hospital, we
need to provide optimum treatment to the psychiatric patients who are admitted and referred here.
I would like to record my utmost appreciation to all the members of the Working Group on this formulary for their great effort to
help in the publication of this latest edition. This is the fourth in the series since it was first launched in year 2001.This reflects the rapid evolution of knowledge in drugs. A special thanks to the Pharmacy Department HBUK for ensuring the development of this formulary conforms
to the highest standards.
It is hoped that this latest edition formulary will continue to play an important role as a useful guide in this hospital. The formulary
committee sincerely wishes that the release of this new edition will be followed by concerted effort by the various stakeholders to make it
implementable on the ground. By doing so, it will be a significant contribution towards the treatment for psychiatric patients. Insya Allah.
Yours Sincerely,
…………………………………….................................................……….
(DR. HJH. RABA’IAH BINTI MOHD. SALLEH, KMN, PMP, AMP),
CHIEF DIRECTOR & PSCHIATRIC CONSULTANT SPECIALIST (FORENSIC),
SPECIAL GRED ‘C’,
HOSPITAL BAHAGIA ULU KINTA,
PERAK DARUL RIDZUAN.
i
MESSAGE FROM CHIEF PHARMACIST
In the name of Allah, the Most Beneficient, the Most Merciful. This is the 4th formulary (August 2014) published by Pharmacy Hospital Bahagia Ulu Kinta. This formulary includes all medications available in this hospital which has been agreed by our ‘Medication and Therapeutic Committee’ hospital level.
This formulary is published as a guide to all health care providers in Hospital Bahagia in giving the utmost treatment to all patients
and the rational of drug application, which helps to maximize effiency and therapeutic effects and also managing cost effectiveness.
This formulary is also published to achieve KPI 11 and 12 under ‘Patient Safety Goals’ which leads to zero percentage medication
errors. Thus with the publication of this formulary, we hope that medication error can be reduced even further at all stages (Right Drug, Right
Dose, Right Frequency, Right Time & Right Patient). Besides that, this formulary also includes side effects and contraindications of each medication.
A special thanks to the Formulary Working Committee of Pharmacy Department. They have helped to shape the contents of this
formulary and provide valuable feedback. I would also like to express deepest appreciation to all the readers of this book. We sincerely hope
that everyone can play a part in providing critical feedback for further improvement.
Yours Sincerely,
…………………………………………….
(PN. HJH. SHAMSIAH BT. DAUD),
CHIEF PHARMACIST U54,
HOSPITAL BAHAGIA ULU KINTA,
PERAK DARUL RIDZUAN.
ii
FORMULARY COMMITTEE
ADVISOR
Puan Shamsiah bt Daud
(Chief Pharmacist U54)
CHAIRMAN
Encik Saravanan a/l Rumasumee
(Pharmacist U48)
CONTRIBUTORS
Puan Shamini a/p Rama
Puan Norhayati bt Mohd Azmir
Puan Hu Sze Qian
Cik Chin Pooi Kuan
Cik Foo See Mun
Cik Leong Pei Loo
Cik Ngeoh Li Yuen
Puan Noor Shakila bt Mohd Rodi
Puan Wong Vi Vian
(Pharmacist U52)
(Pharmacist U48)
(Pharmacist U48)
(Pharmacist U48)
(Pharmacist U48)
(Pharmacist U48)
(Pharmacist U48)
(Pharmacist U44)
(Pharmacist U44)
Cik Juwiza bt Jamaluddin
Puan Khairiatul Adhiyyah bt Mat Zen
Cik Kwan Zuan Er
Cik Tan Yee Mun
Cik Christine Lau Li Ling
Cik Chia Sue Anne
Cik Nicole Liew Ker Xing
Cik Lim Poh Hui
EDITOR
Encik Zulhilmi bin Aladdin
(Pharmacist U44)
iii
(Pharmacist U44)
(Pharmacist U44)
(Pharmacist U44)
(Pharmacist U44)
(Pharmacist U44)
(Pharmacist U41)
(Pharmacist U41)
(Pharmacist U41)
PHARMACY SERVICES CONTACT NUMBER
Chief Pharmacist U54
PHARMACY OPERATIONAL HOUR
5600
In-Patient Pharmacy
In-Patient Pharmacy
Counter
Filling Area
Drug Information
Service (DIS)
Therapeutic Drug
Monitoring (TDM)
Floor Stock
Packing Room
Out-Patient Pharmacy
Pharmacist U48
Counter
Monday - Friday
Rest hour
Rest hour (Friday)
Public Holiday
5609
5012
6083
5610
6207
Out-Patient Pharmacy
Monday - Friday :
Rest hour
:
Rest hour (Friday) :
Oncall Pharmacist
8.00 am - 5.00 pm
1.00 pm - 2.00 pm
12.15 pm - 2.45 pm
5981
5980
Store Pharmacy
Monday - Friday :
Rest hour
:
Rest hour (Friday) :
5013
Store Pharmacy
Pharmacist U48
Office
8.00 am - 5.00 pm
1.00 pm - 2.00 pm
12.15 pm - 2.45 pm
8.00 am - 1.00 pm
6083
Clinical Pharmacy
Clinical Pharmacist’s Room
:
:
:
:
5616
5611
055332333
iv
8.00 am - 5.00 pm
1.00 pm - 2.00 pm
12.15 pm - 2.45 pm
GUIDANCE ON PRESCRIBING
The category of prescribers that are authorized to initiate the prescription for the drug in this formulary is listed as:
A*
A
A/KK
B
C
C+
=
=
=
=
=
=
Consultant/Specialist for specific indication only
Consultant/Specialist
Consultant/Specialist/Family Physicians Specialist
Medical Officer
Paramedical Staff
Paramedical Staff doing midwifery
Dental consultant, dental specialist and dental officers are also included in this category but only for the drugs used in dental treatment. Medicines should be
prescribed only when they are necessary, and in all cases the benefit of administering the medicines should be considered in relation to the risk involved.
Drugs will be dispensed generically. The use of trade names in the formulary is only given as an example; it does not indicate that the particular brand should
be dispensed.
v
PRESCRIPTION WRITING
The drug must be written in generic names. The names of drugs and preparation should be written clearly and not abbreviated. The prescription should be
written legibly and dated. It should be completely filled up with the patient’s name and identification number, drug regimen (dose, frequency, administration
and duration) and must be signed and stamped by the prescriber. The name of the prescriber should be stated. The age and bodyweight of the patient should
preferably be stated, especially for children under 12 years old.
If the incomplete prescription is received, the following procedures will apply:

Attempt must always be made to contact the prescriber to ascertain the intention.

If the attempt is successfully the pharmacist must, where applicable, subsequently arrange for the incomplete/missing details to be inserted by the
prescriber in the prescription.

The pharmacist should endorse the form as “PRESCRIBER CONTACT” (PC) if unable to obtain the written amendment regarding the incomplete
prescription. The amendments should be endorsed and dated by pharmacist.

Incases where the prescriber cannot be contacted, verification should be obtained from the head of department/specialist as endorsed by the Drug
Therapeutic Committee at the local level.

If the pharmacist has any doubts about exercising discretion, an incomplete prescription must be referred back to the prescriber.
vi
THERAPEUTIC DRUG MONITORING (TDM) INFORMATION
Drugs & Therapeutic Range
CARBAMAZEPINE
(Tegretol ®)
Monotherapy:
4-12 µg/ml
Polytherapy:
4-8 µg/ml
PHENYTOIN
(Dilantin ®)
10-20 µg/ml
PHENOBARBITAL
(Luminal ®)
15-40 µg/ml
Half-Life &
Steady State
Single Oral Dose:
t ½ ≈ 36 hours
Repeated Adm:
t½ ≈ 16-24 hours
Steady State:
After 1/52
t ½ ≈ 7-42 hours
Steady State:
After 1/52
t ½ ≈ 1.5-4.9 days
Steady State:
10-25 days
Sampling Time
Trough :
10 minutes before
dose
Common Side Effects
Cardiovascular
Gastrointestional
Neurologic
Ophthalmic
Hematologic
Electrolytes
: hypertension, hypotension, lightheadedness
: nausea, vomiting
: clumsiness, confusion, dizziness, nystagmus, somnolence
: blurred vision, diplopia
: leucopenia
: hyponatraemia
Trough :
10 minutes before
dose
Gastrointestinal
Musculoskeletal
Neurologic
Random :
Toxicity suspected
Psychiatric
: constipation, nausea, vomiting
: spasmodic movement
: ataxia, decreased coordination, dizziness, headache,
insomnia, slurred speech
: feeling nervous
Random :
Toxicity suspected
Trough :
10 minutes before
dose
Random :
Toxicity suspected
Hematologic
Dermatologic
Hepatic
vii
: agranulocytosis, megaloblastic anemia,
thrombocytopenia
: Scaling eczema, stevens-johnson syndrome,
thrombophlebitis
: injury of liver
Drugs & Therapeutic
Range
LITHIUM CARBONATE
0.6 - 1.2 mmol/L
SODIUM VALPROATE
(Epilim ®)
Epilepsy:
50-100 µg/ml
Mania:
50-125 µg/ml
Half-Life &
Steady State
Sampling Time
t ½ ≈ 18-24 hours
(can up to 36 hours in elderly
& 40-50 hours in renal
impairment patient)
Trough :
Just before next dose
(or 8-12 hours post
dose)
Steady State:
4-5 days
Random :
Toxicity suspected
Single Oral Dose:
t ½ ≈ 36 hours
Repeated Adm:
t½ ≈ 16-24 hours
Trough :
10 minutes before
dose
Steady State:
Mono - after 3/7
Poly - after 1/52
Random :
Toxicity suspected
Common Side Effects
Cardiovascular : Cardiac arrhythmia, hypotension, bradycardia, flattened or inverted T waves
(reversible)
Neurologic
: Dizziness, vertigo, slurred speech, sedation, seizure, restlessness, headache,
lethargy
Gastrointestinal : Polydypsia, anorexia, nausea, vomiting, diarrhoea, metallic taste, excessive
salivation
Dermatologic : Dry or thinning of hair, alopecia, rash
Musculoskeletal : Tremor, ataxia, muscle hyperirritability
Opthalmic
: Nystagmus, blurred vision
Others
: Coldness & painful discoloration of fingers & toes, incontinence, polyuria
Cardiovascular
: peripheral edema
Dermatologic
: alopecia, rash
Endocrine metabolic : increased appetite, weight gain
Gastrointestional
: abdominal pain, constipation, diarrhea, indigestion, loss of appetite,
nausea, vomiting
Hematologic
: ecchymosis
Musculoskeletal
: asthenia, backache
Neurologic
: amnesia, ataxia, dizziness, headache, insomnia, somnolence, tremor
Ophthalmic
: amblyopia, blurred vision, diplopia, nystagmus
Electrolytes
: hyponatraemia
viii
Drugs & Therapeutic
Range
Half-Life &
Steady State
VALPROIC ACID AND
SODIUM VALPROATE (ER)
500 MG, TABLET
(Epilim Chrono ®)
t ½ ≈ 8-20 hours
(shorter in children)
Epilepsy:
50-100 µg/ml
Mania:
50-125 µg/ml
Steady State:
Mono - after 3/7
Poly - after 1/52
Sampling Time
Trough :
10 minutes before
dose
Random :
Toxicity suspected
Common Side Effects
Cardiovascular
: peripheral edema
Dermatologic
: alopecia, rash
Endocrine metabolic : increased appetite, weight
gain
Gastrointestional
: abdominal pain,
constipation, diarrhea,
indigestion, loss of
appetite,
nausea, vomiting
Hematologic
: ecchymosis
Musculoskeletal
: asthenia, backache
Neurologic
: amnesia, ataxia, dizziness,
headache, insomnia,
somnolence, tremor
Ophthalmic
: amblyopia, blurred vision,
diplopia, nystagmus
Electrolytes
: hyponatraemia
ix
Additional Point
1.
2.
3.
4.
5.
Prolonged release formulation of Epilim
which reduces peak concentration and
ensure more even plasma concentrations
throughout the day
May be given once or twice daily. The
tablets should be swallowed whole and not
crushed or chewed
Measurement of plasma levels less
dependant upon time of sampling
Steady-state pharmacokinetic data indicate
that the peak concentration (Cmax) and
trough concentration (Cmin) of Epilim
Chrono lie within the effective therapeutic
range of plasma levels found in
pharmacokinetic studies with Epilim enteric
coated (EC)
TDM for Epilim Chrono should be same as
Epilim enteric coated (EC), blood sampling
time : trough level (prior to next dosing)
FORMULA



Sodium
Adults (18 years and older)
IBW (male) = 50 + (2.3 x height in inches over 5 feet)
IBW (female) = 45.5 + (2.3 x height in inches over 5 feet)
Potassium
1-18 years
IBW = (height2 x 1.65)
1000
+
K Deficit (mmol)
Formula 1
= (4.5 - current K+) x 0.4 + Body weight + 1 x Body weight
13.4
13.4
Formula 2
= 4 - current K+ x 0.4 x Body Weight


Body Surface Area (BSA)
BSA (m2) =
Calcium

Adjusted calcium level
= current Ca2+ in mmol/L + 0.02 *40 - current albumin in g/L+

Ideal Body Weight (IBW)
Na+ Deficit (mmol)
= (130 - current Na+) x 60% of body weight in kg
√
ht (cm) x wt (kg)
3600
Estimated Creatinine Clearance (Clcr)
Male
= (140 - age) x Body Weight (kg)
72 x Scr
Female
= (140 - age) x Body Weight (kg) x 0.85
72 x Scr
Body Mass Index (BMI)
BMI = weight (kg)
*height (m)+2
x
1.EMERGENCY
1.1 Toxicology/Antidotes
1.1 TOXICOLOGY/ANTIDOTES
Code
01.01.01
Drug
Generic Name:
Flumazenil,
Injection
Strength Available:
0.1 mg/ml
Category:
B
Indication & Dose
Contraindication
Adverse Effects
Indication:
i) Diagnosis and/or management of benzodiazepine overdose due
to self-poisoning or accidental overdose
ii) Reversal of sedation following anaesthesia with
benzodiazepine
Hypersensitivity
to
flumazenil/
benzodiazepines, cyclic antidepressant
overdose, patients who have been
given a benzodiazepine for control of a
potentially life-threatening condition
(eg, control of intracranial pressure or
status epilepticus)
Cardiac arrhythmias, bradycardia,
dizziness, nausea, vomiting,
seizure, injection site pain,
headache,
abnormal
vision,
blurred vision, agitation
Dosage:
i) Initial, 0.2 mg IV over 30 seconds; if desired level of
consciousness not obtained after an additional 30 seconds, give
dose of 0.3 mg IV over 30 seconds; further doses of 0.5 mg IV
over 30 seconds may be given at 1-minutes intervals if needed to
maximum total dose of 3 mg; patients with only partial response
to 3 mg may require additional slow titration to a total dose of 5
mg; if no response 5 minutes after receiving total dose of 5 mg,
overdose is unlikely to be benzodiazepine and further treatment
with flumazenil will not help
ii) 0.2 mg IV over 15 seconds; if desired level of consciousness is
not obtained after waiting 45 seconds, a second dose of 0.2 mg IV
may be given and repeated at 60-seconds intervals as needed (up
to a maximum of 4 additional times) to a maximum total dose of
1 mg; most patients respond to doses of 0.6 to 1 mg; in the event
of resedation, repeated doses may be given at 20-minutes
intervals if needed; for repeat treatment, no more than 1 mg
(given as 0.5 mg/minute) should be given at any one time and no
more than 3 mg should be given in any one hour
Code
01.01.02
Drug
Generic Name:
Naloxone HCl,
Injection
Strength Available:
0.4 mg/ml
Category:
B
01.01.03
Generic Name:
Activated Charcoal,
Tablet
Strength Available:
250 mg
Category:
B
Indication & Dose
Contraindication
Adverse Effects
Indication:
For the complete/partial reversal of narcotic depression including respiratory
depression induced by opioids such as natural and synthetic narcotics.
Diagnosis of suspected acute opioids overdosage
Hypersensitivity to naloxone
Opiate withdrawal symptoms,
nausea, vomiting, tachycardia,
tremor, sweating, pulmonary
oedema,
hyperventilation,
cardiac dysrhythmia, biliary
colic,
dysphagia,
memory
impairment, seizure, agitation,
dyspnea, laryngeal spasm,
pulmonary
edema,
tachyarrhythmia
Dosage:
Initially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes according to
patient's needs
Indication:
i) Diarrhoea and food poisoning
ii) Reduce absorption of drugs, plant, inorganic poison and chemicals in
poisoning cases
Dosage:
i) ADULT 0.5-1 g given 3-4 times daily.
CHILD half adult dose.
ii) Need to be dissolved in liquid (slurry consistency).
ADULT and CHILD over 12 years: initial 30-100 g or 1-2 g/kg; repeat initial
dose as soon as possible or 20-50 g every 2-6 hours.
CHILD over 1-12 years, 25-50 g or 1-2 g/kg; may repeat half the initial dose
every 2-6 hour as needed.
CHILD to 1 year of age, 1 g/kg; may repeat half the initial dose every 2-6
hours as needed.
For maximum efficacy administer within 1 hour after ingestion of toxic
compound
An unprotected airway, Black stools and gastrointestinal
gastrointestinal tract not disturbances
anatomically intact
Code
Drug
01.01.04
Generic Name:
Antivenene Malaysian
Pit Viper,
Injection
Strength Available:
-
Indication & Dose
Indication:
Bitten by pit viper
Dosage:
Reconstitute content for the vial with 5 ml sterile pyrogen-free
distilled water. Administer by IV infusion 200 ml of normal saline
over a period of 1 - 2 hours
Contraindication
Adverse Effects
Hypersensitivity to any component of
the formulation, unless the benefits
outweigh the risks and appropriate
management for anaphylaxis is
available
Chest pain, hypotension, chills,
nervousness, cellulitis, bruising,
pruritus, rash, urticaria, anorexia,
nausea, coagulation disorder,
back
pain,
circumoral
paraesthesia,
general
paraesthesia, myalgia, asthma,
cough,
dyspnoea,
sputum
increased, wheezing, allergic
reaction,
serum
sickness,
subcutaneous nodule, wound
infection, anaphylaxis, serum
sickness
Hypersensitivity to any component of
the formulation, unless the benefits
outweigh the risks and appropriate
management for anaphylaxis is
available
Anaphylaxis with hypotension,
dyspnea,
urticaris,
Immune
hypersensitivity reaction , shock,
transfusion reaction due to
serum protein reaction ,serum
sickness
Category:
B
01.01.05
Generic Name:
Antivenene Serum
(Cobra),
Injection
Strength Available:
Category:
B
Indication:
Treatment for cobra bites
Dosage:
The reconstituted antivenin should be given by slow intravenous
infusion, approximately 2ml/min.Subsequent dose can be given
every 12 hours according to the clinical symptoms
2.ANAESTHESIA
2.1 Induction/Maintenance
2.2 Neuromuscular Blocker
2.3 Topical Anaesthesia
2.4 Local Anaesthesia
2.5 Miscellaneous Anaesthesia
2.1 INDUCTION / MAINTENANCE
Code
02.01.01
Drug
Generic Name:
Midazolam,
Injection
Strength Available:
5 mg/ml
Category:
A
02.01.02
Generic Name:
Midazolam,
Tablet
Strength Available:
7.5 mg
Category:
A/KK
Indication / Dose
Indication:
Pre-operative sedation, induction of general
anaesthesia, premedication and sedation in
ICU and sedation for minor procedures
Dosage:
Sedative: Usual sedative range 2.5 - 7.5 mg
(about 70 mcg/kg by IV injection over 30
seconds). Premedication by IM injection 70 100 mcg/kg 30 -60 minutes before surgery
ELDERLY: 1 - 1.5 mg/kg.
Induction: Induction by slow IV infusion 200 300 mcg/kg (ELDERLY 100 - 200 mcg/kg.
CHILD over 7 years 150 - 200 mcg/kg);
Maximum: 0.35mg/kg. Sedation in ICU 0.03 0.2 mg/kg/hour
Indication:
Pre and post-operative sedation
Dosage:
ADULT: Usually 7.5 - 15 mg at bedtime; or for
premedication, 30 - 60 minutes before the
procedure.
ELDERLY, debilitated or impaired liver/kidney
function: 7.5 mg
Contraindication
Adverse Effects
Acute
narrow
angle
glaucoma, Muscle stiffness, induration of veins, pain,
hypersensitivity to midazolam products, redness, headache, apnoea, nausea, coughing,
acute alcohol intoxication, shock, lactation vomitting, drowsiness, respiratory depression,
phlebitis, gastrointestinal disturbances, increased
appetite, jaundice, hypotension, bronchospasm,
pain at the site of injection
Acute
narrow
angle
glaucoma, Muscle stiffness, induration of veins, pain,
hypersensitivity to midazolam products, redness, headache, apnoea, nausea, coughing,
acute alcohol intoxication, shock, lactation vomitting, drowsiness, respiratory depression,
phlebitis, gastrointestinal disturbances, increased
appetite, jaundice, hypotension, bronchospasm
Code
02.01.03
Drug
Generic Name:
Propofol,
Injection
Strength Available:
1 % in 10 ml
Category:
A*
Indication / Dose
Indication:
Induction & maintenance of general
anaesthesia. Sedation of ventilated ICU
patients
Dosage:
Induction: 1.5-2.5 mg/ kg at the rate of 20-40
mg every 10 seconds. CHILD more than 8
years: usually 2.5 mg/ kg.
Maintenance: IV 25-50 mg repeated
according response. IV infusion: 4-12 mg/kg/
hour; CHILD more than 3 years: 9-15 mg/kg/
hour.
Sedation: 0.3 - 4 mg/kg/hour up to 3 days
Contraindication
Adverse Effects
Children less than 3 Very common: Local pain on induction
years and obstetric
Common: Hypotension, bradycardia, transient apnoea during
anaesthesia
induction, nausea & vomiting & headache during recovery phase,
withdrawal symptoms in children, flushing in children
Uncommon: Thrombosis & phlebitis
Rare: Epileptiform movements, including convulsions & opisthotonus
during induction, maintenance & recover
Very rare: Rhabdomyolysis, pancreatitis, post-operative fever,
discoloration of urine following prolonged administration,
anaphylaxis - may include angioedema, bronchospasm, erythema &
hypotension - sexual disinhibition, pulmonary oedema, postoperative unconsciousness
2.2 NEUROMUSCULAR BLOCKER
Code
02.02.01
Drug
Generic Name:
Suxamethonium
Chloride,
lnjection
Strength Available:
100 mg/2 ml
Category:
B
Indication / Dose
Indication:
Muscle relaxant as an adjunct to anaesthesia
Dosage:
Initial test dose 5 - 10 mg may be given.
Usual single dose 0.3 - 1.1 mg/kg IV.
Maximum 100 mg according to the depth and
duration of relaxation required. 2.5 - 4 mg/kg
IM, maximum 150 mg
Contraindication
Adverse Effects
Patients who are burnt,
severely hyperkalaemic with
penetrating
eye
wounds,
malignant
hyperpyrexia,
massively traumatised patients
or those with extensive muscle
degeneration
e.g.
recent
paraplegia
Transient muscle fasciculation before relaxation, increased
intraocular and intragastric pressure, post-operative pain,
bradycardia, tachycardia, hypertension, hypotension,
muscarinic effects
2.3 TOPICAL ANAESTHESIA
Code
02.03.01
Drug
Generic Name:
Lignocaine,
Jelly
Strength Available:
2%
Category:
B
02.03.02
Generic Name:
Ethyl Chloride,
Spray
Strength Available:
Category:
C
Indication & Dose
Indication:
Use for endotracheal tubes and instruments,
painful procedures in the ear, nose and throat,
burns, wounds, abrasions, lacerations;
catheterisation of the male and female urethra and
for symptomatic treatment of cystitis and urethritis
Dose:
Apply to affected area 10 mins before
catheterization, etc
Indication:
For minor surgical procedures including lancing
boils, incision and drainage of small abscesses, pain
due to athletic injuries and pain due to injection
administration
Dosage:
Spray to affected area at a distance of about 30 cm
until a fine white film is produced
Contraindication
Adverse Effects
Hypersensitivity to lidocaine or amide type Allergic reactions. Intoxication, cutaneous
of local anaesthetics. Hypovolaemia, heart and hypersensitivity symptoms. Sore throat.
block or other conduction disturbances
Central nervous system excitation followed
by depression with drowsiness, respiratory
failure and coma, numbness of tongue and
perioral region, myocardial depression,
peripheral
vasodilation,
hypotension,
bradycardia, arrhythmia, cardiac arrest.
Prolonged use in the eye may lead to severe
contact keratitis and corneal damage
Hypersensitivity to ethyl chloride products Transient hypertension, narcosis, vomiting
and vascular impairment of the and coma. Thawing of frozen tissue after
extremities. Porphyria. Application on surgery may be painful. Chemical frostbite
broken skin or mucous membranes
may occur following prolonged spraying
onto
the
skin.
Nephrotoxicity
or
hepatotoxicity (long-term exposure)
2.4 LOCAL ANAESTHESIA
Code
02.04.01
Drug
Generic Name:
Bupivacaine,
Injection
Strength Available:
0.5 %
Category:
B
02.04.02
Generic Name:
Lignocaine,
Injection
Strength Available:
2 % (100 mg/5 ml)
Category:
B
Indication & Dose
Indication:
For peripheral sympathetic nerve and epidural
(excluding caudal) anaesthesia and obstetrics
anaesthesia
Dose:
Regional nerve block or epidural block: 15 - 30 ml.
Nerve block of finger or toe: 2 - 6 ml.
Maximum: 2 mg/kg body weight in any 4 hours period,
equivalent to 25 - 30 ml in adults of average weight
Indication:
Local anesth by infiltration IV regional anesthesia and
nerve block. Emergency management of ventricular
arrhythmias particularly after myocardial infarction and
cardiac surgery
Dosage:
Local anesthesia : ADULT Maximum: 200 mg; CHILD
Maximum: 30 mg/kg
Cardiac arrhythmias : ADULT 50-100 mg IV
Maximum: 200-300 mg/hour
CHILD Loading dose: 0.8-1 mg/kg IV repeated if
necessary up to 3-5 mg/kg followed by a continuous
infusion of 10-50 mcg/kg/min.
Contraindication
Adverse Effects
Hypovolaemia, complete heart block,
intravenous regional anaesthesia (Bier's
block). Acute active disease of the CNS
e.g. meningitis, tumours, poliomyelitis &
cranial haemorrhage, active TB or
metastatic lesions in the vertebral
column. Septicaemia. Pernicious anaemia
with subacute combined degeneration of
the spinal cord. Pyrogenic infection of the
skin at or adjacent to the site of puncture.
Cardiogenic or hypovolaemic shock.
Coagulation disorders or ongoing
anticoagulant treatment
Confusion, nervousness, dizziness,
tinnitus, respiratory depression and
convulsion,
hypotension
and
bradycardia,
hypersensitivity,
arrhythmias and cardiac arrest;
methemoglobinaemia;
seizures,
restlessness, prolonged block
Local inflammation and/or sepsis,
septicaemia. Hypovolaemia, heart block
and other conduction disturbances,
bradycardia, cardiac decompensation or
hypotension
Nervousness,
dizziness,
sedation,
blurred vision, tinnitus, gastrointestinal
effects,
dose-related
methaemoglobinaemia and cyanosis.
Restlessness, excitement, nervousness,
paraesthesia,
vomiting,
muscle
twitching and tremors, convulsions.
Numbness of tongue and perioral
region, light headedness, sedation, CNS
depression, respiratory failure and
coma.
Arrhythmias,
bradycardia,
cardiac arrest, anaphylaxis. Lassitude,
amnesia, foetal intoxication
2.5 MISCELLANEOUS ANAESTHESIA
Code
02.05.01
Drug
Generic Name:
Atropine Sulphate,
Injection
Strength Available:
1 mg/ml
Category:
B
Indication & Dose
Indication:
i) Reduce vagal inhibition,salivary and bronchiol
secretion in anaesthesia
ii) Reversal of excessive bradycardia
iii) Reversal of effect of competitive muscle relaxants
iv) Overdosage with other compounds having
muscarinic action
v) Organophosphate poisoning
Dosage:
i) ADULT 300-600 mcg IM/SC 30-60 minutes before
anaesthesia or 300-600 mcg IV immediately before
induction of anaesthesia
ii) ADULT 0.5-1 mg repeated, every 3-5 minutes. Max
Dosage: 0.04 mg/kg body weight
iii) ADULT 0.6-1.2 mg before or with
anticholinesterase
iv) ADULT 0.5-1 mg IV/SC, repeated every 2 hour
v) ADULT 2 mg IV/IM, every 30 minutes according to
clinical response. Cholinesterase reactivator should be
given at the earliest possible time
Contraindication
Adverse Effects
Hypersensitivity
to
atropine
or
anticholinergics, narrow-angle glaucoma,
reflux
oesophagitis,
obstructive
gastrointestinal
disease/uropathy,
ulcerative colitis or toxic megacolon,
unstable cardiovascular status in acute
haemorrhage or thyrotoxicosis
Constipation, transient bradycardia
(followed by tachycardia, palpitations &
arrhythmias),
reduced
bronchial
secretions,
urinary
urgency
&
retention, dilatation of the pupils with
loss of accommodation, photophobia,
dry mouth, flushing & dryness of the
skin
3.ANALGESICS
3.1 Non-Opiod Analgesics
3.2 Opiod Analgesics
3.3 Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs)
3.4 Neuropathic Pain
3.1 NON-OPOID ANALGESICS
Code
03.01.01
Drug
Generic Name:
Acetylsalicylic Acid
Soluble,
Tablet
Contraindication
Gastric haemorrhage, hypersensitivity,
thrombocytopenia,GI
disturbances;
prolonged bleeding time, rhinitis, urticaria
and epigastric discomfort; angioedema,
salicylism, tinnitus; bronchospasm
Generic Name:
Paracetamol,
Tablet
Indication:
Mild to moderate pain and pyrexia
Nephropathy
Allergic reactions, skin rash
Strength Available:
500 mg
Dose:
ADULT: 500 - 1000 mg every 4 - 6 hours, maximum
of 4 g daily
Nephropathy
Allergic reactions, skin rash
Category:
C
Indication:
Mild to moderate pain
Adverse Effects
Gastric and duodenal ulcers, haemorrhagic
diathesis, hypersensitivity to aspirin or
other NSAIDs, children under 12 years
old.Hypersensitivity (attacks of asthma,
Dose:
angioedema,
urticaria
or
rhinitis);
300 - 900 mg every 4 - 6 hours as required. Max 4 g
pregnancy (third trimester); patients with
daily. Use in children not recommended
haemophilia or haemorrhagic disorders;
gout; severe renal or hepatic impairment;
lactation
Strength Available:
300 mg
03.01.02
Indication / Dose
Category:
C
03.01.03
Generic Name:
Paracetamol,
Syrup
Indication:
Mild to moderate pain and pyrexia
Strength Available:
120 mg/5 ml
Dose:
CHILD: up to 1 year: 60 - 120 mg. 1 - 5 years: 120 240 mg. 6 - 12 years: 240 - 480 mg per dose.
Repeat every 4 - 6 hours when necessary.
Maximum of 4 doses in 24 hours
Category:
C
3.2 OPIOID ANALGESICS
Code
03.02.01
Drug
Generic Name:
Pethidine HCl,
Injection
Strength Available:
50 mg/ml
Category:
B
03.02.02
Generic Name:
Tramadol HCl,
Capsule
Strength Available:
50 mg
Category:
A / KK
Indication / Dose
Contraindication
Adverse Effects
Indication:
For relief of moderate to severe pain (medical and
surgical), pre-anaesthetic medication and
obstetrical analgesia
Hypersensitivity, concurrent use of
MAOIs, intracranial lesions causing
increased pressure, atrioventricular
flutter, respiratory depression, renal
failure and a predisposition to
convulsions or seizures. Head injury,
brain tumour. Cardiac arrhythmias.
Concurrent use of MAOIs. Preeclampsia, eclampsia. Convulsive states.
Diabetic acidosis. Acute alcoholism or
delerium tremens. Severe liver disease,
incipient encephalopathy, low platelet
count, coagulation disorders or receiving
anticoagulant treatment. Continuous IV
infusion in renal impairment. Patientcontrolled analgesia in young children &
adult with poor cognitive function
Respiratory depression, dizziness, sweating,
disorientation, hallucination,agitation, tremor,
multifocal
myoclonus,
convulsion,
Gastrointestinal disturbances, hypotension,
hypertension, bradycardia, urine retention,
Lightheadedness,
dizziness,
sedation,
sweating, bizzare feeling, disorientation,
hallucinations, psychosis. Dry mouth, nausea,
vomiting,
constipation.
Hypotension,
vasodilation,
tachycardia,
bradycardia,
gangrene. Rash, pruritus, urticaria, erythema,
injection site complications, anuria. Increased
biliary tract pressure, choledochoduodenal
sphincter
spasm.
Neurotoxicity,
neuropsychiatric toxicity. Hyperactivity or
agitation, depression, mental clouding,
dysphoria
Narcotic
withdrawal
treatment,
hypersensitivity, acute alcoholism. Acute
intoxication with alcohol, analgesics,
sedatives or psychotropic drugs. MAOI
therapy
Sweating, dizziness, vomiting, dry mouth,
gastrointestinal
disturbances,
cerebral
convulsions especially on co-medication with
neuroleptics, physical dependence. Rarely,
palpitations, tachycardia, faintness, circulatory
collapse, headaches, constipation, skin
reactions. Very rarely, muscular weakness,
altered appetite, micturition disturbances
Dose:
ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if
necessary.
CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/
kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12
years: 25 - 50 mg IM
Indication:
Post-operative pain, chronic cancer pain,
analgesia/pain relief for patients with impaired
renal function
Dose:
50 - 100 mg every 4 hours. Max 400 mg daily. Not
recommended in children
Code
03.02.03
Drug
Indication / Dose
Generic Name:
Morphine Sulphate,
Injection
Indication:
For moderate to severe pain especially that
associated with neoplastic disease
Strength Available:
10 mg/ml
Dose:
ADULT: 10 - 20 mg/kg or more SC or IM every 4
hours in terminal pain
CHILD: Up to 1 month: 0.15 mg/kg body weight; 1 12 months: 0.2 mg/kg body weight; 1 - 5 years: 2.5
- 5 mg ; 6 - 12 years: 5 - 10 mg
Category:
B
Contraindication
Adverse Effects
Acute bronchial asthma, respiratory
insufficiency, severe CNS depression, GI
obstruction, biliary colic (these conditions
are not contra-indications in patients who
are terminally ill), hypersensitivity to
morphine, MAOIs
Constipation, nausea, vomiting, drowsiness,
dry
mouth,
psychomimetic
effect
(dysphoria,
hallucination,
nightmare),
urinary retention, respiratory depression
(rare). Convulsions; dry mouth, headache,
vertigo; palpitations; hypothermia; pruritus,
urticaria; tachycardia, bradycardia; blurred
vision; miosis; dependency
3.3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
Code
03.03.01
Drug
Generic Name:
Diclofenac Sodium,
Tablet
Strength Available:
50 mg
Category:
B
03.03.02
Indication / Dose
Indication:
Pain and inflammation in rheumatic disease
Dose:
ADULTS : Initial dose of 150 mg daily. Mild or long
term: 75 - 150 mg daily in 2 to 3 divided doses after
food
PAEDS : 1 year and above : 1 - 3 mg/kg body
weight daily
Generic Name:
Diclofenac Sodium,
Injection
Indication:
Pain and inflammation in rheumatic disease
Strength Available:
75 mg/3 ml
Dose:
75 mg once daily (2 times daily in severe cases) for
not more than 2 days
Contraindication
Adverse Effects
Hypersensitivity, rhinitis, urticaria, asthma Epigastric pain, GI disturbances, slight
or allergic reactions to aspirin or other anti dizziness
-inflammatory agents
Hypersensitivity to diclofenac or any
component of the formulation, aspirin or
other NSAIDs, asthma, rhinitis, porphyria,
pregnancy (third trimester)
Pruritus, rash, contact dermatitis, pain, dry
skin, exfoliation, paraesthesia, constipation,
diarrhoea, headache, dizziness, vertigo,
nausea,
vomiting,
gastrointestinal
disorders, anorexia, increase transaminases
Category:
A
03.03.03
Generic Name:
Diclofenac,
Emulgel
Strength Available:
1%
Category:
A
Indication:
Post-traumatic inflammation of the tendons,
ligaments & joints. Localised forms of soft tissue
rheumatism and degenerative rheumatism
Dose:
Apply 3 - 4 times daily and gently rubbed in
Hypersensitivity to diclofenac or other Allergic or non allergic contact dermatitis.
NSAIDs, proctitis and isopropanol or Generalized skin rash, hypersensitivity and
propylene glycol
photosensitivity reactions
Code
03.03.04
03.03.05
Drug
Generic Name:
Mefenamic Acid,
Tablet
Strength Available:
250 mg
Indication / Dose
Indication:
Mild to moderate pain
Category:
B
Dose:
ADULT: 250 - 500 mg 3 times daily after meals.
CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4
times daily for not longer than 7 days except in
juvenile arthritis
Generic Name:
Ketoprofen,
Gel
Indication:
As a short term treatment for traumatic lesions,
sprains, tendinitis, oedema, bruises
Strength Available:
2.5 %
Dose:
Apply twice daily. Maximum 20 g daily
Contraindication
Adverse Effects
Gastrointestinal
ulceration
or Diarrhoea,
skin
rash,
allergic,
inflammatory bowel disease, renal/hepatic glomerulonephritis,
non-oliguric
renal
impairment
failure,
thrombocytopenia,
reversible
haemolytic
anaemia,
hypertension,
oedema, myocardial infarction
Avoid in patient with exudative Pruritus and localised erythema
dermatoses, eczema, sores, infected skin.
Do not apply to the mucous membranes or
eyes
Category:
A
3.4 NEUROPATHIC PAIN
Code
Drug
03.04.01
Generic Name:
Methyl Salicylate 25 %,
Ointment
Indication:
Relief of pain associated with musculoskeletal
discomfort
Strength Available:
25 %
Dose:
To be applied to affected area
Category:
C
Indication / Dose
Contraindication
Patient with
idiosyncrasy
aspirin
or
Adverse Effects
salicylate Extreme overdosage results in excessive
irritation, tinnitus, nausea, vomiting
4.ANTIINFECTIVES
4.1 Antibacterial Drugs
4.2 Antifungal Drugs
4.3 Antiviral Drugs
4.4 Antihelmintics Drugs
4.1 ANTIBACTERIAL DRUGS
Code
04.01.01
Drug
Generic Name:
Amoxicillin,
Capsule
Strength Available:
250 mg, 500 mg
Category:
B
04.01.02
Generic Name:
Amoxicillin Trihydrate,
Syrup
Strength Available:
125 mg/5 ml
Category:
B
04.01.03
Generic Name:
Amoxicillin 500 mg &
Clavulanate 125 mg,
Tablet (Augmentin®)
Strength Available:
625 mg
Category:
A/KK
Indication & Dosage
Indication:
Infections caused by susceptible strains of gram positive and
gram negative organisms
Contraindication
Adverse Effects
Hypersensitivity to penicillins
Diarrhoea, indigestion, urticarial or
erythematous rash, hepatitis, cholestatic
jaundice
Hypersensitivity to penicillins
Diarrhoea, indigestion, urticarial or
erythematous rash, hepatitis, cholestatic
jaundice
Hypersensitivity to penicillins,
possible cross sensitivity with
other β-lactams. History of
penicillin-associated cholestatic
jaundice/hepatic dysfunction
Diarrhoea,
indigestion,
nausea,
vomiting,
candidiasis,
rash,
pseudomembranous colitis, hepatitis,
cholestatic
jaundice,
crystalluria,
erythema multiforme, Stevens-Johnson
syndrome, toxic epidermal necrolysis,
reversible
leucopaenia,
thrombocytopaenia,
haemolytic
anaemia, CNS disturbances
Dosage:
ADULT: 250 - 500 mg 3 times daily
CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly
Indication:
Infections caused by susceptible strains of gram positive and
gram negative organisms
Dosage:
CHILD less than 10 years: 125 - 250 mg 8 hourly
CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
Indication:
Infections due to beta-lactamase producing strain where
amoxicillin alone is not appropriate. Respiratory tract, skin, soft
tissue, GUT infection, septicaemia, peritonitis, post-operative
infection & osteomyelitis
Dosage:
ADULT & CHILD more than 12 years: Mild to moderate
infections: 625 mg twice daily. Severe infections: 1 g twice daily
Code
04.01.04
Drug
Generic Name:
Ampicillin Sodium &
Sulbactam Sodium,
Tablet (Unasyn®)
Strength Available:
375 mg
Indication & Dosage
Indication:
Treatment of susceptible bacterial infections
Dosage:
ADULT & CHILD more than 30 kg: 375 - 750 mg twice daily. Maximum: 3 g
daily
Contraindication
Adverse Effects
History of allergic reaction to GI disturbances, phlebitis, skin
any penicillins
rashes,
itching,
blood
disorders, anaphylaxis and
superinfection
Category:
A/KK
04.01.05
Generic Name:
Indication:
Ampicillin Sodium 1 g & Treatment of susceptible bacterial infections
Sulbactam Sodium 500
mg, Injection
Dosage:
(Unasyn®)
ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g
Sulbactam
Strength Available:
CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections:
1.5 g
1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly
Category:
NEONATES: First week of life, 75mg/kg/day in divided doses every 12 hour
A
History of allergic reaction to GI disturbances, phlebitis, skin
any penicillins
rashes,
itching,
blood
disorders, anaphylaxis and
superinfection
04.01.06
Generic Name:
Bacampicillin,
Tablet
Hypersensitivity to penicillins
Strength Available:
400 mg
Category:
B
Indication:
Infections caused by ampicillin-sensitive gram positive & gram negative
microorganisms
Dosage:
ADULT: 400 mg twice daily. Severe infection: 800 mg twice daily
CHILD more than 25 kg: 12.5 - 25 mg/kg 12 hourly
Diarrhoea,
indigestion,
urticarial or erythematous rash,
hepatitis, cholestatic jaundice
Code
Drug
04.01.07
Generic Name:
Benzylpenicillin,
Injection (Penicillin G)
Strength Available:
5 mega units (3 g)
04.01.08
Indication & Dosage
Indication:
i) Infections caused by susceptible organisms
ii) Infective endocarditis
Category:
B
Dosage:
i) ADULT: 600 - 1200 mg IM 4 times daily, increased if
necessary in more serious infections. CHILD: 50 - 100 mg/
kg body weight daily IV in 2 - 4 divided doses
ii) ADULT: 7.2 g daily by slow IV infusion in 6 divided doses
Generic Name:
Ceftriaxone, Injection
Indication:
Infections caused by susceptible organisms
Strength Available:
1g
Category:
A
Dosage:
ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12
hour intervals
INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body
weight daily. CHILD with body weight 50 kg or more: adult
dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight
daily, not to exceed 50 mg/kg
Contraindication
Adverse Effects
History of anaphylaxis, accelerated Hypersensitivity
reactions,
GI
(e.g. hives) or serum sickness reaction disturbances, eosinophilia, haemolytic
to previous penicillin administration
anaemia, leucopenia, agranulocytosis.
Convulsions in the presence of severely
reduced renal function, epilepsy,
meningitis or cerebral oedema or
during
cardiopulmonary
bypass
procedure
Hypersensitivity to cephalosporins.
Neonates aged less than or 28 days if
they require treatment with calciumcontaining
intravenous
solutions,
including calcium-containing infusions
such as parenteral nutrition, because of
the risk of precipitation of ceftriaxonecalcium
GI upsets, haematological changes, skin
reactions,
coagulation
disorders,
phlebitis,
agranulocytosis,
renal
precipitations
Code
04.01.09
Drug
Generic Name:
Cefuroxime Axetil,
Tablet
Strength Available:
250 mg
04.01.10
Indication:
Upper respiratory tract, GUT, skin & soft tissue
infections, urinary tract infection (UTI),
pyelonephritis
Category:
A/KK
Dosage:
ADULT: 250 mg twice daily ;UTI: 125 mg twice daily
CHILD: 125 mg twice daily. Maximum 250 mg/day
Generic Name:
Cloxacillin Sodium,
Suspension
Indication:
Treatment of susceptible bacterial infections,
notably penicillinase-producing staphylococci
Strength Available:
125 mg/5 mL
Category:
B
04.01.11
Indication & Dosage
Generic Name:
Cloxacillin Sodium,
Capsule
Strength Available:
250 mg, 500 mg
Category:
B
Contraindication
Hypersensitivity to cephalosporins
Adverse Effects
GI
disturbances
pseudomembraneous
hypersensitivity reactions,
headache, superinfection
occasionally
colitis,
eosinophilia,
Hypersensitivity to cloxacillin products/ Occasional rashes, GI upsets, anaphylaxis
penicillins
Dosage:
CHILD 2 - 10 years: 250 mg 6 hourly, less than 2
years: 125 mg 6 hourly
Indication:
Treatment of susceptible bacterial infections,
notably penicillinase-producing staphylococci
Dosage:
ADULT: 250 - 500 mg every 6 hours
CHILD: 2 - 10 years: 250 mg 4 times daily; less than
2 years: 125 mg 4 times daily
Hypersensitivity to cloxacillin products/ Occasional rashes, GI upsets, anaphylaxis
penicillins
Code
04.01.12
Drug
Generic Name:
Cloxacillin Sodium,
Injection
Strength Available:
500 mg
Category:
B
04.01.13
Indication & Dosage
Indication:
Treatment of susceptible bacterial infections,
notably penicillinase-producing staphylococci
infections
Contraindication
Adverse Effects
Hypersensitivity to cloxacillin or penicillins
Fever, rash, nausea, vomiting, diarrhoea,
hepatotoxicity, anaphylaxis
Dosage:
ADULT: 250 to 500 mg every 6 hours depending on
type and severity of infection
CHILD less than 20 kg: 25 to 50 mg/kg/day in
equally divided doses every 6 hours
Generic Name:
Doxycycline,
Capsule
Indication:
Infections due to susceptible organisms
Strength Available:
100 mg
Dosage:
ADULT: 200 mg on the first day followed by 100 mg
daily. Severe infections: 200 mg daily
Hypersensitivity
to
tetracyclines/ GI distress, anorexia, maculopapular and
doxycycline,
porphyria,
pregnancy, erythematous rash, tooth discolouration in
lactation, children less than 12 years
children
Category:
B
04.01.14
Generic Name:
Erythromycin
Ethylsuccinate,
Suspension
Strength Available:
200 mg/5 ml
Category:
B
Indication:
Treatment of susceptible bacterial infections
Dosage:
CHILD: mild to moderate infection: 30 - 50 mg/kg/
day in equally divided doses every 6 hours. For
more severe infection this dose may be doubled.
Doses may be given 2 - 3 times a day
Hypersensitivity, porphyria
Abdominal discomfort, mild allergic
reaction; liver dysfunction with or without
jaundice; reversible hearing loss, prolonged
Q-T interval, ventricular arrhythmias, GI
disturbances
Code
04.01.15
Drug
Generic Name:
Erythromycin
Ethylsuccinate,
Tablet
Strength Available:
400 mg
Indication & Dosage
Indication:
Treatment of susceptible bacterial infections
Dosage:
ADULT: 400 mg 6 hourly or 800 mg 12 hourly.
Maximum 4 g/day.
CHILD: 30 - 50 mg/kg/day in 2 - 4 divided doses
Contraindication
Hypersensitivity, porphyria
Adverse Effects
Abdominal discomfort, mild allergic
reaction; liver dysfunction with or without
jaundice; reversible hearing loss, prolonged
Q-T interval, ventricular arrhythmias, GI
disturbances
Category:
B
04.01.16
04.01.17
Generic Name:
Ethambutol HCL,
Tablet
Indication:
Tuberculosis
Strength Available:
400 mg
Category:
B
Dosage:
ADULT: 15-25 mg/kg daily (max 1200 mg) or 50
mg/kg biweekly (max 2000 mg).
CHILD: 15-25 mg/kg daily or 25-35 mg/kg thrice
weekly
Generic Name:
Isoniazid,
Tablet
Indication:
i) Tuberculosis
ii) Tuberculous meningitis
Strength Available:
100 mg
Category:
B
Dosage:
i) & ii) ADULT 5-8mg/kg daily (max 300 mg) or 1520 mg/kg biweekly (max 1200 mg)
Optic neuritis; history of previous adverse Generally well tolerated but may provoke
effects with ethambutol
reversible retrobulbar neuritis with a
reduction of visual acuity, central scotoma
& green-red colour blindness, allergic
rashes,
GI
disturbances,
jaundice,
peripheral
neuritis,
confusion,
hallucinations, joint pain, fever, malaise,
headache, dizziness, anorexia & abdominal
pain
Acute liver disease, hypersensitivity to Peripheral neuropathy and hepatotoxicity,
isoniazid
psychiatric
sign
or
symptom,
agranulocytosis, anaemia, megaloblastic
anaemia, thrombocytopenia, systemic lupus
erythematosus, seizure
Code
04.01.18
Drug
Indication & Dosage
Generic Name:
Metronidazole,
Tablet
Indication:
Anaerobic infection
Strength Available:
200 mg
Dosage:
800 mg initially followed by 400 mg 8 hourly.
CHILD: 7.5 mg/kg every 8 hours
Contraindication
Adverse Effects
Hypersensitivity
to metronidazole.
Chronic alcohol
dependence
Unpleasant taste in mouth, furry tongue,
gastrointestinal
disturbances,
urticaria,
angioedema, drowsiness, dizziness, headache,
ataxia, skin rashes, pruritus, darkening of urine,
peripheral
neuropathy
or
transient
epileptiform seizures, leucopenia, nausea,
vomiting, erythema multiforme, hepatitis,
jaundice, thrombocytopenia, aplastic anaemia,
myalgia, arthralgia
Hypersensitivity
to metronidazole
GI disturbances, urticaria, angioedema,
drowsiness, dizziness, headache, ataxia, skin
rashes, pruritus, darkening of urine, peripheral
neuropathy or transient epileptiform seizures,
leucopenia, anaphylaxis
Category:
B
04.01.19
Generic Name:
Metronidazole,
Injection
Indication:
Anaerobic infection
Strength Available:
500 mg / 100 ml
Dosage:
ADULT: 500 mg IV infusion 8 hourly
CHILD: 7.5 mg/kg body weight every 8 hours. Neonates: 15 mg/kg LD,
followed by 7.5 mg/kg every 12 hourly. 1 month to 18 years: 7.5 mg/kg
(maximum 500 mg) every 8 hours
Category:
A
04.01.20
Generic Name:
Phenoxymethyl
Penicillin,
Tablet (Penicillin V)
Indication:
Hypersensitivity
i) Treatment or prophylaxis of infections caused by susceptible organisms to penicillin
ii) Prophylactic, rheumatic fever
Strength Available:
125 mg
Dosage:
i) ADULT: 500 - 750 mg 6 hourly
CHILD: up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6
hourly
ii) ADULT: 125 - 250 mg twice daily.
CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours.
Maximum: 3 g/day
Category:
C
Skin rashes, anaphylaxis, urticaria, fever, joint
pain. Haemolytic anaemia, blood disorders,
gastrointestinal distress & superinfection
Code
04.01.21
Drug
Generic Name:
Pyrazinamide,
Tablet
Indication:
Tuberculosis
Strength Available:
500 mg
Dosage:
ADULT: 20-40 mg/kg daily (max 1500 mg) or 50
mg/kg biweekly (max 2000 mg).
CHILD : 20-30 mg/kg daily or 30-40 mg/kg thrice
weekly
Category:
B
04.01.22
Indication & Dosage
Generic Name:
Rifampicin,
Capsule
Strength Available:
150 mg, 300 mg
Category:
B
Indication:
i) Tuberculosis
ii) Leprosy
iii) Prophylaxis for meningococcal meningitis
Dosage:
i) ADULT: 450 - 600 mg as a single morning dose.
CHILD: 10 - 20 mg/kg body weight daily in 1 - 2
doses. Directly observed therapy (DOT): 10 mg/kg
twice weekly or 3 times/week. Maximum: 600 mg
ii) 600 mg/day
iii) 600 mg twice daily for 2 days
Contraindication
Adverse Effects
Porphyria, severe liver damage, acute liver Liver toxicity depending on treatment
disease, pregnancy, lactation
duration & concomitant therapy. Transient
increase in serum transminase levels, acute
atrophy of the liver. Nausea, vomiting,
anorexia, diarrhoea, abdominal pain.
Hyperuricaemia may occur with dosages
more than 2 g/day
Hypersensitivity and jaundice patient
Flushing, itching, gastrointestinal reactions,
pseudomembranous
colitis,
hepatitis,
thrombocytopenia, muscle weakness. Flu
syndrome may occur with intermittent
dosage regimens. May produce a reddish
brown discoloration of body fluids
Code
Drug
Indication & Dosage
Contraindication
Adverse Effects
04.01.23
Generic Name:
Rifampicin 150 mg,
Isoniazid 75 mg,
Pyrazinamide 400 mg
& Ethambutol HCl 275
mg, Tablet (Akurit 4)
Indication:
Treatment of both pulmonary and extrapulmonary
tuberculosis, in the intensive treatment phase
Combined preparation not suitable for use
in children. History of drug-induced
hepatitis, acute liver diseases regardless of
their origin, peripheral neuritis
Reddish discoloration of body fluids,
increased
hepatic
enzyme
levels,
gastrointestinal disturbances, tiredness,
drowsiness, headache, dizziness, ataxia,
leucopenia, eosinophilia, flushing, itching,
rash, disturbances in the menstrual cycle,
induction of crisis in Addison patients, 'flulike' symptoms, disturbances of liver
function, hepatitis, peripheral neuropathy,
agranulocytosis,
eosinophilia,
thrombocytopenia, allergic reactions, lupus
erythematosus-like syndrome, pellagra,
gynaecomastia, hyperuricaemia, interstitial
nephritis,
dysuria,
photosensitivity,
porphyria, reversible retrobulbar neuritis
with a reduction of visual acuity, central
scotoma and green-red color blindness,
jaundice, peripheral neuritis, confusion,
hallucinations, joint pain, fever, malaise,
anorexia and abdominal pain
Hypersensitivity to other aminoglycosides
Ototoxicity, nephrotoxicity, shock, vitamin
K and vitamin B deficiency, Steven-Johnson
syndrome
Strength Available:
-
Dosage:
ADULT: 30 - 37 kg: 2 tablets daily, 38 - 54 kg: 3
tablets daily, 55 - 70 kg: 4 tablets daily, more than
70 kg: 5 tablets daily
Category:
B
04.01.24
Generic Name:
Streptomycin Sulphate,
Injection
Indication:
Tuberculosis
Strength Available:
1g
Dosage:
0.5 - 1 g IM of Streptomycin base daily or at longer
intervals, cumulative dose should not exceed 100 g
Category:
B
Code
04.01.25
Drug
Generic Name:
Sulphamethoxazole
400 mg &
Trimethoprim 80 mg,
Tablet (Bactrim/
Co-Trimazole)
Strength Available:
480 mg
Category:
B
Indication & Dosage
Indication:
i) Severe or complicated infections due to
susceptible infection
ii) Treatment and prophylaxis of pneumocystis
carinii pneumonia (PCP) in immunocompromised
patients
Dosage:
i) ADULT: 1 - 3 tablets twice daily
ii) Treatment: ADULT & CHILD over 4 weeks: 120
mg/kg/day in 2 - 4 divided doses for 14 days.
Prophylaxis: ADULT: 960 mg once daily or 960 mg
on alternate days (3 times a week) or 960 mg twice
daily on alternate days (3 times a week)
CHILD; 6 weeks - 5 months: 120 mg twice daily on
3 consecutive days or 7 days per week; 6 months 5 years: 240 mg; 6 - 12 years: 480 mg
Contraindication
Adverse Effects
Marked liver parenchymal damage, blood
dyscrasias, severe renal impairment,
pregnancy, hypersensitivity. Use with
caution in premature babies or full-term
infants in the neonatal period
Gastrointestinal upsets, stomatitis, glossitis
and skin rashes, tinnitus, erythema
multiforme, Stevens-Johnson syndrome,
Lyell's syndrome, leucopenia, neutropenia,
thrombocytopenia,
agranulocytosis,
megaloblastic anaemia, pancytopenia or
purpura, hyperkalaemia
4.2 ANTIFUNGAL DRUGS
Code
04.02.01
Drug
Generic Name:
Griseofulvin,
Tablet
Strength Available:
125 mg
Category:
B
04.02.02
Generic Name:
Ketoconazole,
Tablet
Strength Available:
200 mg
Category:
A / KK
Indication & Dosage
Indication:
Dermatophyte infections of the skin, scalp, hair
and nails, where topical therapy has failed or
inappropriate
Dosage:
ADULT: 500 mg daily up to 1 g daily in divided
doses,
CHILD: 10 mg/kg daily in divided doses or as a
single dose
Indication:
i) Pityriasis versicolor
ii) Systemic mycosis (other skin mycoses)
iii) Nail infections
Dosage:
i) 200 mg with meal once daily for 10 days
ii) 200 - 400 mg daily for 4 weeks - 6 months
iii) 200 - 400 mg daily for 6 - 12 months. Maximum
400 mg daily
Contraindication
Adverse Effects
Established porphyria, hepatocellular Oral thrush, gastrointestinal distress, taste
failure, SLE and related conditions, perversion, dizziness, confusion, headache,
pregnancy
depression, insomnia, fatigue, peripheral
neuritis, photosensitivity, skin rashes,
urticaria,
erythema
multiforme,
leucopaenia, proteinuria
Liver disease, recovery phase of hepatitis, GI disturbances; pruritus; elevated liver
known hypersensitivity, acute porphyria
function tests. Rarely, acute allergic
reactions,
hepatitis,
gynaecomastia,
photophobia, alopecia
4.3 ANTIVIRAL DRUGS
Code
04.03.01
Drug
Generic Name:
Acyclovir,
Tablet
Strength Available:
800 mg
Category:
A / KK
Indication & Dosage
Indication:
i) Mucocutaneous Herpes Simplex infection in
immunocompromised and AIDS patients
ii) Primary and recurrent Varicella Zoster infection in
immunocompromised and AIDS patients
iii) Severe Kaposi Varicella Eruption (Eczema herpeticum)
iv) Severe primary HSV infections (eg. Neonatal herpes,
encephalitis, eczema herpeticum, genital herpes, gingival
stomatitis, vaginal delivery with maternal vulva herpes)
v) Severe and complicated varicella infection (eg. Encephalitis,
purpura fulminans)
vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura
fulminans, immunocompromised patients and facial, sacral and
motor zoster)
Dosage:
i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less
than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400
mg 4 times daily
ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2
years, half adult dose; more than 2 years, adult dose
v) ADULT: 800 mg 5 times daily for 7 days
vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5
days, CHILD 6 years: 800 mg four times daily. CHILD less than 2
years; 400 mg 4 times daily, more than 2 years; 800 mg 4 times
daily
Contraindication
Patients known to be hypersensitivity
to acyclovir
Adverse Effects
Skin rashes; GI effects; fatigue
4.4 ANTIHELMINTIC DRUGS
Code
04.04.01
Drug
Generic Name:
Albendazole,
Tablet
Strength Available:
200 mg
Category:
C
04.04.02
Generic Name:
Albendazole,
Suspension
Strength Available:
200 mg / 5 ml
Category:
C
Indication & Dosage
Indication:
i) Single or mixed infestations of intestinal
parasites
ii) Strongyloides infection
Contraindication
Adverse Effects
Patients
with
hypersensitivity
to
albendazole or to the benzimidazole drug
class, pregnancy (avoid pregnancy for at
least one month following therapy)
Gastrointestinal discomfort, dizziness,
headache, erythema multiforme, StevensJohnson
syndrome,
agranulocytosis,
aplastic anemia, leukopenia, pancytopenia,
thrombocytopenia, hepatotoxicity
Patients
with
hypersensitivity
to
albendazole or to the benzimidazole drug
class. Pregnancy (avoid pregnancy for at
least one month following therapy)
Gastrointestinal discomfort, dizziness,
headache, erythema multiforme, StevensJohnson
syndrome,
agranulocytosis,
aplastic anemia, leukopenia, pancytopenia,
thrombocytopenia, hepatotoxicity
Dosage:
i) ADULT and CHILD over 2 years : 400 mg as a
single dose
ii) 400 mg as a single dose for 3 consecutive days.
CHILD 12 - 24 months : half adult dose
Indication:
i) Single or mixed infestations of intestinal
parasites
ii) Strongyloides infection
Dosage:
i) ADULT and CHILD over 2 years : 400 mg as a
single dose
ii) 400 mg as a single dose for 3 consecutive days.
CHILD 12 - 24 months : half adult dose
5.CARDIOVASCULAR
5.1 Positive Inotropic Drugs
5.2 Diuretics
5.3 Anti-Arrhythmic Drugs
5.4 Beta-Adrenoceptor Blocking Drugs
5.5 Drug Affecting The Renin-Angiotensin System
and Some Other Antihypertensive Drugs
5.6 Nitrates, Calcium-Channel Blockers and
Potassium-Channel Activators
5.7 Sympathomimetics
5.8 Anticoagulants and Protamine
5.9 Antiplatelet Drugs
5.10 Antifibrinolytic Drug and Haemostatics
5.11 Lipid Regulating Drugs
5.12 Miscellaneous Cardiovascular
5.1 POSITIVE INOTROPIC DRUGS
Code
05.01.01
Drug
Generic Name:
Digoxin,
Tablet
Strength Available:
0.25 mg, 0.0625 mg
Category:
B
05.01.02
Generic Name:
Digoxin,
Injection
Strength Available:
250 mcg/ml
Category:
A
05.01.03
Generic Name:
Dopamine,
Injection
Strength Available:
40 mg/ml
Category:
B
Indication & Dose
Contraindication
Indication:
Heart failure , with atrial fibrillation, supraventricular arrhythmias
(particularly, atrial fibrillation)
Adverse Effects
Ventricular fibrillation,
ventricular tachycardia
except in certain cases,
digitalis toxicity, beriberi
heart
disease,
Dosage:
hypersensitivity
to
Rapid digitalisation: 0.75 -1.5 mg in divided doses over 24 hours; less urgent
digoxin, some cases of
digitalisation, 250 mcg-500 mcg daily (higher dose may be divided).
hypersensitive carotid
Maintenance: 62.5 mcg -500 mcg daily (higher dose may be divided)
sinus syndrome
according to renal function and , in atrial fibrillation, on heart rate
response; usual range, 125-250 mcg daily (lower dose may be appropriate
in elderly)
Nausea, vomiting, anorexia, diarrhoea,
abdominal pains, salivation, sweating;
headache, facial pain, malaise, fatigue,
drowsiness, depression, disorientation,
mental
confusion,
delirium,
hallucination,
visual
disturbance.
hypokalaemia, ventricular premature
contractions, atrial or ventricular
arrhythmias and conduction defects
Indication:
Heart failure with atrial fibrillation, supraventricular arrhythmias
(particularly atrial fibrillation)
Nausea, vomiting, anorexia, diarrhoea,
abdominal pains, salivation, sweating;
headache, facial pain, malaise, fatigue,
drowsiness, depression, disorientation,
mental
confusion,
delirium,
hallucination,
visual
disubance,
hypokalaemia, ventricular premature
contractions, atrial or ventricular
arrhythmias and conduction defects
Dosage:
Rapid digitilisation: ADULT & CHILD over 10 years, initially 0.75 - 1.5 mg,
followed by 250 mcg 6 hourly until digitilisation is complete
Indication:
Non-hypovolemic hypotension
Dosage:
Initial dose 2-5 mcg/kg/min with incremental changes of 5-10 mcg/kg/min
at 10-15 minutes intervals until adequate response is noted. Most patients
are maintained at less than 20 mcg/kg/min. If dosage exceeds 50 mcg/kg/
min, assess renal function frequently
Ventricular fibrillation,
ventricular tachycardia
except in certain cases,
digitalis toxicity, beriberi
heart
disease,
hypersensitivity
to
digoxin, some cases of
hypersensitive carotid
sinus syndrome
Pheochromocytoma,
Increased heart rate, blood pressure
tachyarrhythmias
or and ventricular ectopic activity, anginal
ventricular fibrillation
pain,
nonspecific
chest
pain,
palpitations and shortness of breath,
nausea, headache
5.2 DIURETICS
Code
05.02.01
Drug
Generic Name:
Frusemide,
Injection
Indication:
Pulmonary oedema
Strength Available:
10 mg/ml
Dosage:
Initially 20 -40 mg IM or slow IV (rate not
exceeding 4 mg/min).
CHILD: 0.5 - 1.5 mg/kg. Max: 20 mg daily
Category:
B
05.02.02
Indication / Dose
Generic Name:
Frusemide,
Tablet
Indication:
Pulmonary oedema
Strength Available:
40 mg
Dosage:
ADULT: Initial 40 - 80 mg on morning if required,
can be increased to a max of 1 g/day in certain
cases especially in chronic renal failure
CHILD: 1 - 3 mg/kg daily
Category:
B
Contraindication
Adverse Effects
Anuria, hypersensitivity to furosemide, Hypokalaemia,
hyperuricaemia,
hepatic coma and pre-coma. Severe hypotension, hyperglycaemia
hypokalaemia, severe hyponatraemia,
hypovolaemia
with
or
without
concomitant hypotension
Anuria, hypersensitivity to furosemide, Hypokalaemia,
hyperuricaemia,
hepatic coma and pre-coma. Severe hypotension, hyperglycaemia
hypokalaemia, severe hyponatraemia,
hypovolaemia
with
or
without
concomitant hypotension
Code
05.02.03
Drug
Generic Name:
Spironolactone,
Tablet
Strength Available:
25 mg
Category:
B
05.02.04
Indication / Dose
Indication:
Oedema and ascites in cirrhosis of the liver,
congestive heart failure
Dosage:
ADULT: 100 - 200 mg daily in divided doses.
Increase to 400 mg if required.
CHILD: initially 3 mg/kg daily in divided doses
Generic Name:
Hydrochlorothiazide,
Tablet
Indication:
Diuretic, hypertension
Strength Available:
25 mg, 50 mg
Dosasge:
ADULT: Diuretics; 25-200 mg daily. Hypertension
12.5-25 mg daily
CHILD: Oedema and hypertension; Adjunct; 1 to 2
mg/kg ORALLY daily in single or two divided doses;
Children 2-12 years old MAX dose, not to exceed
100 mg ORALLY daily
Infants less than 6 months old, may require doses
up to 3 mg/kg ORALLY daily in two divided doses,
Infants up to 2 yrs old: MAX dose, not to exceed
37.5 mg ORALLY daily
Category:
B
Contraindication
Adverse Effects
Hypersensitivity, hyperkalaemia, renal
failure, anuria, patients receiving other
potassium-sparing diuretics or potassium
supplements
Headache, drowsiness, gastrointestinal
disturbances
including
cramp
and
diarrhoea, ataxia, mental confusion,
hirsutism, deepening of the voice,
menstrual irregularities, impotence, skin
rashes, hyponatraemia, hyperkalaemia
Anuria, concurrent lithium therapy, renal Metabolic
disturbances,
electrolyte
decompensation
imbalance,
anorexia,
gastrointestinal
disturbances, headache, dizziness, postural
hypotension,
paresthesia,
impotence,
yellow vision, hypersensitivity. Rarely
cholestatic jaundice, pancreatitis, blood
dyscrasias
5.3 ANTI-ARRHYTHMIC DRUGS
Code
05.03.01
Drug
Generic Name:
Adenosine,
Injection
Strength Available:
3 mg/ml
Category:
B
05.03.02
Indication / Dose
Indication:
Rapid conversion of paroxysmal supraventricular
tachycardia to sinus rhythm
Dosage:
ADULT: Initially: 3 mg given as a rapid IV bolus
(over 2 seconds). Second dose: If the first dose
does not result in elimination of the
supraventricular tachycardia with in 1 or 2
minutes, 6 mg should be given also as a rapid IV
bolus. Third dose: If the second dose does not
result in elimination of the supraventicular
tachycardia with in 1-2 minutes, 12 mg should be
given also as a rapid IV bolus
Generic Name:
Lignocaine HCl,
Injection
Indication:
Ventricular tachycardia and ventricullar fibrillation.
To be diluted before use
Strength Available:
2 % (20 mg/ml)
Dosage:
50-100 mg IV as a bolus, repeated after 5 minutes
if necessary. Maintenance : 1-4 mg/min by IV
infusion under ECG monitoring
Category:
B
Contraindication
Adverse Effects
Bradycardia,
bronchoconstrictive
or
bronchospastic lung disease (eg. asthma).
Hypersensitivity to adenosine, seconddegree or third-degree AV block (unless
pacemaker fitted), sinus node disease (eg.
sick sinus syndrome)
Facial flush, dyspnoea, a feeling of thorasic
constriction, nausea, lightheadedness,
feeling
of
discomfort,
sweating,
palpitations,
hyperventilation,
head
pressure, apprehension, blurred vision,
burning sensation, bradycardia, chest pains,
headache, dizziness, heaviness in arms,
arm, back and neck pains; metallic taste
Hypersensitivity
to
amide
local
anesthetics, Stokes-Adams syndrome,
Wolff-Parkinson-White syndrome,severe
degrees
of
sinoatrial,
AV
or
intraventricular block in absence of
pacemaker, ophthalmic use
Nervousness,
dizziness,
paraesthesia,
drowsiness, tinnitus, disorientation, blurred
vision, tremor, convulsions, respiratory
depression, hypotension, bradycardia
5.4 BETA – ADRENOCEPTOR BLOCKING DRUGS
Code
05.04.01
Drug
Generic Name:
Metoprolol,
Tablet
Strength Available:
100 mg
05.04.02
Indication / Dose
Indication:
Hypertension, angina, myocardial infarction,
arrhythmias
Category:
B
Dosage:
Hypertension: Initially 100 mg to maximum 400 mg
daily, Angina: 50 mg - 100 mg in 2 - 3 times daily.
Myocardial infarction: 200 mg daily in divided
doses. Arrythmias: 50 mg - 300 mg in 2 - 3 times
daily
Generic Name:
Atenolol,
Tablet
Indication:
Hypertension, angina pectoris, myocardial
infarction and arrhythmias
Strength Available:
50 mg, 100 mg
Category:
B
Dosage:
Hypertension and arrythmias; 50 - 100 mg daily,
Angina; 100 mg daily, Myocardial infarction;
individualized
Contraindication
Adverse Effects
Hypersensitivity to metoprolol products, Lassitude, gastrointestinal and sleep pattern
bradycardia, 2nd and 3rd degree AV block disturbances; rarely, non-specific skin
overt cardiac failure, cardiogenic shock, reactions and coldness of extremities
obstructive pulmonary disease
Hypersensitivity to atenolol products, Chronic heart failure, AV block, bradycardia,
bradycardia, 2nd and 3rd degree AV block bronchospasm, dizziness, vertigo, nausea,
overt cardiac failure, cardiogenic shock, fatigue, diarrhoea
metabolic acidosis, severe peripheral
circulatory disturbances, sick sinus
syndrome
Code
05.04.03
Drug
Generic Name:
Propanolol HCL,
Tablet
Strength Available:
40 mg
Category:
B
Indication / Dose
Indication:
i) Hypertension
ii) Angina
iii) Myocardial infarct
iv) Cardiac arrhythmia
v) Portal hypertension
vi) Migraine
vii) Thyrotoxicosis
Dosage:
i) Initially 80 mg twice daily increased as required
to a usual range of 160 - 320 mg daily. CHILD: Initial
doses of 1 mg/kg in divided doses, can be
increased to 2 - 4 mg/kg/day in divided doses
ii) Initial dose of 40 mg 2 - 3 times daily.
Maintenance 120 - 240 mg daily
iii) 40 mg 4 times daily for 2 - 3 days then 80 mg
twice daily, beginning 5 - 21 days after infarction
iv) 10 - 40 mg 3 - 4 times daily
v) Initially 40 mg twice daily. The dose may be
increased as required up to 160 mg twice daily
vi) Initial prophylaxis dose: 40 mg 2 - 3 times daily.
The dose may be increased at weekly intervals up
to 160 mg daily
vii) Adjunct: 10 - 40 mg 3 - 4 times daily
CHILD: Arrythmias, thyrotoxicosis: 0.25 - 0.5 mg/kg
3 - 4 times daily as required
Contraindication
Adverse Effects
Hypersensitivity to propranolol, asthma,
bradycardia, 2nd and 3rd degree AV block,
cardiogenic shock, overt cardiac failure,
obstructive airway disease
Bronchospasm, bradycardia, depression,
nausea, vomiting, dizziness, central nervous
system effects, muscle cramps, fluid
retention, skin rashes, dry mouth
Code
05.04.04
Drug
Generic Name:
Bisoprolol Fumarate,
Tablet
Strength Available:
2.5 mg, 5 mg
Category:
B
Indication / Dose
Contraindication
Adverse Effects
Indication:
Treatment of stable moderate to severe congestive
cardiac failure in addition to ACEI's and diuretics
Hypersensitivity,
cardiac
failure,
pulmonary oedema, pregnancy, severe
asthma or severe chronic obstructive
pulmonary disease, hypotension
Arrythmia, bradycardia, chest pain,
oedema, hypotension, dizziness, headache,
fatique, diarrhoea, nausea, impotency,
cough, rhinitis
Dosage:
1.25 mg once daily to 5 - 10 mg daily
5.5 DRUGS AFFECTING THE RENIN-ANGIOTENSIN SYSTEM AND SOME OTHER
ANTIHYPERTENSIVE DRUGS
Code
05.05.01
Drug
Generic Name:
Enalapril,
Tablet
Strength Available:
5 mg, 20 mg
Category:
B
05.05.02
Generic Name:
Prazosin HCL,
Tablet
Strength Available:
1 mg, 2 mg, 5 mg
Category:
B
Indication / Dose
Indication:
i) Hypertension
ii) Congestive heart failure
Dosage:
i) Initially 5 mg daily, (ELDERLY 2.5 mg once daily),
usual maintenance dose 10 - 20 mg daily.
Maximum: 40 mg/day in 1 - 2 divided doses
ii) Initially 2.5 mg daily, usual maintenance dose 20
mg daily in 1 - 2 divided doses; maximum: 40 mg/
day
Indication:
Hypertension
Dosage:
Initially 0.5 mg 2 - 3 times daily, the initial dose on
retiring to bed at night; increased to 1 mg 2 - 3
times daily after 3 - 7 days: further increased if
necessary to maximum 20 mg daily
Contraindication
Adverse Effects
Angioedema induced by other angiotensin
converting enzyme (ACE) inhibitors.
hypersensitivity to this or any other
angiotensin converting enzyme inhibitor.
Pregnancy (second and third trimesters
particularly)
Dizziness, headache, diarrhoea, fatigue,
asthenia, cough, orthostatic hypotension,
hyperkalaemia, angioneurotic oedema
(discontinue therapy)
Hypersensitivity to prazosin products or Dizziness, orthostatic hypotension, oedema,
other quinazolines
palpitations,
urinary
incontinence,
dyspnoea, priapism, headache, lack of
energy, nausea
Code
05.05.03
Drug
Generic Name:
Captopril,
Tablet
Strength Available:
25 mg
05.05.04
Indication / Dose
Indication:
i) Hypertension
ii) Congestive heart failure
iii) Post-myocardial infarction
iv) Diabetic nephropathy
Category:
B
Dosage:
i) Initially 12.5 mg twice daily. Maintenance: 50 mg 2 - 3 times daily,
may be increased to maximum 450 mg/day
ii) Initially 6.25 - 12.5 mg 3 times daily, increase after several days to 25
- 50 mg 3 times daily
iii) Initially 6.25 mg daily, gradually increased to 37.5 mg daily in
divided doses
iv) 75 - 100 mg daily in divided doses
Generic Name:
Perindopril,
Tablet
Indication:
i) Hypertension
ii) Congestive heart failure
iii) Stable coronary artery disease
Strength Available:
4 mg
Category:
B
Dosage:
i) 4 mg as single dose, may be increased to a single 8 mg dose.
ELDERLY: Start treatment with 2 mg dose. In renal insufficiency, dose
should be adapted according to creatinine clearance
ii) Single starting oral dose of 2 mg should be increased to a single 4 mg
once BP acceptability has been demonstrated
iii) 4 mg once daily for 2 weeks, may be increased to 8 mg once daily.
ELDERLY: 2 mg once daily for 1 week, then 4 mg once daily for the
following week, may be increased up to 8 mg once daily
Contraindication
Adverse Effects
Angioedema induced by other
angiotensin converting enzyme
(ACE) inhibitors during prior
exposure. Anuric renal failure
during prior exposure to ACE
inhibitors. Hypersensitivity to
this or any other ACE inhibitor.
Pregnancy (second and third
trimester pregnancy)
Rash,
pruritus,
flushing,
angioedema, loss of taste
perception,
stomatitis,
gastrointestinal irritation and
abdominal pain, leucopenia,
cough
Angioedema induced by other
angiotensin converting enzyme
(ACE) inhibitors. Hypersensitivity
to this or any other angiotensin
converting enzyme inhibitor.
Pregnancy (second and third
trimesters particularly)
Gastrointestinal
disorders,
dizziness, headaches, mood and
or sleep disorders, asthenia, taste
disorder, cramps, localized skin
rashes, dry cough, angioneurotic
oedema
5.6 NITRATES, CALCIUM-CHANNEL BLOCKERS, AND POTASSIUM-CHANNEL ACTIVATORS
Code
05.06.01
Drug
Generic Name:
Diltiazem HCL,
Tablet
Strength Available:
30 mg
Category:
B
05.06.02
Indication / Dose
Indication:
Treatment of angina pectoris in the following cases;
i) inadequate response or intolerance to beta-blockers
and Isosorbide Dinitrate
ii) contraindication to beta-blockers
iii) coronary artery spasm
Contraindication
Adverse Effects
Acute
myocardial
infarction
with Headache,
dizziness,
peripheral
pulmonary congestion, atrial fibrillation or oedema, gingival hyperplasia, AV block,
flutter (IV dose forms): i) Accessory bypass bradycardia
tract
(Wolff-Parkinson-White,
LownGanong-Levine) ii) Short PR syndromes.
Hypersensitivity to this or other calcium
channel blocker
Dosage:
60 mg 3 times daily (elderly initially twice daily);
increased if necessary to 360 mg daily
Generic Name:
Felodipine,
Tablet
Indication:
Hypertension
Strength Available:
5 mg
Dosage:
Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once
daily in the morning
Hypersensitivity to felodipine or other
calcium channel blockers, symptomatic
hypotension, peripheral vascular disease,
persistent
dermatologic
reactions,
cardiovascular arterial disease and
congestive haeart failure
Flushing,
headache,
palpitations,
dizziness, fatigue. Ankle swelling
(appears to be dose-related). Mild
gingival hyperplasia
For sublingual:Severe anaemia, early
myocardial
infarction,
increased
intracranial
pressure,
symptomatic
hypotension, hypersensitivity to organic
nitrates
Flushing, dizziness,throbbing headache,
vomiting,
restlessness,
blurred
vision,tachycardia,bradycardia
,
hypotension (which can be severe),
syncope,
and
cyanosis
rarely),methaemoglobinaemia,
respiratory impairment
Category:
A / KK
05.06.03
Generic Name:
Glyceryl Trinitrate,
Tablet
Strength Available:
0.5 mg
Category:
B
Indication:
Prophylaxis and treatment of angina and left
ventricular failure
Dosage:
0.5-1 mg sublingually
Code
05.06.04
Drug
Generic Name:
Nifedipine,
Tablet
Strength Available:
10 mg
Category:
B
05.06.05
Indication / Dose
Indication:
Hypertension
Dosage:
Initial dose of 10 mg twice daily. Usual range 10 30 mg 3 times daily. Maximum: 120 - 180 mg per
day
Generic Name:
Amlodipine,
Tablet
Indication:
Hypertension
Strength Available:
5 mg, 10 mg
Dosage:
5 mg once daily. Max: 10 mg
Contraindication
Adverse Effects
Hypersensitivity
to
nifedipine, Peripheral oedema, headache, dizziness,
symptomatic hypotension, persistent tachycardia
dermatologic reactions, chronic heart
failure
Hypersensitivity
to
amlodipine, Headache, dizziness, gingival hyperplasia,
symptomatic hypotension, persistent tachycardia, peripheral oedema
dermatologic reactions, congestive heart
failure
Category:
B
05.06.06
Generic Name:
Isosorbide Dinitrate,
Tablet
Strength Available:
10 mg
Category:
B
Indication:
Prophylaxis and treatment for;
i) Angina
ii) Left ventricular failure
Dosage:
i) 30 - 120 mg daily in divided doses
ii) 40 - 160 mg, up to 240 mg if required; in acute
episodes: 5 - 10 mg by sublingually
Hypersensitivity to organic nitrates, GI disturbances, headache, hypotension,
anaemia, symptomatic hypotension
tachycardia
5.7 SYMPATHOMIMETICS
Code
05.07.01
Drug
Generic Name:
Adrenaline Acid
(Epinephrine)
Tartrate,
Injection
Strength Available:
1 mg/ml
Indication / Dose
Indication:
Cardiopulmonary resuscitation
Dosage:
1 mg by intravenous injection repeated every 3-5
minutes according to response
Category:
B
05.07.02
Generic Name:
Ephedrine HCl,
Injection
Strength Available:
30 mg/ml
Category:
B
Indication:
Treatment of bronchial spasm in asthma, adjunct to
correct haemodynamic imbalances and treat
hypotension in epidural and spinal anaesthesia
Dosage:
By IM, SC or IV. Severe, acute bronchospasm : 12.525 mg. Further dosage should be determine by
patient response. When used as a pressor agent :
ADULT 25 - 50 mg SC/IM. If necessary, a second IM
dose of 50 mg or an IV dose of 25 mg may be given.
Direct IV injection, 10 - 25 mg may be given slowly.
Maximum parenteral ADULT dose : 150 mg in 24
hours. CHILD : 3 mg/kg or 100 mg/m2 SC or IV daily,
in 4 - 6 divided doses
Contraindication
Adverse Effects
Cardiac
dilatation,
coronary Hypertension, arrhythmias, nausea, vomiting,
insufficiency. Within 2 weeks of MAOI headache, shortness of breath, sneezing
use.Organic brain damage, narrow-angle
glaucoma. Shock. Concurrent use with
local anesthetics for injection of certain
areas (eg; fingers, toes, ears); increased
risk of vasoconstriction and sloughing of
tissue. oncurrent use with cyclopropane
or
halogenated
hydrocarbon
anaesthetics; may produce fatal
ventricular arrhythmias. Labor; may
delay the second stage
Anaesthesia with cyclopropane or
halothane, diabetes (for ephedrine
injection). Hypersensitivity to ephedrine
or other sympathomimetic amines.
Hypertension or other cardiovascular
disorders, obstetrical procedures with
maternal blood pressure, lactation
Nervousness, anxiety, apprehension, fear,
tension, agitation, excitation, restlessness,
weakness, irritability, insomnia, dizziness,
lightheadness, vertigo, confusion, delirium,
hallucinations
or
euphoria.
Throbbing
headache, respiratory difficulty, fever or a
feeling of warmth, pallor, dryness of the nose
and throat, precordial pain, sweating, mild
epigastric distress, anorexia, nausea or
vomiting. Acute urinary retention or difficulty in
urination. May initially decrease urine
formation. Palpitation and tachycardia.
Extrasystoles and potentially fatal arrhythmias
including ventricular fibrillation especially in
patients with organic heart disease
Code
05.07.03
Drug
Generic Name:
Noradrenaline Acid
Tartrate
(Norepinephrine
Bitartrate),
Injection
Strength Available:
1 mg/ml
Category:
A
Indication / Dose
Indication:
Septic shock and shock where peripheral vascular
resistance is low
Dosage:
Infuse and titrate to desired pressure response.
Range: 0.05 - 0.5 mcg/kg/minute
Contraindication
Blood volume deficit
Adverse Effects
Peripheral
vascular
thrombosis,
concomitant cyclopropane and halothane
anaesthesia,
profound
hypoxia.
Coadministration with MOAIs or tricyclic
antidepressants. Sulfite allergy (seen more
frequently in asthmatic than nonasthmatic
patients)
5.8 ANTICOAGULANT AND PROTAMINE
Code
05.08.01
Drug
Indication / Dose
Generic Name:
Warfarin,
Tablet
Indication:
Treatment and prophylaxis of thromboembolic disorders
Strength Available:
1 mg, 2 mg, 3 mg,
5 mg
Dosage:
Initially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR
(taken at the same time each day)
Category:
B
05.08.02
Generic Name:
Heparin Sodium in
Sodium Chloride,
Injection
Strength Available:
50 units/5 ml
Category:
B
Indication:
To maintain patency of peripheral venous catheters
Dosage:
Flush with 5 ml (50 units) every 4 hours or as required
Contraindication
Adverse Effects
Haemorrhagic
tendencies,
pregnancy, blood dyscrasias,
hypersensitivity to warfarin
products
Haemorrhage,
alopecia,
fever,
gastrointestinal
disorders,
hypersensitivity
reactions, `purple toes'.
Occasionally skin necrosis
(obese elderly patients),
jaundice,
hepatic
dysfunction,
nausea,
vomiting, pancreatitis
Hypersensitivity in patients Haemorrhage,
cutaneous
who are actively bleeding or necrosis, thrombocytopenia,
have blood dyscrasias, in anaphylaxis, hyperkalaemia
patients with haemophilia or
other blood disorders and in
cases where sufficient blood
coagulation tests are not
available
5.9 ANTIPLATELET DRUGS
Code
Drug
05.09.01
Generic Name:
Acetylsalicylic Acid 100
mg, Glycine 45 mg,
Tablet (Cardiprin)
Strength Available:
100 mg
Indication / Dose
Indication:
Prevention of myocardial infarct, stroke, vascular
occlusion and deep vein thrombosis. Transient
ischaemic attacks
Contraindication
Adverse Effects
Bleeding disorders. Hypersensitivity to Nausea, vomiting, dyspepsia, GI ulceration,
salicylate
haematemesis,
malaena.
Occasionally
hepatotoxicity
Dosage:
1 tablet daily
Category:
B
05.09.02
Generic Name:
TIclopidine HCL,
Tablet
Strength Available:
250 mg
Category:
A / KK
Indication:
i) Prevention of thrombotic stroke for patients who
are sensitive /intolerant to Acetysalicylic Acid
ii) Maintenance of coronary bypass surgery or
angioplasty
iii) Maintenance of patency of access in patients on
chronic haemodialysis
Dosage:
250 mg twice daily taken with food
Hypersensitivity to ticlopidine or its Minor gastrointestinal disorders. Rarely
components, patients with active bleeding cutaneous
allergic
manifestations,
disorders.
Neutropenia
or thrombocytopenia, cholestatic icterus and
thrombocytopenia,
severe
liver or rise in transaminases. Neutropenia and
impairment
thrombocytopenia (monitor full blood
count weekly initially)
5.10 ANTIFIBRINOLYTIC DRUGS AND HAEMOSTATICS
Code
05.10.01
Drug
Indication / Dose
Generic Name:
Tranexamic Acid,
Capsule
Indication:
Haemorrhage associated with excessive fibrinolysis
Strength Available:
250 mg
Dosage:
ADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily.
CHILD: 25 mg/kg/day 2-3 times daily. Menorrhagia
(initiated when menstruation has started), 1 g 3
times daily for up to 4 days; maximum 4 g daily
Category:
B
Contraindication
Adverse Effects
Severe renal impairment, thromboembolic Nausea, vomiting, diarrhoea, hypotension,
disease, intravascular clotting process, thrombosis, disturbances in colour vision
disturbance of colour vision and
subarachnoid haemorrhage
5.11 LIPID REGULATING DRUGS
Code
05.11.01
Drug
Generic Name:
Gemfibrozil,
Capsule
Strength Available:
300 mg
Category:
A /KK
05.11.02
Generic Name:
Simvastatin,
Tablet
Strength Available:
10 mg, 20 mg, 40 mg
Category:
B
Indication & Dose
Contraindication
Adverse Effects
Indication:
Hypersensitivity to gemfibrozil, severe Dizziness, chest pain, fatigue, rash, pruritis,
Treatment of hyperlipoprotinaemias (TYPES IIA, IIB, hepatic or renal dysfunction, gall stones, dermatitis, urticaria, pain in extremities,
neonates, children, pregnancy, lactation
abdominal and epigastric pain, diarrhoea,
III, IV, V)
vomiting, flatulence, gout, headache,
Dosage:
paraesthesia, blurred vision. Myalgia,
ADULT: 1200 mg/day in 2 divided doses, 30
rhabdomyolysis
especially
when
minutes before breakfast and dinner. Dose range
coadministered with a statin
from 0.9-1.5 g daily
Indication:
Hypercholesterolaemia and coronary heart disease
intolerant or not responsive to other forms of
therapy
Dosage:
10 - 20 mg once daily. Maximum: 80 mg daily
Hypersensitivity to simvastatin products, Abdominal pain, flatulence, constipation,
active liver disease, pregnancy and asthenia and headache, rarely hepatitis,
lactation
hypersensitivity
syndrome,
upper
respiratory infection
5.12 MISCELLANEOUS CARDIOVASCULAR
Code
05.12.01
Drug
Generic Name:
Trimetazidine,
Tablet
Strength Available:
20 mg
Category:
B
Indication / Dose
Indication:
Prophylactic treatment of episodes of angina
pectoris
Dosage:
20 mg 3 times daily
Contraindication
Concomitant administration with MAOIs
Adverse Effects
Gastrointestinal disorders such as nausea
and vomiting
6.DERMATOLOGY
6.1 Emollient and Barrier Preparation
6.2 Topical Local Anaesthetics and Antipruritics
6.3 Topical Corticosteroids
6.4 Preparations for Eczema and Psoriasis
6.5 Sunscreens and Camouflagers
6.6 Shampoo and Other Preparations For
Scalp Conditions
6.7 Anti-Infective Skin Preparations
6.8 Disinfectants, Skin Cleansers and Antiseptics
6.9 Miscellaneous Dermatology
6.1 EMOLLIENT AND BARRIER PREPARATION
Code
06.01.01
Drug
Indication & Dosage
Generic Name:
Aqueous,
Cream
Indication:
Dry skin
Strength Available:
30 gm & 100 gm
Dosage:
As a soap or apply to the skin as an emollient
cream
Contraindication
Adverse Effects
Not known
Not known
Not known
Rash or irritation
Hypersensitivity to any component
Hypersensitivity to any component
Category:
C
06.01.02
Generic Name:
Calamine,
Cream
Indication:
Prickly heat or insect bites
Strength Available:
25 gm
Dosage:
Apply to the affected area as required, 1-3 times
daily
Category:
C
06.01.03
Generic Name:
Paraffin Yellow Soft,
Cream (Vaseline®)
Indication:
Xerosis and ichthyosis
Strength Available:
30 gm
Dosage:
Apply to the affected area
Category:
C
6.2 TOPICAL LOCAL ANAESTHETICS & ANTIPRURITICS
Code
06.02.01
Drug
Indication & Dosage
Generic Name:
Calamine,
Lotion
Indication:
Prickly heat or insect bites
Strength Available:
120 ml
Dosage:
Apply to the skin as required and allow to dry, 1-3
times daily
Contraindication
Adverse Effects
Not known
Rash or irritation
Children less than 2 year. Hypersensitivity
to manizole products
Ocassional skin irritation or sensitivity,
contact dermatitis, vaginal burning due to
cream base
Category:
C
06.02.02
Generic Name:
Miconazole,
Cream
Strength Available:
2 % in 15 gm
Category:
B
Indication:
i) Fungal infections: Tinea pedis, Tinea corporis,
Tinea capitis and other dermatophyte infections
caused by Trichophyton and Epidermophyton
species
ii) Antifungal agent that has been in various
candida infections including vaginal candidiasis
Dosage:
Apply sparingly and rub gently onto affected area 1
-2 times daily continuing for 14 days after lesions
have healed
6.3 TOPICAL CORTICOSTEROIDS
Code
06.03.01
Drug
Indication:
Eczemas, prurigo nodularis, psoriasis (excluding
widespread plaque psoriasis)
Strength Available:
0.1 % (1:4) in 15 gm
Dosage:
Apply sparingly to affected area 2 - 3 times daily
then reduced to once daily when improvement
occurs
Category:
A
06.03.02
Indication & Dosage
Generic Name:
Betamethasone 17Valerate,
Cream
Generic Name:
Hydrocortisone,
Cream
Strength Available:
1 % in 15 gm
Category:
B
Indication:
Inflammatory and pruritic manifestations of
corticosteroid responsive dermatoses
Dosage:
Apply sparingly to affected area 2 - 3 times daily
until condition improve, then reduce frequency
Contraindication
Adverse Effects
Viral diseases, bacteria and fungal Local skin atrophy, striae, systemic
infection, acne, rosacea and perioral hypercorticism, folliculitis, hypertrichosis,
dermatitis.
Hypersensitivity
to acneiform eruptions, hypopigmentation
betamethasone products
and allergic contact dermatitis
Fungal
and
bacterial
infections, Local atrophic skin changes, impaired skin
tuberculosis of the skin, viral disease of healing
the skin, acne vulgaris, rosacea, perioral
dermatitis.
Hypersensitivity
to
hydrocortisone
6.4 PREPARATIONS FOR ECZEMA AND PSORIASIS
Code
06.04.01
Drug
Generic Name:
Salicylic Acid,
Cream
Strength Available:
2 % in 30 gm
Indication & Dosage
Indication:
Seborrhoeic dermatitis, scalp psoriasis and
hyperkeratotic skin conditions
Contraindication
Adverse Effects
Hypersensitivity to salicylic acid. Age less Local irritation
than 2 years, diabetes with impaired
circulation
Dosage:
Apply sparingly to the affected area 2-3 times daily
Category:
C
06.04.02
Generic Name:
Zinc Oxide,
Cream
Strength Available:
15 gm
Category:
C
Indication:
Skin protective in various skin conditions such as
nappy rash, eczema and problem skin
Dosage:
Apply 3 times daily or as required
Weeping dermatoses
Hypersensitivity to any component
6.5 SUNSCREENS & CAMOUFLAGERS
Code
06.05.01
Drug
Generic Name:
Salicylic Acid, Lactic Acid &
Oxypolyethoxydodicane,
Solution (Duofilm®)
Strength Available:
10 ml
Indication & Dosage
Indication:
Hardened skin, corns, callosities and warts
Contraindication
Adverse Effects
Hypersensitivity use in children less Local irritation
than 2 years, diabetes impaired
circulation
Dosage:
One drop to be applied to the affected area twice
daily
Category:
A / KK
6.6 SHAMPOOS AND OTHER PREPARATIONS FOR SCALP CONDITIONS
Code
06.06.01
Drug
Indication & Dosage
Generic Name:
Selenium Sulphide,
Shampoo
Indication:
Dandruff, seborrheic dermatitis of scalp
Strength Available:
2.5 % in 120 ml
Dosage:
Dandruff: apply 5-10 mL topically twice weekly for
2 weeks, then 1-4 times per month, as needed,
leave on for 2-3 min, then rinse thoroughly.
Seborrheic dermatitis of scalp: apply 5-10 mL
topically twice weekly for 2 weeks, then 1-4 times
per month, as needed, leave on for 2-3 min, then
rinse thoroughly
Category:
A / KK
Contraindication
Adverse Effects
Acute inflammation or exudation, Oiliness or dryness of hair and scalp,
broken skin, hypersensitivity to drug
hair
discoloration,
cutaneous
sensitization and alopecia
6.7 ANTI-INFECTIVE SKIN PREPARATIONS
Code
Drug
06.07.01
Generic Name:
Benzoic Acid
Compound, Ointment
(Ung Whitfields)
Strength Available:
30 gm
Indication & Dosage
Indication:
Tinea infections of thickened skin of palms and soles
Contraindication
Adverse Effects
Hypersensitivity, use in children less Local irritation
than 2 years, diabetes impaired
circulation
Dosage:
Apply sparingly to affected area once or twice daily
Category:
C
06.07.02
Generic Name:
Benzyl Benzoate,
Emulsion
Indication:
Scabies and pediculosis
Strength Available:
25 % in 60 ml
Dosage:
After bath, apply over the whole body, neck down and leave on
for 24 hours then wash off. Reapply for another 24 hours, the
first repeat application should be within 5 days of the initial
application, a third application may be required in some cases
Category:
C
06.07.03
Generic Name:
Fusidic Acid,
Cream
Strength Available:
2 % in 15 gm
Category:
A
Indication:
Skin infections caused by staphylococci, streptococci,
corynebacterium minutissumun and other sodium fusidatesensitive organisms
Dosage:
Apply to affected area 2 - 3 times daily
Hypersensitivity to benzyl benzoate
May be irritant to the skin of some
patients,
burning
sensation
especially
on
genitalia
and
excoriations occasionally rashes,
stinging and contact dermatitis,
local irritation, particularly in
children, splash contact with benzyl
benzoate may produce irritation to
the eyes and mucous membranes
Infections caused by non-susceptible Rashes, irritation,
organisms in particular Pseudomonas contact dermatitis
aeruginosa
pruritus
and
Code
06.07.04
Drug
Generic Name:
Gamma Benzene
Hexachloride,
Lotion
Strength Available:
0.1 % in 100 ml
Indication & Dosage
Indication:
Scabies
Dosage:
Apply lotion to entire body from neck down for 8
to 12 hours, then rinse
Category:
C
06.07.05
Generic Name:
Neomycin,
Cream
Indication:
Infections of the skin due to susceptible organisms
Strength Available:
0.5 % in 15 gm
Dosage:
Apply sparingly to affected area up to 3 times daily
(For short term use, 1 - 2 weeks)
Contraindication
Adverse Effects
Pregnancy and premature babies,
lactation. Avoid in patients with a history
of epilepsy (e.g. HIV, history of head
trauma or prior seizure, CNS tumor,
excessive alcohol consumption) or who
have a low body-weight, hypersensitivity
to lindane products, Norwegian (crusted)
scabies ,other skin conditions (e.g. atopic
dermatitis, psoriasis) that may increase
systemic absorption
Seizures, dermatitis, dizziness, eczema,
papular lesions, itching, Henoch- Schonlein
purpura, percutaneous absorption, atypical
leukaemia, aplastic anemia and abnormal
vision on the use of lindane cream
Hypersensitivity to neomycin or other Skin sensitization or contact dermatitis. The
aminoglycosides
sensitivity disappears when treatment is
discontinued
Category:
B
06.07.06
Generic Name:
Silver Sulfadiazine
(SSD),
Cream
Strength Available:
1 % in 15 gm
Category:
B
Indication:
Prevention and treatment of infections in severe
burns, leg ulcers where infections may prevent
healing and for the prophylaxis of infections in skin
grafting
Dosage:
Burns: Apply 3 mm thick layer twice daily with
sterile applicator. Leg ulcer: apply at least 3 times a
week
Hypersensitivity to silver or to silver
sulphadiazine. Pregnant women at or near
term (increased kernicterus). Preterm
infants or newborns during first two
months
Transient leucopenia has occurred with
topical silver, haemolytic anaemia, probable
febrile reaction, irritation, itching and
burning at the application site, argyria,
hyperpigmentation
6.8 DISINFECTANTS, SKIN CLEANSERS & ANTISEPTICS
Code
06.08.01
Drug
Generic Name:
Acriflavine,
Lotion
Strength Available:
0.1 % in 120 ml
Category:
C
06.08.02
Generic Name:
Chlorhexidine
Gluconate,
Solution
Strength Available:
5 % in 120 ml
Category:
C
06.08.03
Indication & Dosage
Indication:
Infected skin, lesions, cuts, abrasions, wounds and
burns
Contraindication
Hypersensitivity to acriflavine compound
Hypersensitivity to acriflavine compound
Hypersensitivity to any of its components
Mucosal
irritation
(discontinue
if
desquamation), parotid gland swelling,
irritation and gastrointestinal disturbances.
Inhalation of solvent vapours may give rise
to nausea, headaches and dizziness
Dosage:
Apply undiluted three times daily to the affected
part
Indication:
i) Preoperative skin disinfection
ii) Wounds or burns
iii) Emergency disinfection of instruments
Dosage:
i) 1 : 10 in 70 % Alcohol
ii) 1 : 100 Water for injection
iii) 1 : 10 in 70 % Alcohol
Generic Name:
Potassium
Permanganate,
Solution
Indication:
Hypersensitivity to any component
Cleansing and deodorising suppurative eczematous
reactions and wounds
Strength Available:
1: 10,000 in 100 ml
Dosage:
As soaks or wet dressing 1 - 3 times daily or as
required
Category:
C
Adverse Effects
Irritant to tissues and stain skin brown
Code
Drug
06.08.04
Generic Name:
Hydrogen Peroxide 20
volume,
Solution
Indication:
Skin disinfection, particularly cleansing and
deodorising wounds and ulcers
Strength Available:
100 ml
Dosage:
Hydrogen Peroxide 6% (=approx. 20 vol) shall be
dispensed. For cleansing wounds: 1.5 % to 6 %
solution apply 2-3 times daily or when nescessary.
As a mouthwash: rinse the mouth for 2-3 minutes
with 15 ml of hydrogen peroxide 6 % diluted in half
a tumblerful of warm water 2-3 times daily.
Disinfecting cleaned equipment: immersion for 30
minutes in 6 % solution. As ear drop for removal of
wax: hydrogen peroxide 6 % diluted with 3 parts of
water preferably just before use
Category:
C
06.08.05
Generic Name:
Povidone Iodine,
Solution
Strength Available:
10 % (equivalent to 1
% iodine) in 60 ml
Category:
B
Indication & Dosage
Indication:
Skin operation prior to surgery, in cleansing open
wounds, as an antiseptic for operative wounds
infections
Dosage:
To be applied undiluted in pre-operative skin
disinfection and general antisepsis
Contraindication
Adverse Effects
Should not be used in abscesses
Hypersensitivity to iodine
component of the formulation
Bleaching effect on hair, irritating burn on
the skin, mucous membrane and eye.
Continued use as a mouthwash may cause
reversible hypertrophy of the papillae of
the tongue
or
any Rash, pruritus, local oedema
6.9 MISCELLANEOUS DERMATOLOGY
Code
Drug
06.09.01
Generic Name:
Protein Free
Haemodialysate, Jelly
(Solcoseryl Gel®)
Strength Available:
10 % in 20 gm
Indication & Dosage
Indication:
Trophic lesions in patients with arterial occlusive disease and with
chronic venous insufficiency, burn injuries, impaired wound
healing, decubitus ulcers and skin ulcer caused by irradiation
Contraindication
Hypersensitivity
component
to
Adverse Effects
any Allergic skin reactions
Dosage:
Apply 3 - 5 times daily
Category:
A
06.09.02
Generic Name:
Colchicine, Tablet
Strength Available:
0.5 mg
Category:
B
Indication:
i) Acute gout and prophylaxis of recurrent gout.
ii) Leucocytoclastic Vasculitis either cutaneous or systemic
involvement, Behcet's syndrome, Urticarial vasculitis, Systemic
sclerosis, Sweet's syndrome and severe recalcitrant aphthous
stomatitis
Dosage:
i) Initial dose, 0.5-1.2 mg, then 0.5-0.6 mg every hour until relief of
pain is obtained or vomiting or diarrhoea occurs (Maximum : 8
mg). The course should not be repeated within 3 days. Prevention
of attacks during initial treatment with allopurinol or uricosuric
drugs: 0.5 mg 1-3 times daily.
ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a
maximum of 3 mg/day
Serious GI, renal, hepatic &
cardiac disorders and those with
blood dyscrasias, hypersensitivity
to colchicine, children under 2
years old, pregnancy, debilitated
patients, SC/IM administration
Bone marrow depression with
aplastic
anaemia,
peripheral
neuritis, myopathy, hair loss,
gastrointestinal
disturbances,
epigastric pain, diarrhoea, nausea,
vomiting,
myelosuppression,
abdominal
pain,
diarrhoea,
gastrointestinal
haemorrhage,
rashes, renal and hepatic damage in
excessive doses. Rarely peripheral
neuritis, myopathy, alopecia and
with chronic therapy blood disorders
like
agranulocytosis,
aplastic
anaemia
7.EAR, NOSE & OROPHARYNX
7.1 Ear Preparation
7.2 Oropharynx Preparation
7.3 Antihistamine, Hyposensitisation & Allergic Emergencies
7.1 EAR PREPARATION
Code
07.01.01
Drug
Generic Name:
Chloramphenicol,
Ear Drops
Strength Available:
5%
Category:
C
07.01.02
Generic Name:
Paradichlorobenzene, Turpentine Oil and
Chlorbutol, Ear Drops (Cerumol ®)
Strength Available:
Category:
B
07.01.03
Generic Name:
Framycetin Sulphate 0.5 %, Dexamethasone
0.05 % and Gramicidin 0.005 %, Ear Drops
(Sofradex ®)
Strength Available:
Category:
A / KK
Indication & Dose
Indication:
Acute otitis media, otitis externa with
perforation
Dosage:
Apply 2 - 3 drops into the ear 2 - 3 times
daily. Not to be used for long term
Indication:
Occlusion or partial occlusion of the
external auditory meatus by soft wax or
wax plug
Contraindication
Adverse Effects
Hypersensitivity to chloramphenicol
products,
perforated
tympanic
membrane, chronic otitis media with
perforation
Sensitivity
to
the
vehicle
propylene glycol, local irritation
with symptoms of burning,
itching,
urticaria,
transient
stinging
Otitis externa, seborrhoeic dermatitis, Not known
eczema affecting the external ear,
perforated eardrums
Dosage:
Instill 5 drops into the ears , repeat twice a
day for up 3/7
Indication:
Otitis externa
Dosage:
Apply 2 - 3 drops 3 to 4 times daily
Herpes simplex infection, viral diseases Sensitivity reactions
of cornea and conjuctiva, tuberculosis
and fungal diseases of eyes, herpetic
keratitis
7.2 OROPHARYNX PREPARATION
Code
07.02.01
Drug
Generic Name:
Thymol Compound Gargle
Strength Available:
Category:
C
07.02.02
Generic Name:
Choline Salicylate 8.7 %,
Cetylkonium Chloride 0.01 %,
Dental Gel (Oral Aid)
Strength Available:
-
Indication & Dose
Indication:
For sore throat and minor mouth
inflammation
Contraindication
Not known
Adverse Effects
Irritant to the gastric mucosa
Dosage:
To be gargled 3-4 times daily
Indication:
For relief of the pain and discomfort in mouth
ulcers and sores, infant teething and denture
irritation
Dosage:
Apply to area 4 times daily
Infants less than 4 months or in patients Not known
with a history of salicylate sensitivity.
Preparations containing aspirin should
not be given to young children during
treatment to avoid any risk of excessive
salicylate levels
Category:
B
07.02.03
Generic Name:
Chlorhexidine Gluconate,
Mouthwash
Indication:
As a gargle
Strength Available:
0.2 %
Dosage:
Rinse mouth with 10 ml for about 1 minute
twice daily
Category:
C
Patients who have previously shown a Occasionally, irritative skin reactions,
hypersensitivity
reaction
to extremely rare, generalised allergic
chlorhexidine. However, such reaction reactions
are extremely rare
7.3 ANTIHISTAMINES, HYPOSENSITISATION & ALLERGIC EMERGENCIES
Code
07.03.01
Drug
Generic Name:
Cetirizine HCl,
Tablet
Strength Available:
10 mg
Category:
A / KK
07.03.02
Generic Name:
Chlorpheniramine
Maleate,
Injection
Strength Available:
10 mg/ml
Indication & Dose
Indication:
Urticaria, allergic dermatoses (insect bites, atopic eczema),
perennial rhinitis, allergic rhinitis
Contraindication
Adverse Effects
Hypersensitivity to cetirizine or Somnolence, fatigue, headache and dry
hydroxyzine
mouth
Dosage:
ADULT and CHILD over 6 years: 10 mg daily or 5 mg twice daily.
CHILD 2-6 years: 5 mg once daily or 2.5 mg twice daily
Indication:
Allergic conditions
Hypersensitivity
chlorpheniramine
to Drowsiness, dizziness, stinging or
burning sensation at injection site,
hypotension, CNS stimulation, tinnitus,
blurred vision, irritability, lassitude
Hypersensitivity
chlorpheniramine
to Drowiness, dizziness, hypotension, CNS
stimulation, tinnitus, blurred vision,
irritability, lassitude
Dosage:
10 - 20 mg IM or SC, repeated if required. Not to exceed 40 mg
in 24 hours. 10 - 20 mg over 1 minute by slow IV
Category:
B
07.03.03
Generic Name:
Chlorpheniramine
Maleate,
Syrup
Indication:
Symptomatic treatment of allergic conditions responsive to
antihistamine
Strength Available:
2 mg/5 ml
Dosage:
CHILD 1 - 2 years : 1 mg twice daily, 2 - 5 years : 1 mg every 4 6 hours (maximum 6 mg daily), 6 - 12 years : 2 mg every 4 - 6
hours (maximum 12 mg daily)
Category:
C
Code
07.03.04
Drug
Generic Name:
Chlorpheniramine
Maleate,
Tablet
Indication:
Symptomatic treatment of allergic conditions
responsive to antihistamines
Strength Available:
4 mg
Dosage:
ADULT : 4 mg every 4 - 6 hours. Maximum 24 mg daily
CHILD 1 - 2 years : 1 mg twice daily, 2 - 5 years : 1 mg
every 4 - 6 hours (maximum 6 mg daily), 6 - 12 years :
2 mg every 4 - 6 hours (maximum 12 mg daily)
Category:
C
07.03.05
Generic Name:
Hydroxyzine HCl,
Tablet
Indication:
Allergic pruritus.
Strength Available:
25 mg
Dosage:
Initially 25 mg at night, increased if necessary up to 25
mg 3-4 times daily
ADULT and CHILD more than 10 years : 50 - 75 mg; 6 10 years: 25 - 50 mg; 1 - 5 years: 12.5 - 25 mg; to be
taken daily in divided doses
Category:
A
07.03.06
Indication & Dose
Generic Name:
Loratadine,
Tablet
Indication:
Allergic rhinitis and allergic dermatoses
Strength Available:
10 mg
Dosage:
ADULT and CHILD over 6 years: 10 mg once daily.
CHILD 2 - 6 years: 5 mg once daily
Category:
B
Contraindication
Hypersensitivity to chlorpheniramine
Pregnancy,
breastfeeding
hypersensitivity reaction
Hypersensitivity to loratadine
Adverse Effects
Drowsiness, dizziness, hypotension, CNS
stimulation, tinnitus, blurred vision,
irritability, lassitude
and Sleepiness,
drowsiness,
headache,
dizziness, weakness, depression and
irritability, dry mouth, chest tightness,
tremor, convulsions, hypersensitivity
reactions (wheezing, shortness of breath)
Headache, sedation, nervousness
Code
07.03.07
Drug
Generic Name:
Loratadine 5 mg and
Pseudoephedrine Sulphate
120 mg,
Tablet (Clarinase ®)
Indication & Dose
Indication:
For treatment of allergic rhinitis and allergic dermatoses
Dosage:
ADULT and CHILD over 12 years 1 tablet twice daily
Strength Available:
Category:
A / KK
07.03.08
Generic Name:
Bromhexine HCl,
Tablet
Strength Available:
8 mg
Category:
B
07.03.09
Generic Name:
Bromhexine HCl,
Elixir
Strength Available:
4 mg/5 ml
Category:
B
Indication:
Secretolytic therapy in acute and chronic bronchopulmonary
diseases associated with abnormal mucous secretion and
impaired mucous transport
Contraindication
Adverse Effects
Narrow-angle glaucoma, urinary
retention, severe coronary artery
disease, severe
hypertension,
concomitant therapy with MAOIs
or within 10 days of continuing
such treatment, hyperthyroidism,
hepatic and renal impairment,
hypersensitivity to loratadine or
pseudoephedrine
Headache, nervousness, dizziness,
tachycardia, rhinitis, pruritis, acne,
insomnia, fatigue, pharyngitis,
somnolence, nausea, palpitations,
tachycardia
Hypersensitivity to bomhexine
Gastrointestinal
ulceration,
pregnancy and lactation
Hypersensitivity to bromhexine
Nausea, anorexia,
abdominal
discomfort and pain, headache,
allergic reactions. Gastrointestinal
disturbance, headache, dizziness,
sweating, skin rash, transient rise
in serum transaminase
Dosage:
ADULT and CHILD more than 12 years : 8 mg 3 times daily, 6 12 years : 4 mg 3 times daily, 2 - 6 years : 4 mg 2 times daily
Indication:
Secretolytic therapy in acute and chronic bronchopulmonary
diseases associated with abnormal mucous secretion and
impaired mucous transport
Dosage:
ADULT and CHILD more than 12 years : 10 ml 3 times daily, 6
- 12 years : 5 ml 3 times daily, 2 - 6 years : 2.5 ml 3 times
daily, less than 2 years : 1.25 ml 3 times daily
Code
07.03.10
Drug
Generic Name:
Triprolidine HCl 2.5 mg and
Pseudoephedrine HCl 60 mg,
Tablet (Actifed)
Indication:
Decongestion of the upper respiratory tract in common cold,
hay fever, allergic and vasomotor rhinitis and aerotitis
Strength Available:
-
Dosage:
Drowsiness, sleep disturbances, skin rashes, dryness of nose,
mouth and throat, hypotension or hypertension, tachycardia,
anorexia, nausea, vomiting, constipation, diarrhoea, abdominal
pain, wheezing, tightness of chest, impotence, blurred vision,
urinary retention
Category:
B
07.03.11
Indication & Dose
Generic Name:
Cinnarizine,
Tablet
Indication:
Vestibular disorders
Strength Available:
25 mg
Dosage:
One tablet 3 times daily
Contraindication
Adverse Effects
Angle-closure
glaucoma, Drowsiness, sleep disturbances,
hypersensitivity to triprolidine skin rashes, dryness of nose, mouth
products, neonates
and throat, hypotension or
hypertension,
tachycardia,
anorexia,
nausea,
vomiting,
constipation, diarrhoea, abdominal
pain, wheezing, tightness of chest,
impotence, blurred vision, urinary
retention
Avoid in porphyria
Gastrointestinal
disturbances,
epigastric pain, nausea and
vomiting,
tinnitus,
lupus
erythematosus
Hypersensitivity
to
diphenhydramine or other
antihistamines of similar
chemical structure, lactation,
newborns or infants
Sedation, dizziness, coordination
problems, dry mucous membranes,
blurred vision, paradoxical CNS
stimulation,
nasal
stuffiness,
palpitation, epigastric discomfort
Category:
B
07.03.12
Generic Name:
Indication:
Diphenhydramine HCl 14 mg/5 Cough
ml and Ammonium Chloride
135 mg/5 ml Expectorant
Dosage:
(Benadryl)
ADULT : 5 - 10 ml 2 - 3 times daily
CHILD : 2.5 - 5 ml 2 - 3 times daily
Strength Available:
Category:
C
Code
07.03.13
Drug
Indication & Dose
Generic Name:
Promethazine HCl,
Syrup
Indication:
Allergic conditions
Strength Available:
5 mg/5 ml
Dosage:
CHILD 2 - 5 years: 5 - 15 mg daily, 5 - 10 years : 10 25 mg daily
Category:
B
Contraindication
Adverse Effects
Hypersensitivity
to
promethazine. Sedation, gastrointestinal disturbances,
Comatose patients, acute attack of antimuscarinic effects, muscular weakness,
asthma, children under 2 years
tinnitus, allergic reactions, blood disorders,
respiratory depression
8.ENDOCRINE
8.1 Drugs Used In Diabetes
8.2 Thyroid and Antithyroids Drugs
8.3 Corticosteroids
8.4 Miscellaneous Endocrine
8.1 DRUGS USED IN DIABETES
Code
08.01.01
Drug
Generic Name:
Acarbose,
Tablet
Strength Available:
50 mg
Category:
A / KK
Indication & Dose
Indication:
Only for treatment of:
i) Non insulin dependent diabetes mellitus
(NIDDM) when diet therapy is insufficient
ii) Non insulin dependent diabetes mellitus
(NIDDM) in combination with existing conventional
oral therapy where glycaemic control is inadequate
Contraindication
Adverse Effects
Patients less than 18 years, chronic Flatulence and bowel sounds, diarrhoea
intestinal disorders associated with and abdominal pain
distinct disturbances of digestion and
absorption, conditions which may
deteriorate as a result of increased
intestinal gas formation, pregnancy,
lactation, severe renal impairment
Dosage:
Initially 50 mg daily, increase to 3 times daily up to
100 mg 3 times daily. Max 200 mg 3 times daily
08.01.02
Generic Name:
Dextrose,
Powder
Indication:
Strength Available:
75 gm
Dosage:
Use as a diagnostic agent for diabetes
75 gm stat
Category:
B
08.01.03
Generic Name:
Glibenclamide,
Tablet
Indication:
Strength Available:
5 mg
Range: 2.5 - 15 mg daily (with or immediately after
breakfast). Initially 2.5 mg daily increasing by 2.5
mg required for metabolic control. Max: 15 mg
daily
Category:
B
Diabetes mellitus type 2
Dosage:
Do not use concentrated solutions of Thrombophlebitis, rebound hypoglycaemia,
dextrose in patients with anuria, diabetic hypokalaemia
coma and hyperglycaemia, intracranial or
intraspinal
haemorrhage,
delirium
tremens in dehydrated patients and
glucose-galactose
malabsorption
syndrome
Diabetes mellitus type 1, diabetic coma, Gastrointestinal
disturbance,
blood
severe renal or renal impairment, dyscrasia, increase appetite, weight gain,
pregnancy
skin rashes, pruritus, hypersensitivity
reaction
Code
08.01.04
Drug
Generic Name:
Gliclazide,
Tablet
Indication:
Strength Available:
80 mg
Initially 40-80 mg daily. Total daily dose may vary
from 80- 320 mg orally. A single dose should not
exceeding 160 mg when higher doses are required,
a twice daily split dosage as advised and should be
divided. Adjust dose according to patient's
individual response
Category:
B
08.01.05
Indication & Dose
Generic Name:
Insulin Recombinant
Synthetic Human short
-acting (Actrapid)
Strength Available:
100 IU/ml
Penfill: 3 ml
Vial: 10 ml
Category:
B
Diabetes mellitus type 2
Dosage:
Indication:
Insulin dependent diabetes mellitus, non insulin
dependent diabetes unresponsive to treatment to
diet or oral hypoglycaemics, hyperkalaemia to
assure proper utilisation of glucose and reduce
glucosuria in non diabetic patients receiving
parenteral nutrition
Dosage:
Dose to be individualised. The average daily insulin
requirement is between 0.5-1.0 units/kg body
weight
Contraindication
Adverse Effects
Diabetes type 1. Severe renal or hepatic Nausea,
headache,
rashes
and
insufficiency,
diabetic
ketoacidosis, gastrointestinal
disturbances.
Rarely,
diabetic
precoma.
Pregnancy
and haematological disorders
lactation. Avoid concomitant treatment
with miconazole preparation
Hypoglyacemia, insulinoma
Rare incidence of allergy and lipoatrophy
Code
08.01.06
Drug
Generic Name:
Insulin Recombinant
Synthetic Human
intermediate-acting
(Insulatard)
Strength Available:
100 IU/ml
Indication & Dose
Indication:
Contraindication
Adverse Effects
Hypoglyacemia, insulinoma
Rare incidence of allergy and lipoatrophy
Hypoglyacemia, insulinoma
Rare incidence of allergy and lipoatrophy
Insulin dependent diabetes mellitus, non insulin
dependent diabetes unresponsive to treatment to
diet or oral hypoglycaemics, hyperkalaemia to
assure proper utilisation of glucose and reduce
glucosuria in non diabetic patients receiving
parenteral nutrition
Penfill: 3 ml
Vial: 10 ml
Category:
B
08.01.07
Generic Name:
Insulin Recombinant
Synthetic Human premixed (Mixtard)
Strength Available:
100 IU/ml
Penfill: 3 ml
Category:
B
Dosage:
Dose to be individualised. The daily insulin
requirement is usually between 0.3 and 1.0 IU/kg /
day
Indication:
Insulin dependent diabetes mellitus, non insulin
dependent diabetes unresponsive to treatment to
diet or oral hypoglycaemics, hyperkalaemia to
assure proper utilisation of glucose and reduce
glucosuria in non diabetic patients receiving
parenteral nutrition
Dosage:
Dose to be individualised. The average daily insulin
requirement is between 0.5-1.0 units/kg body
weight
Code
08.01.08
Drug
Generic Name:
Metformin HCl,
Tablet
Strength Available:
500 mg
Category:
B
08.01.09
Generic Name:
Gliclazide, Modified
Release Tablet
Strength Available:
30 mg
Category:
B
Indication & Dose
Contraindication
Adverse Effects
Diabetic pre-coma, ketoacidosis, renal
impairment, chronic liver disease, cardiac
failure, hypoxaemia, history of lactic
acidosis, acute alcohol intoxication,
hypoxia
Anorexia, nausea, vomiting, diarrhoea
(usually transient), abdominal pain, metalic
taste, rarely lactic acidosis (withdraw
treatment),
decreased
vitamin-B12
absoption, erythema
Known hypersensitivity to gliclazide,
excipients and other sulphonylureas and
sulphonamides. Type 1 diabetes, diabetic
Dosage:
Initially, 30mg daily at breakfast time, may increase precoma and coma, diabetic ketoacidosis,
severe renal or hepatic insufficiency,
in successive steps to 60, 90 or 120 mg daily at 1
treatment with miconazole, pregnancy
month intervals. Max daily dose: 120 mg
and lactation.
Hypoglycemia,
gastrointestinal
disturbances, skin and subcutaneous tissue
disorders, raised liver enzymes, transient
visual
disturbances,
hematologic
disturbances.
Indication:
Diabetes mellitus
Dosage:
Initial: 500 mg orally twice daily with food.
Maintainance: titrate in 500 mg increment s
weekly, Doses up to 2000 mg daily may be divided
into 2 equal doses
Indication:
Diabetes mellitus type 2
8.2 THYROID AND ANTITHYROID DRUGS
Code
08.02.01
Drug
Indication & Dose
Generic Name:
Carbimazole,
Tablet
Indication:
Strength Available:
5 mg
ADULT: Initially 10 - 60 mg daily in divided doses.
Maintenance: 5 - 20 mg daily
Hyperthyroidism
Dosage:
Contraindication
Adverse Effects
May be given to pregnant women. Nausea, mild gastrointestinal disturbance,
Treatment should be discontinued 3 - 4 rashes, bone marrow supression
weeks before delivery. Infants should not
breast fed by mothers taking carbimazole
Category:
B
08.02.02
Generic Name:
Levothyroxine
Sodium,
Tablet
Strength Available:
100 mcg
Category:
B
Indication:
Hypothyroidism
Dosage:
ADULT: 1.7 mcg/kg/day orally in a single daily dose
(usual maintenance dose is 100 - 125 mcg/day 70
kg adult)
CHILD; 0 - 3 months: 10 - 15 mcg/kg/day; 3 - 6
months: 8 - 10 mcg/kg/day; 6 - 12 months: 6 - 8
mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12
years: 4 - 5 mcg/kg/day; more than 12 years: 2 -3
mcg/kg/day
Untreated hyperthyroidism; uncorrected Nervousness, excitability, tremor, muscle
adrenal failure; recent myocardial weakness, cramps, sweating, flushing, heat
infarction
intolerance,
headache,
insomnia,
tachycardia, palpitations, angina pectoris,
excessive
weight
loss,
menstrual
irregularities,
diarrhoea,
vomiting,
convulsions, cardiac arrhythmia, heart
failure, coma, myocardial infarction,
osteopenia, pseudotumor cerebri, seizure
8.3 CORTICOSTEROIDS
Code
08.03.01
Drug
Generic Name:
Hydrocortisone
Sodium Succinate,
Injection
Indication:
Strength Available:
100 mg
Dosage:
Category:
C
08.03.02
Indication & Dose
Generic Name:
Prednisolone,
Tablet
Strength Available:
5 mg
Category:
B
Contraindication
Adverse Effects
Hypersensitivity, systemic fungal infection
Fluid and electrolyte disturbances, muscle
weakness, peptic ulcer
Conditions responsive to systemic or local
glucocorticoid injection therapy especially in
emergencies
Initially 100 - 500 mg IV over 30 seconds to more
than 10 minutes. Dose may be repeated at
intervals of 2, 4 or 6 hours
Indication:
i) Replacement therapy for primary and secondary
adrenocortical insufficiency
ii) Adrenogenital syndrome
iii) Other therapy
Dosage:
i) 5 - 25 mg daily in divided doses
ii) 10 - 20 mg/m2 body surface daily in divided
doses
iii) ADULT: 5 - 60 mg daily.
CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 8 hours or as a single daily
Hypersensitivity
infection
and
systemic
fungal Fluid and electrolyte disturbances, muscle
weakness and peptic ulcer, osteoporosis,
abdominal distention, nausea and vomiting
8.4 MISCELLANEOUS ENDOCRINE
Code
08.04.01
Drug
Indication & Dose
Generic Name:
Bromocriptine
Mesilate,
Tablet
Indication:
Strength Available:
2.5 mg
i) Initially 1 - 1.25 mg at bedtime increased
gradually, usual dose: 7.5 mg daily in divided doses.
Max 30 mg daily
ii) 1.25 - 2.5 mg at bedtime for 3 days and may be
increased by 1.25 - 2.5 mg every 3 - 7 days up to 30
mg a day in divided doses
Category:
A / KK
i) Hypogonadism or Galactorrhoea
ii) Acromegaly
Dosage:
Contraindication
Adverse Effects
Hypersensitivity
to
bromocriptine
products, toxaemia
of
pregnancy,
hypertension in postpartum and during
puerperium
Hypotension, peripheral vasoconstriction,
dyskinesias, fatigue, nausea, vomiting,
constipation,
drowsiness,
confusion,
psychomotor excitation, hallucinations,
dyskinesias, dryness of the mouth, leg
cramps, allergic skin reactions. On
prolonged treatment, reversible pallor of
fingers and toes
9.GASTROINTESTINAL
9.1 Dyspepsia
9.2 Antispasmodics and Drugs Altering Gut Motility
9.3 Antidiarrhoeals
9.4 Local Preparations For Anal and Rectal Disorders
9.5 Laxatives
9.6 Antiemetic
9.7 Ulcer-Healing Drugs
9.8 Miscellaneous Gastrointestinal
9.1 DYSPEPSIA
Code
09.01.01
Drug
Indication & Dose
Generic Name:
Magnesium Trisilicate,
Mixture
Indication:
Heartburn, dyspepsia
Strength Available:
-
Dosage:
10-20 ml 3-4 times daily before meals
Contraindication
Adverse Effects
Acute surgical abdomen,
hypersensitivity to antacids,
hypophosphataemia
Diarrhoea, systemic alkalosis has
been reported when administered
orally with cation-exchange resins
Hypersensitivity to antacids,
hypophosphataemia
Diarrhoea
Hypersensitivity to antacids,
hypophosphataemia
Gastrointestinal cramps, flatulence,
belching, alkalosis on prolong use
Category:
C
09.01.02
Generic Name:
Magnesium Trisilicate,
Tablet
Indication:
Heartburn, dyspepsia
Strength Available:
-
Dosage:
ADULT : 1-2 tablet to be chewed up to 6 times
a day before meals
CHILD over 6 years : one tablet to be taken 3-4
times a day
Category:
C
09.01.03
Generic Name:
Sodium Bicarbonate, Magnesium
Carbonate, Tincture Cardamom
Compound, Mixture (Carminative)
Strength Available:
Category:
C
Indication:
Heartburn, for rapid relief of dyspepsia
Dosage:
ADULT : 10-20 ml 3 times daily
9.2 ANTISPASMODICS AND DRUGS ALTERING GUT MOTILITY
Code
09.02.01
Drug
Indication & Dose
Generic Name:
Hyoscine
N-Butylbromide,
Tablet
Indication:
Gastrointestinal tract and genito-urinary tract
spasm, dyskinesia of the biliary system
Strength Available:
10 mg
Dosage:
ADULT : 10-20 mg 3-4 times daily.
CHILD 6-12 years: 10 mg 3 times daily
Contraindication
Adverse Effects
Obstructive disease of the gastrointestinal
or urinary tract, narrow-angle glaucoma,
cardiac tachyarrhythmias, myasthenia
gravis, prostatic hypertrophy with urinary
retention
Xerostomia,
dyshidrosis,
tachycardia,
urinary hesistancy and retention, allergic
reactions, skin reactions, confusions,
excitement, constipation, paralytic ileus
Obstructive disease of the gastrointestinal
or urinary tract, narrow-angle glaucoma,
cardiac tachyarrhythmias, myasthenia
gravis, prostatic hypertrophy with urinary
retention, paraben allergy (multi-dose vial
for injection contains parabens)
Xerostomia,
dyshidrosis,
tachycardia,
urinary hesistancy and retention, allergic
reactions, skin reactions, confusions,
excitement, constipation, paralytic ileus,
rarely
anaphylactoid
reactions
&
anaphylactic shock
Category:
B
09.02.02
Generic Name:
Hyoscine
N-Butylbromide,
Injection
Indication:
Gastrointestinal tract and genito-urinary tract
spasm, dyskinesia of the biliary system
Strength Available:
20 mg/ml
Dosage:
ADULT : 20 - 40 mg. Max : 40 mg 6 - 8 hourly.
CHILD : 0.5 mg/kg/dose
Category:
B
9.3 ANTIDIARRHEAL
Code
09.03.01
Drug
Generic Name:
Diphenoxylate with
Atropine Sulphate,
Tablet (Lomotil)
Strength Available:
-
Indication & Dose
Indication:
Acute diarrhoea
Dosage:
ADULT initially 4 tablet followed by 2 tablet 4 times
daily until diarrhoea is controlled
Category:
B
Contraindication
Adverse Effects
Hypersensitivity
to
diphenoxylate
hydrochloride or atropine, jaundice, acute
diarrhoeal conditions like antibiotic
associated diarrhoea, pseudomembranous
enterocolitis, acute ulcerative colitis and
infective diarrhoeas. Paralytic ileus and a
ganglionosis. Not recommended for use in
children
Euphoria, paraesthesia, central nervous
system effects, anoneurotic oedema and
other allergic reactions, toxic megacolon,
paralytic ileus, gastrointestinal disturbance.
Atropine
effects:
Hyperthermia,
tachycardia, urinary retention, flushing, dry
skin and mucous membranes. At
therapeutic dose- dryness of the mouth,
difficulty in swallowing, thirst, reduce
bronchial
secretion,
mydriasis
with
cycloplegia
9.4 LOCAL PREPARATION FOR ANAL AND RECTAL DISORDER
Code
09.04.01
Drug
Generic Name:
Bismuth Subgallate
and Benzyl Benzoate,
Suppository (Anusol)
Strength Available:
Category:
C
Indication & Dose
Indication:
For relief of pruritus, burning and soreness in
patients with haemorrhoids and perianal conditions
Dosage:
Insert 1 suppository night and morning after bowel
movements; do not use for longer than 7 days
Contraindication
Hypersensitivity to any component of
preparation
Adverse Effects
Local irritation
9.5 LAXATIVES
Code
09.05.01
Drug
Generic Name:
Bisacodyl,
Tablet
Strength Available:
5 mg
Category:
C
09.05.02
Generic Name:
Bisacodyl,
Suppository
Strength Available:
10 mg
Category:
C
Indication & Dose
Indication:
i) Constipation
ii) Bowel preparation for radiological procedures
and surgery
Contraindication
Adverse Effects
Ileus, intestinal obstruction, acute Rarely,electrolyte and fluid imbalances,
abdominal conditions, rectal bleeding, abdominal discomfort, diarrhoea, rectal
appendicitis
burning, vomiting
Dosage:
i) ADULT and CHILD over 10 years: 5-10 mg
CHILD 4-10 years: 5 mg. To be taken at night for
effect on the following morning
ii) ADULT: 10-20 mg the night before procedures,
CHILD over 4 years: 5 mg the night before
procedures.
Indication:
i) Constipation
ii) Bowel preparation for radiological procedures
and surgery
Dosage:
i) ADULT and CHILD over 10 years: 10 mg
CHILD less than 10 years: 5 mg insert rectally
ii) ADULT: 10-20 mg
CHILD over 4 years: 5 mg the following morning
before procedures insert rectally
Ileus, intestinal obstruction, acute Rarely,electrolyte and fluid imbalances,
abdominal conditions, rectal bleeding, abdominal discomfort, diarrhoea, rectal
appendicitis
burning, vomiting
Code
Drug
09.05.03
Generic Name:
Glycerin 25 % and
Sodium Chloride 15 %,
Enema (Ravin Enema)
Strength Available:
-
Indication & Dose
Indication:
Constipation
Contraindication
Adverse Effects
Hypersensitivity to any component in Rectal discomfort, burning sensation
the preparation
Dosage:
1 enema as required
Category:
C
09.05.04
Generic Name:
Lactulose,
Liquid
Strength Available:
3.35 gm/5 ml
Category:
C
09.05.05
Indication:
i) Constipation
ii) Hepatic encephalopathy
Flatulence,
discomfort
cramps
and
abdominal
Nausea,
vomiting,
undiagnosed
abdominal pain, pregnancy, difficulty
swallowing,
bedridden
patients,
children less than 3 years
Anal seepage of paraffin and
consequent
anal
irritation
after
prolonged use, granulomatous reactions
caused by absorption of small quantities
of liquid paraffin, lipoid pneumonia and
interference with the absorption of fat
soluble vitamins
Dosage:
i) ADULT: 15 ml twice daily adjusted to patient's need.
CHILD: 0.5 ml/kg/dose once or twice daily
ii) 30-50 ml 3-4 times daily, dose adjusted to produce 2-3
soft stools daily
CHILD: 1 ml/kg/dose 3-4 times daily
Generic Name:
Paraffin,
Liquid
Indication:
Constipation
Strength Available:
-
Dosage:
ADULT: 10-30 ml daily at night but should not be taken
immediately before going to bed. CHILD not
recommended
Category:
C
Galactosaemia, intestinal obstruction
9.6 ANTIEMETICS
Code
09.06.01
Drug
Generic Name:
Metoclopramide HCl,
Tablet
Strength Available:
10 mg
Category:
B
09.06.02
Generic Name:
Metoclopramide HCl,
Injection
Strength Available:
10 mg/2 ml
Category:
B
Indication & Dose
Indication:
i) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux
oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting
ii) Promote bowel transit during diagnostic procedures
Dosage:
i) ADULT over 20 years: 10 mg 3 times daily
ADULT between 12 - 20 years: 5 mg 3 times daily
CHILD under 12 years: 0.12 mg/kg/dose 6 - 12 hourly
ii) Single dose 5 - 10 minutes before examination
ADULT and CHILD over 15 years: 10 - 20 mg
CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly
Indication:
i) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux
oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting
ii) Promote bowel transit during diagnostic procedures
Dosage:
i) ADULT over 20 years: 10 mg 3 times daily
ADULT between 12 - 20 years: 5 mg 3 times daily
CHILD under 12 years: 0.12 mg/kg/dose 6 - 12 hourly
ii) Single dose 5 - 10 minutes before examination
ADULT and CHILD over 15 years: 10 - 20 mg
CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly
Contraindication
Adverse Effects
Concomitant therapy with drugs
which are likely to cause
extrapyramidal reactions, epileptics,
gastrointestinal
haemorrhage,
obstruction
(mechanical),
or
perforation, hypersensitivity to
metoclopramide,
pheochromocytoma
Extrapyramidal effects (especially
in children and young adults),
hyperprolactinaemia,
tardive
dyskinesia,
drowsiness,
restlessness, anxiety, drowsiness,
fatigue, akathisia, insomnia,
depression,
neuroleptic
malignant syndrome, diarrhoea,
bronchospasm
and
cardiac
conduction abnormalitie
Concomitant therapy with drugs
which are likely to cause
extrapyramidal reactions, epileptics,
gastrointestinal
haemorrhage,
obstruction
(mechanical),
or
perforation, hypersensitivity to
metoclopramide,
pheochromocytoma
Extrapyramidal effects (especially
in children and young adults),
hyperprolactinaemia,
tardive
dyskinesia,
drowsiness,
restlessness, anxiety, drowsiness,
fatigue, akathisia, insomnia,
depression,
neuroleptic
malignant syndrome, diarrhoea,
bronchospasm
and
cardiac
conduction abnormalitie
Code
09.06.03
Drug
Generic Name:
Prochlorperazine
Mesylate,
Injection
Indication:
i) Severe nausea and vomiting
ii) Vertigo/labyrinthine disorders
Strength Available:
12.5 mg/ml
Dosage:
Deep IM injection, 12.5 mg repeated if necessary
after 6 hours and then followed by an oral dose.
Not recommended in children
Category:
B
09.06.04
Indication & Dose
Generic Name:
Prochlorperazine
Maleate,
Tablet
Indication:
i) Severe nausea and vomiting
ii) Vertigo/labyrinthine disorders
Strength Available:
5 mg
Dosage:
i) Injection IM 12.5 mg stat and repeated if
necessary after 6 hours or orally 20 mg stat
followed by 10 mg after 2 hours. Prevention: 5 - 10
mg 2 - 3 times a day. CHILD (over 10 kg only) 250
mcg/kg 2 - 3 times a day
ii) For labyrinthine disorders 5 mg 3 times daily,
gradually increased to 30 mg daily in divided doses,
then reduced after several weeks to 5 - 10 mg
daily. Not recommended in children
Category:
B
Contraindication
Adverse Effects
CNS depression or coma, bone marrow
depression,
phaeochromocytoma,
hypersensitivity
to
phenothiazines,
comatose states, cardiovascular collapse
Extrapyramidal symptoms, drowsiness,
postural hypotension, coma, neuroleptic
malignant syndrome, cholestatic jaundice,
leucopenia
and
agranulocytosis,
constipation, dry mouth, urinary retention,
liver damage and insomnia
CNS depression or coma, bone marrow
depression,
phaeochromocytoma,
hypersensitivity
to
phenothiazines,
comatose states, cardiovascular collapse
Extrapyramidal symptoms, drowsiness,
postural hypotension, coma, neuroleptic
malignant syndrome, cholestatic jaundice,
leucopenia
and
agranulocytosis,
constipation, dry mouth, urinary retention,
liver damage and insomnia
9.7 ULCER-HEALING DRUGS
Code
09.07.01
Drug
Generic Name:
Ranitidine,
Tablet
Adverse Effects
Category:
B
Dosage:
i) 150 mg twice daily (at morning and night) or 300 mg on night
for 4-8 weeks. Maintenance: 150-300 mg on night
ii) 150 mg twice daily or 300 mg on night for 8-12 weeks
iii) 150 mg daily or twice daily
iv) 150 mg and may be increased as necessary to 6 g/day
to Gastrointestinal disturbances, diarrhoea, altered liver
function tests (rarely liver damage), headache,
dizziness, rash and tiredness. Rare side-effects
include acute pancreatitis, bradycardia, AV block,
confusion, depression and hallucinations particularly
in the elderly or the very ill, hypersensitivity
reactions (including fever, arthralgia, myalgia,
anaphylaxis),
blood
disorders
(including
agranulocytosis,
leucopenia,
pancytopenia,
thrombocytopenia) and skin reactions (including
erythema multiforme and toxic epidermal
necrolysis). There have been occasional reports of
gynaecomastia and impotence
Generic Name:
Ranitidine,
Injection
Indication:
Hypersensitivity
i) Benign gastric/ duodenal ulceration, reflux oesophagitis,
ranitidine.
Zollinger Ellison Syndrome
ii) Stress ulcer prophylaxis in post-operative and high risk patients
to Gastrointestinal disturbances, diarrhoea, altered liver
function tests (rarely liver damage), headache,
dizziness, rash and tiredness. Rare side-effects
include acute pancreatitis, bradycardia, AV block,
confusion, depression and hallucinations particularly
in the elderly or the very ill, hypersensitivity
reactions (including fever, arthralgia, myalgia,
anaphylaxis),
blood
disorders
(including
agranulocytosis,
leucopenia,
pancytopenia,
thrombocytopenia) and skin reactions (including
erythema multiforme and toxic epidermal
necrolysis). There have been occasional reports of
gynaecomastia and impotence
Strength Available:
25 mg/ml
Category:
B
Indication:
i) Benign gastric and duodenal ulcer
ii) Reflux oesophagitis
iii) Non-ulcer dyspepsia
iv) Zollinger-Ellison Syndrome
Contraindication
Hypersensitivity
ranitidine.
Strength Available:
150 mg
09.07.02
Indication & Dose
Dosage:
i) ADULT: Slow IV injection of 50 mg diluted to 20 ml and given
over at least 2 minutes. May be repeated every 6-8 hours or IV
infusion at rate of 25 mg/hour for 2 hours, may be repeated at 68 hours intervals or IM.
CHILD: 1 mg/kg/dose 6-8 hourly.
ii) Initial slow IV injection of 50 mg, then continuous infusion of
125-250 mcg/kg/hour
Code
09.07.03
Drug
Generic Name:
Omeprazole,
Capsule
Strength Available:
20 mg
Category:
A
Indication & Dose
Indication:
i) Reflux oesophagitis
ii) For eradication of Helicobacter pylori infection
iii) Benign peptic ulcer not responding to
conventional therapy
iv) Zollinger-Ellison Syndrome.
Dosage:
i) 20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks
ii) 20 mg twice daily in combination with any of the
2 antibiotics (clarithromycin 500 mg twice daily,
amoxicillin 1 g twice daily or metronidazole 400 mg
twice daily) for 1 - 2 weeks
iii) 20 mg once daily for 4 - 6 weeks
iv) ADULT: 20 - 120 mg once daily adjusted
according to the patient's response.
CHILD: 0.4 - 0.8 mg/kg/day
Contraindication
Adverse Effects
Hypersensitivity to omeprazole or to any Gastrointestinal effects such as diarrhoea,
of its components
nausea and constipation, headache, cough,
upper respiratory tract infection, rash
9.8 MISCELLANEOUS GASTROINTESTINAL
Code
09.08.01
Drug
Generic Name:
Essential
Phospholipids,
Capsule
Strength Available:
-
Indication & Dose
Indication:
Nutritional supplement in liver disorders
Contraindication
Not known
Adverse Effects
Not known
Dosage:
ADULT 1-2 capsules three times daily with meals
Category:
A / KK
09.08.02
Generic Name:
Monobasic Sodium
Phosphate 48 %,
Dibasic Sodium
Phosphate 18 %
(Fleet Phospho
Soda ®)
Strength Available:
Category:
A
Indication:
Bowel cleansing prior to colonoscopy, radiological
examination or bowel surgery
Dosage:
45 ml diluted with half a glass (120 ml) of water, followed
by one full glass (240 ml) of water to be taken depending
on the time of the procedure. For morning procedure, 45
ml dilute with half glass of water should be taken at 7 am
and the second 45 ml at 7 pm on the day before the
procedure. For afternoon procedure, the first dose should
be taken at 7 pm on the day before and the second dose
at 7 am on the day of the procedure. Solid food must not
be taken during the preparation period; clear fluids or
water can be taken liberally. Not recommended for use in
children
Gastrointestinal obstruction, gastric Nausea and bloating, abdominal cramps,
retention, gastro-intestinal ulceration, vomiting
perforated bowel, congestive cardiac
failure, toxic colitis, toxic megacolon or
ileus
Code
Drug
Indication & Dose
09.08.03
Generic Name:
Sodium Biphosphate
16 % & Sodium
Phosphate 6 % Enema
(Fleet Enema ®)
Indication:
Bowel cleansing before colonic surgery,
colonoscopy or radiological examination to ensure
the bowel is free of solid contents. It is not to be
used for treatment of constipation
Strength Available:
Category:
A
09.08.04
Adverse Effects
Gastrointestinal
obstruction,
gastric Local irritation and tenesmus
retention, gastro-intestinal ulceration,
perforated bowel, congestive cardiac
failure, toxic colitis, toxic megacolon or
ileus
Dosage:
ADULT 133 ml (1 bottle) administered rectally.
CHILD more than 2 years half the adult dose
Generic Name:
Diosmin 450 mg and
Hesperidin 50 mg,
Tablet (Daflon)
Indication:
i) Haemorrhoids
ii) Chronic venous insufficiency
Strength Available:
500 mg
Dosage:
i) Acute attack: 6 tablets daily for the first 4 days,
then 4 tablets daily in 2 divided doses for 3 days
and 2 tablets thereafter. Chronic: 2 tablets daily
ii) 2 tablets daily with meals
Category:
A / KK
Contraindication
Hypersensitivity to any component of Minor
gastrointestinal
preparation
neurovegetative disorders
disturbances,
10.GENITOURINARY
10.1 Miscellaneous Genitourinary
10.1 MISCELLANEOUS GENITOURINARY
Code
Drug
10.01.01
Generic Name:
Potassium Citrate and
Citric Acid,
Mixture
Strength Available:
3 g/10 ml
Category:
C
Indication & Dosage
Indication:
For systemic or urine alkalinization
Dosage:
ADULT: 15-30 ml well diluted with water
CHILD up to 1 year: 2.5 ml 3 times daily; 1 - 5 years:
5 ml 3 times daily; 6 - 12 years: 10 ml 3 times daily.
To be taken well diluted with water, after meals
and at bedtime
Contraindication
Adverse Effects
Severe renal impairment with oliguria, Hyperkalaemia, metabolic alkalosis, nausea,
azotemia or anuria, Addison's disease, vomiting, diarrhoea, mild diuresis
adynamic episodica hereditaria, acute
dehydration,
heat cramps, severe
myocardial damage, potassium citrate in
patients with hyperkalemia, sodium
citrate for patients on sodium restriction
11.IMMUNOLOGY PRODUCTS & VACCINES
11.1 Vaccines and Antisera
11.1 VACCINES & ANTISERA
Code
11.01.01
Drug
Indication & Dosage
Generic Name:
Tetanus Toxoid,
Injection
Indication:
Immunization against tetanus infection
Strength Available:
-
Dosage:
0.5 ml at 2 months followed by second dose after 4 weeks and third dose after
another 4 weeks. Booster every 10 years
Contraindication
Adverse Effects
Hypersensitivity to any
component of the vaccine,
febrile illness or acute
infection
Local reaction, fever, headache
and malaise, brachial (cervical)
neuritis,
Guillain-Barre
syndrome, nausea, arthralgia,
anaphylaxis,
Arthus
type
urticaria
Category:
C+
11.01.02
Generic Name:
Hepatitis B Vaccine,
Injection
Indication:
Immunisation against infections caused by Hepatitis B virus
Strength Available:
-
Dosage:
ADULTS over 20 years: 10 mcg/dose
ADOLESCENT 11 - 19 years: 5 mcg/dose
NEWBORN and CHILD up to 10 years: 2.5 mcg/dose
INFANTS born to HBsAg positive mothers: 3 doses of 0.5 ml each. Second dose
to be given after 1 month and booster dose after 6 months
Category:
C+
11.01.03
Generic Name:
Typhoid Vaccine,
Injection
Indication:
Active immunization against typhoid fever in adult and child more than 2 years
Strength Available:
-
Dosage:
ADULTS over 20 years: 10 mcg/dose
ADOLESCENT 11 - 19 years: 5 mcg/dose
NEWBORN and CHILD up to 10 years: 2.5 mcg/dose
INFANTS born to HBsAg positive mothers: 3 doses of 0.5 ml each. Second dose
to be given after 1 month and booster dose after 6 months
Category:
B
Hypersensitivity to any of Fatigue,
malaise,
nausea,
the components
diarrhoea, reactions at injection
site
Acute
febrile
or
gastrointestinal
illness,
hypersensitivity to any
component of the vaccine,
immunodeficiency,
pregnancy and lactation
Redness, pain and swelling at
injection site. Fever, headache,
general aches, malaise, nausea
and itching. Very rarely, allergic
reactions
including
anaphylactoid reactions
12.NEUROLOGY
12.1 Antimigraine Drugs
12.2 Antiepileptics
12.3 Drugs For Dementia
12.4 Drugs Used in Parkinsonism
and Related Disorders
12.5 Miscellaneous Neurology
12.1 ANTIMIGRAINE DRUGS
Code
12.01.01
Drug
Indication & Dose
Generic Name:
Pizotifen,
Tablet
Indication:
Prophylactic treatment of vascular headache
Strength Available:
0.5 mg
Dose:
ADULT: 0.5 mg in the evening for first 2 days, then
0.5 mg mid-day and evening for next 2 days, then
0.5 mg 3 times daily
CHILD: Up to 1.5 mg daily in divided doses
Category:
B
Contraindication
Adverse Effects
Hypersensitivity to the drug. Children less Sedation, dizziness, dry mouth and
than 2 years. Postural giddiness
constipation. Increased appetite, sedation,
nausea, fatigue. Rarely, hypersensitivity
reactions, face oedema, rash, central
nervous system stimulation, hallucinations,
seizures, depression, drowsiness, headache,
palpitation, arrhythmias, gastrointestinal
disturbance, palpitations, blood disorders,
convulsions,
sweating,
myalgia,
paraesthesias, extrapyramidal effects, sleep
disturbances, confusion, tinnitus, tremor,
hypotension, hair loss
12.2 ANTIEPILEPTICS
Code
12.02.01
Drug
Generic Name:
Carbamazepine,
Tablet
Strength Available:
200 mg
Category:
B
12.02.02
Indication & Dose
Indication:
i) Epilepsy
ii) Trigeminal neuralgia
Adverse Effects
Hypersensitivity to carbamazepine
products or tricyclic compounds,
bone marrow suppression, porphyria.
Concomitant MAOIs, pregnancy
Rash, Stevens-Johnson Syndrome, nausea,
drowsiness, dizziness, ataxia, blood
dyscrasias, confusion, agitation, visual
disturbance, constipation or diarrhoea,
anorexia, leukopenia, blood disorders,
Syndrome of Inappropriate ADH (SIADH),
cardiac
conduction
abnormalities,
gynaecomastia. Allergic skin reactions,
leukopenia, vomiting, accommodation
disorders, diplopia, raised liver enzymes,
thrombocytopenia and hyponatraemia,
exfoliative dermatitis
Hypersensitivity to carbamazepine
products or tricyclic compounds,
bone marrow suppression, porphyria.
Concomitant MAOIs, pregnancy
Rash, Stevens-Johnson Syndrome, nausea,
drowsiness, dizziness, ataxia, blood
dyscrasias, confusion, agitation, visual
disturbance, constipation or diarrhoea,
anorexia, leukopenia, blood disorders,
Syndrome of Inappropriate ADH (SIADH),
cardiac
conduction
abnormalities,
gynaecomastia. Allergic skin reactions,
leukopenia, vomiting, accommodation
disorders, diplopia, raised liver enzymes,
thrombocytopenia and hyponatraemia,
exfoliative dermatitis
Dose:
i) ADULT: 100 - 200 mg 1 - 3 times daily increased
gradually to usual dose of 0.8 - 1.2 g daily in divided
doses.
CHILD: Up to 1 year: 100 - 200 mg daily; 1 - 5 yrs: 200 400 mg daily; 5 - 10 years: 400 - 600 mg daily; 10 - 15
years: 0.6 - 1 g daily
ii) ADULT: Initially, 100 mg once or twice daily gradually
increased as necessary. Maintenance: 400-800 mg daily
in 2-4 divided doses. Max: 1.2 g daily
Generic Name:
Carbamazepine CR,
Tablet
Indication:
Epilepsy
Strength Available:
400 mg
Dosage:
ADULT: Initial, 200 mg twice daily for the first week, may
increase dosage by 200 mg/day at weekly intervals until
optimal response is obtained. Maximum 1.6 g/day.
CHILD: usual maximum dosage 1000 mg/day in children
12-15 years of age, 1200 mg/day in patients above 15
years of age
Category:
A
Contraindication
Code
12.02.03
Drug
Generic Name:
Lamotrigine,
Tablet
Strength Available:
50 mg, 100 mg
Category:
A
Indication / Dose
Contraindication
Adverse Effects
Indication:
Hypersensitivity to lamotrigine products, Dizziness, fatigue, headache, hypersensitivity
i) Adjunctive or monotherapy for partial seizures hepatic impairment
reactions, rashes, malaise, leukopenia,
and generalised tonic-clonic seizures not
thrombocytopenia, photosensitivity, blurred
satisfactorily controlled with other antiepileptic
vision, conjunctivitis, drowsiness, insomnia,
drugs
ataxia, nausea. Irritability, drowsiness,
ii) Prevention of mood episodes in adult 18
insomnia, tremor, nystagmus, ataxia, diplopia,
years and above with bipolar disorder,
blurred vision, gastrointestinal disturbances,
predominately by preventing depressive
arthralgia, pain including back pain. Rarely,
episodes
severe skin reactions including StevensJohnson syndrome and toxic epidermal
necrolysis
Dosage:
i) Up to 200 mg daily in single or divided dosage
ii) 25- 200 mg daily
Code
12.02.04
Drug
Generic Name:
Levetiracetam,
Tablet
Strength Available:
500 mg
Category:
A*
Indication / Dose
Indication:
i) Monotherapy therapy in the treatment of partial onset
seizures with or without secondary generalization in
patients from age 16 years of age with newly diagnosed
epilepsy
ii) Adjunctive treatment in partial onset seizures with or
without secondary generalization in adults and children
from 4 years of age with epilepsy; juvenile myoclonic
epilepsy and idiopathic generalized tonic clonic epilepsy
from 12 years of age
Dosage:
i) Monotherapy ADULTS and ADOLESCENT (from 16
years) : Starting dose: 250 mg twice daily, Increase dose
to 500 mg twice daily after 2 week. Dose can be further
increased by 250 mg twice daily every 2 week depending
upon the clinical response. Max: 1500 mg twice daily.
ii) ADULT more than 18 years and ADOLESCENT (12-17
years) more than or equal to 50 kg: Initially 500 mg twice
daily may be increased up to 1500 mg twice daily. Dose
changes can be made in 500 mg twice daily increments or
decrements 2-4 weekly.
CHILD (4-11 years) and ADOLESCENT (12-17 years) less
than 50 kg : Initially 10 mg/kg twice daily, may be
increased up to 30 mg/kg twice daily. Dose changes
should not exceed increments or decrements of 10 mg/kg
twice daily every 2 weeks.
CHILD more than or equal to 50 kg: Adult dose
Contraindication
Hypersensitivity
products
to
Adverse Effects
levetiracetam Asthenia,
somnolence,
dizziness,
anorexia, diarrhoea, nausea, dyspepsia,
rash, diplopia
Code
12.02.05
Drug
Indication / Dose
Generic Name:
Phenobarbitone,
Tablet
Indication:
Epilepsy
Strength Available:
30 mg
Dosage:
ADULT: 60 - 180 mg daily on.
CHILD: Up to 8 mg/kg daily
Contraindication
Hypersensitivity
to
products, porphyria
Adverse Effects
phenobarbital Hypersensitivity,
rash,
hypotension,
drowsiness, ataxia, respiratory depression,
dyskinesias
Category:
B
12.02.06
Generic Name:
Phenytoin Sodium,
Capsule
Indication:
Epilepsy
Strength Available:
30 mg, 100 mg
Dosage:
ADULT and CHILD more than 6 years: 300-400 mg/
day in 3 - 4 divided doses before meals. Maximum:
600 mg/day
CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses.
Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/
day
Category:
B
Hypersensitivity to phenytoin or hydantoin
products, sinus bradycardia, SA block,
second and third degree AV block and
Adams-Stokes syndrome (intravenous
phenytoin only)
Nystagmus, ataxia, lethargy, blood
dyscrasias, cardiovascular toxicity, nausea,
vomiting, headache, tremor, insomnia,
gingival
hypertrophy,
acne,
lupus
erythematosus,
Stevens-Johnson
syndrome, leukopenia, megaloblastic
anaemia, hirsutism, hepatitis. Slurred
speech, decreased coordination, mental
confusion, constipation, toxic hepatitis,
liver
damage,
hematopoietic
complications,
dermatological
manifestations, agranulocytosis, bullous
dermatosis, granulocytopenic disorder,
liver
damage,
nephrotoxicity,
pancytopenia, purpuric rash, scaling
eczema,
thrombocytopenia,
toxic
epidermal necrolysis
Code
12.02.07
Drug
Generic Name:
Phenytoin Sodium,
Injection
Indication:
Status epilepticus
Strength Available:
250 mg/5 ml
Dosage:
i) Status epilepticus: ADULT 10 - 15 mg/kg by slow IV.
Maximum 50 mg/minute. Maintenance: 100 mg orally/IV
every 6 - 8 hours. CHILD 15 - 20 mg/kg by slow IV. Maximum:
1 - 3 mg/kg/minute
ii) Neurosurgery 100 - 200 mg IM approximately at 4 hourly
interval
Category:
B
12.02.08
Indication / Dose
Generic Name:
Sodium Valproate,
Tablet
Strength Available:
200 mg
Category:
B
Indication:
Epilepsy
Dosage:
ADULT: Initially 600 mg/day in 2 - 3 divided doses, dose may
be increased by 200 mg at 3-day intervals to max 2.5 g/day.
Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day).
CHILD: More than 20 kg. Initially 400 mg/day with spaced
increases until control is achieved (usually 20-30 mg/kg/day),
dose may be increased to 35 mg/kg/day. Less than 20 kg, 20
mg/kg/day, in severe cases the dose may be increased
provided plasma concentration can be monitored
Contraindication
Adverse Effects
Hypersensitivity to phenytoin or
hydantoin
products,
sinus
bradycardia, SA block, second and
third degree AV block and AdamsStokes
syndrome
(intravenous
phenytoin only)
Nystagmus, ataxia, lethargy, blood
dyscrasias, cardiovascular toxicity,
nausea, vomiting, headache, tremor,
insomnia, gingival hypertrophy, acne,
lupus erythematosus, Stevens-Johnson
syndrome, leukopenia, megaloblastic
anaemia, hirsutism, hepatitis. Slurred
speech,
decreased
coordination,
mental confusion, constipation, toxic
hepatitis, liver damage, hematopoietic
complications,
dermatological
manifestations,
agranulocytosis,
bullous dermatosis, granulocytopenic
disorder, liver damage, nephrotoxicity,
pancytopenia, purpuric rash, scaling
eczema, thrombocytopenia, toxic
epidermal necrolysis
Hepatic disease or significant hepatic
dysfunction, hypersensitivity to
valproate sodium, valproic acid or
divalproex sodium, porphyria
Nausea, vomiting, headache, dizziness,
ataxia, tremor, weight gain, transient
hair loss, oedema, thrombocytopenia,
leukopenia.
Liver
dysfunction,
gastrointestinal disorders
Code
12.02.09
Drug
Indication:
Epilepsy
Strength Available:
200 mg/5 ml
Dosage:
CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until
control is achieved (usually 20-30 mg/kg/day), dose may be increased to
35 mg/kg/day. Less than 20 kg, 20 mg/kg/day. Severe cases: 50 mg/kg
daily
Category:
B
12.02.10
Indication / Dose
Generic Name:
Sodium Valproate,
Syrup
Generic Name:
Valproic Acid and
Sodium Valproate
(ER), Tablet
(Epilim Chrono ®)
Strength Available:
500 mg
Category:
B
Indication:
i) In the treatment of generalized or partial epilepsy, particularly with
the following patterns of seizures:absence, myoclonic, tonic-clonic,
atonic-mixed as well as, for partial epilepsy:simple or complex seizures,
secondary generalized seizures, specific syndrome (West, LennoxGastatut)
ii) Treatment and prevention of mania associated with bipolar disorders
Dosage:
i) ADULTS: Dosage should start at 500 mg daily increasing by 200 mg at
three-day intervals until control is achieved. This is generally within the
dosage range 1000 mg to 2000 mg per day
CHILD: > 20 kg: 500 mg/day (irrespective of weight) with spaced
increases until control is achieved
ii) ADULTS: Intial dose of 1000 mg/day, to be increase rapidly as possible
to achieve lowest therapeutic dose, which produce desired clinical
effects. Recommend initial dose is 1000 mg & 2000 mg daily. Max dose
3000 mg daily
Contraindication
Adverse Effects
Hepatic disease or significant
hepatic
dysfunction,
hypersensitivity to valproate
sodium, valproic acid or
divalproex sodium, porphyria
Nausea, vomiting, headache,
dizziness, ataxia, tremor, weight
gain, transient hair loss, oedema,
thrombocytopenia (dose related),
leukopenia.
Gastrointestinal
disorders, liver failure, children
under the age of two years are at
increased risk, pancreatitis
Hepatic disease or significant
hepatic
dysfunction,
hypersensitivity to divalproex
sodium , urea cycle disorders
Gastrointestinal: abdominal pain,
diarrhea, indigestion, loss of
appetite,
nausea,
vomiting
asthenia,
dizziness,
feeling
nervous, headache, insomnia,
somnolence, tremor , amblyopia,
blurred vision, diplopia, infectious
disease, influenza, palpitations,
tachycardia, hyperammonemia,
Pancreatitis , thrombocytopenia,
Liver
failure
,
Immune
hypersensitivity reaction (rare),
hyperammonemic
encephalopathy,
ototoxicity,
deafness
Code
12.02.11
Drug
Generic Name:
Clonazepam,
Tablet
Strength Available:
2 mg
Category:
B
Indication / Dose
Indication:
i) Epilepsy
ii) Non-epileptic myoclonus
Dosage:
i) ADULT: Initially, 1 mg given at night for 4 nights,
gradually increased over 2-4 week. Elderly: 500
mcg. Maintenance: 4-8 mg daily. Maximum
dosage: 20 mg/day
CHILD: 5-12 years: Initially, 0.5 mg daily; 1-5 years:
0.25 mg daily. Maintenance (given in 2-4 divided
doses): 5-12 years: 3-6 mg daily; 1-5 years: 1-3 mg
daily; infants: 0.5-1 mg daily. Maximum 200 mcg/
kg/day
ii) ADULT: Initially, 250 mcg twice daily, increased
after 3 days up to 1 mg daily. Max: 4 mg daily
Contraindication
Adverse Effects
Hypersensitivity to clonazepam products
and benzodiazepines, severe liver disease,
narrow angle glaucoma, respiratory
depression, acute pulmonary insufficiency
Drowsiness, ataxia, aggravation of seizure,
fatigue, dizziness. Tiredness, sleepiness,
lassitude, muscular hypotonia, muscle
weakness, light-headedness, ataxia, slowed
reaction, poor concentration, restlessness,
confusion, agitation, excitability, irritability,
disorientation,
anterograde
amnesia,
depression. Increased production of saliva
or bronchial secretions in infants and young
children,
coordination
disturbances,
vertigo, anorexia, visual disturbances, libido
changes
12.3 DRUGS FOR DEMENTIA
Code
12.03.01
Drug
Generic Name:
Donepezil HCl,
Tablet
Strength Available:
5 mg, 10 mg
Category:
A
12.03.02
Indication & Dose
Contraindication
Adverse Effects
Indication:
Treatment of mild to moderate dementia in Alzheimer's disease, as well as
in patients with severe Alzheimer's disease. (psychiatrists and neurologists
only)
Hypersensitivity
to
donepezil hydrochloride
and
piperidine
derivatives.
Pregnancy
and lactation
Diarrhoea, muscle cramps, nausea,
vomiting,
insomnia,
fatigue,
dizziness, hallucination, agitation,
loss of appetite
Hypersensitivity
to
rivastigmine,
other
carbamate
derivatives
and other components of
the product
Vomiting,
nausea,
anorexia,
decreased
appetite,
anxiety,
depression, insomnia, dizziness,
headache, diarrhoea, dyspepsia,
abdominal pain, application site
reaction
Hypersensitivuty to either
memantine hydrochloride
or any components of the
tablet, renal impairment
(CrCl
<50
mL/min),
current or history of
seizures
Hypertension,
constipation,
dizziness, somnolence, headache,
pain, Stevens-Johnson syndrome,
deep venous thrombosis, hepatitis,
liver failure, cerebral infarction,
cerebrovascular accident, grand mal
seizure, intracranial hemorrhage,
seizure, transient ischemic attack,
acute renal failure, neuroleptic
malignant syndrome
Dose:
5 - 10 mg once daily at bedtime. Maximum 10 mg daily
Generic Name:
Rivastigmine
Transdermal,
Patch
Indication:
Mild to moderately severe dementia associated with Alzheimer's or
Parkinson's disease
Strength Available:
4.6 mg/24 hr,
9.5 mg/24 hr
Dosage:
Initial, 4.6 mg/24 hr patch TOPICALLY once daily; after a minimum of 4
weeks and good tolerability, increase the dose to 9.5 mg/24 hr patch once
daily
Category:
A*
12.03.03
Generic Name:
Memantine HCI,
Tablet
Strength Available:
10 mg, 20 mg
Category:
A*
Indication:
As monotherapy or as adjunctive therapy with cholinesterase inhibitors for
the symptomatic treatment of patients with moderate to severe
Alzheimer’s disease
Dosage:
Adult Initially 5 mg/day on the 1st week, 5 mg twice a day on the 2nd
week, then 15 mg/day (10mg in the morning and 5 mg in the evening) on
the 3rd week. From the 4th week on, continue treatment with
maintenance dose of 20 mg/day (10 mg twice a day). Max: 20 mg/day
12.4 DRUGS USED IN PARKINSONISM AND RELATED DISORDERS
Code
12.04.01
Drug
Generic Name:
Benzhexol,
Tablet
Strength Available:
2 mg
Category:
B
12.04.02
Indication & Dose
Indication:
i) Parkinson's disease
ii) Drug induced parkinsonism
iii) Dystonias
Dose:
ADULT: Initially 1 mg daily. Maintenance: 5 - 15 mg
daily in 3 - 4 divided doses
CHILD: 0.02 mg/kg/dose 8 hourly, gradually
increasing to 0.1 - 0.3 mg/kg/dose
Generic Name:
Orphenadrine,
Injection (Norflex®)
Indication:
Painful muscle spasm
Strength Available:
60 mg/2 ml
Dosage:
Initially 150 mg daily in divided doses. Max: 400 mg
daily
Category:
A
Contraindication
Adverse Effects
Children under 3 years, narrow-angle
glaucoma, closed-angle glaucoma, tardive
dyskinesias,
prostatic
enlargement,
paralytic ileus, chronic pulmonary disease,
sick sinus syndrome, thyrotoxicosis,
cardiac failure with tachycardia, lactation
Severe mental disturbances, confusion,
drowsiness, restlessness, hallucinations,
excitement, nausea and vomiting, dry
mouth, blurring of vision, constipation,
urinary retention, glaucoma
Glaucoma, prostatic hypertrophy or Nausea, vomiting, blurred vision, rarely
bladder neck obstruction, myasthenia rash or drowsiness
gravis
Code
12.04.03
Drug
Generic Name:
Levodopa 200 mg,
Benserazide 50 mg
Tablet (Madopar®)
Strength Available:
250 mg
Category:
B
12.04.04
Generic Name:
Procyclidine HCl,
Injection
Strength Available:
10 mg/2 ml
Category:
B
Indication / Dose
Indication:
Parkinson's Disease
Dosage:
Initial: 100/25 mg 1-2 times/day, increase every 34 days until therapeutic effect, optimal dosage:
400/100 mg to 800/200 mg/day divided into 4-6
doses. Dose: 200/50 mg used only when
maintenance therapy is reached and not to exceed
levodopa 1000-1200 mg/benserazide 250-300 mg
per day
Indication:
i) All forms of Parkinson's disease (idiopathic
paralysis agitants), post-encephalitis and
arteriosclerosis
ii) To control troublesome extrapyramidal
symptoms induced by neuroleptic drugs including
pseudo-parkinsonism, acute dystonic reactions and
akathisia
Dosage:
By IM injection 5 - 10 mg repeated if necessary
after 20 minutes. Maximum 20 mg daily. By IV
injection 5 - 10 mg
Contraindication
Adverse Effects
Hypersensitivity to this drug. Patient on
MAOIs therapy with decompensated
endocrine, renal or hepatic function,
cardiac disorders, psychiatric diseases or
closed-angle
glaucoma.
Pregnancy.
Patients less than 25 years. Lactation.
Combination
with
MAOIs
(except
selegiline)
Anorexia, nausea and vomiting, diarrhoea,
insomnia, agitation, cardiac arrhythmias,
postural hypotension (rarely labile
hypertension), dizziness, tachycardia,
arrhythmias, reddish discoloration of urine
and
other
body
fluid,
rarely
hypersensitivity, abnormal involuntary
movement. Lost or change of taste.
Abnormal involuntary movements. Rarely,
skin reactions, haemolytic anaemia, mild,
transient
leukopenia
and
thrombocytopenia. Agitation, anxiety,
insomnia, hallucination, delusion and
temporal disorientation in the elderly
Closed-angle glaucoma, narrow-angle
glaucoma, hypersensitivity to procyclidine
products, gastrointestinal tract or urinary
outflow
obstruction,
prostatic
hypertrophy, tardive dyskinesia in patients
on neuroleptic drugs
Excitability, dizziness, hallucinations (seen
on abuse), dry mouth, constipation,
urinary retention, agitation, restlessness,
convulsions
12.5 MISCELLANEOUS NEUROLOGY
Code
12.05.01
Drug
Generic Name:
Diazepam,
Injection
Strength Available:
10 mg/2 ml
Category:
B
Indication & Dose
Indication:
i) Status epilepticus
ii) Skeletal muscle spasm
iii) Anxiety disorders
Dose:
i) Status epilepticus, by slow IV: 5-10 every 10-15
minute (rate not more than 5 mg/min), to a total
dose of 30 mg, may repeat in 2 hour if needed.
Infants 30 days to 5 years, 0.05-0.3 mg/kg/dose
given over 2-3 minutes, every 15-30 minutes to a
total dose of 5 mg, repeat in 2-4 hours if necessary.
CHILD more than 5 years, 1 mg by slow IV, every 2-5
minutes, maximum 10 mg, repeat in 2-4 hours if
necessary
ii) Skeletal muscle spasm, by slow IV or IM, 5-10 mg
repeated if necessary in 3-4 hours. CHILD (tetanus):
30 days - 5 years, 1-2 mg IM or IV slowly every 3-4
hours as needed. 5 years and above, 5-10 mg IM or
IV slowly every 3-4 hours if needed
iii) Anxiety disorders, 2-10 mg by slow IV (not more
than 5 mg/min). Repeat if necessary every 3-4 hours
Contraindication
Adverse Effects
Respiratory depression, acute pulmonary
insufficiency, severe hepatic impairment,
acute narrow angle glaucoma, myasthenia
gravis, hypersensitivity to diazepam
products, patients less than 6 months old,
alcohol intoxication, central nervous
system depression
Drowsiness,
dizziness,
vertigo,
hallucinations, blurred vision, confusion,
muscle weakness, fatigue, incontinence or
urinary retention, constipation, rashes,
changes in libido, leukopenia and
gastrointestinal,
hypotension,
ataxia,
respiratory
depression,
sedation,
depression, headache, nausea, tremor,
withdrawal
syndrome,
neutropenia,
hepatotoxicity,
pancytopenia,
thrombocytopenia,
blood
dyscrasias,
bradycardia,
dependence/abuse.
Paradoxical reactions in children and
elderly
Code
12.05.02
Drug
Generic Name:
Diazepam,
Tablet
Contraindication
Drowsiness,
dizziness,
vertigo,
hallucinations, blurred vision, confusion,
muscle weakness, fatigue, incontinence
or urinary retention, constipation, rashes,
changes in libido, leukopenia and
gastrointestinal, hypotension, ataxia,
respiratory
depression,
sedation,
depression, headache, nausea, tremor,
withdrawal syndrome, neutropenia,
hepatotoxicity,
pancytopenia,
thrombocytopenia, blood dyscrasias,
bradycardia,
dependence/abuse.
Paradoxical reactions in children and
elderly
Generic Name:
Diazepam,
Rectal Solution
Indication:
Status epilepticus, skeletal muscle spasm
Strength Available:
5 mg
Dosage:
Status epilepticus - ADULT: 0.5 mg/kg repeated
after 12 hours if necessary
CHILD (febrile convulsions, prolonged or
recurrent): 0.5 mg/kg (maximum 10 mg), repeated
if necessary.
Not recommended for children below 2 years
Drowsiness,
dizziness,
vertigo,
hallucinations, blurred vision, confusion,
muscle weakness, fatigue, incontinence
or urinary retention, constipation, rashes,
changes in libido, leukopenia and
gastrointestinal disturbances. Paradoxical
reactions in children and elderly
Category:
B
Category:
C
Indication:
i) Muscle spasm of varied aetiology, including
tetanus
ii) Anxiety disorders
Adverse Effects
Respiratory depression, acute pulmonary
insufficiency, severe hepatic impairment,
acute narrow angle glaucoma and
untreated
open
angle
glaucoma,
myasthenia gravis, hypersensitivity to
diazepam products, patients less than 6
Dosage:
months old, alcohol intoxication and
i) ADULT: 2-10 mg 3-4 times daily
central nervous system depression.
CHILD 6 months and older: 0.12 - 0.8 mg/kg daily in
Pregnancy and lactation
divided doses, every 6-8 hours
ii) ADULT : 2 mg 3 times daily, increased in severe
anxiety to 15 - 30 mg daily in divided doses
ELDERLY (or delibitated) half adult dose
CHILD (night terrors), 1 - 5 mg at bedtime
Strength Available:
5 mg
12.05.03
Indication / Dose
Respiratory depression, acute pulmonary
insufficiency, severe hepatic impairment,
acute narrow angle glaucoma, myasthenia
gravis
13.NUTRITIONS &
BLOOD DISORDER
13.1 Fluids and Electrolytes
13.2 Minerals
13.3 Vitamins
13.4 Miscellaneous Nutrition and Blood Disorder
13.1 FLUIDS AND ELECTROLYTES
Code
13.01.01
Drug
Generic Name:
Oral Rehydration Salt
Strength Available:
Category:
C
13.01.02
Generic Name:
Potassium Chloride,
Injection
Strength Available:
1 gm/ 10 ml
(10 % w/v)
Category:
B
Indication & Dose
Indication:
Replacement of fluid and electrolytes loss in
diarrhea
Contraindication
Patients
with
hyperkalaemia
renal
Adverse Effects
failure
or Hypernatremia, nausea and vomiting
Dosage:
ADULT: 200 - 400 ml ( 1 - 2 sachets ) for every
loose motion
CHILD: 200 ml (1 sachet) for every loose motion. In
severe dehydration 100 ml/kg for 3 - 4 hours
INFANT: 1 - 1.5 times their usual feed volume (50
ml per stool for small infant)
Indication:
For the correction of severe hypokalaemia and
when sufficient potassium cannot be taken by
mouth
Dosage:
By slow IV infusion depending on the deficit or the
daily maintenance requirements. 1 g diluted in 500
ml normal saline or glucose and given slowly over 2
- 3 hours
Acute
dehydration,
heat
cramps, Nausea,
vomiting,
gastrointestinal
hyperkalaemia, renal failure and in ulceration, electrocardiogram changes
conditions in which potassium retention is
present or where additives of potassium
and chloride could be clinically
detrimental
Code
13.01.03
Drug
Generic Name:
Potassium Chloride,
Tablet
Strength Available:
600 mg
Category:
B
13.01.04
Generic Name:
Water for Injection
Strength Available:
Category:
C+
13.01.05
Generic Name:
Sodium Lactate
Compound
(Hartmanns Solution/
Ringer-lactate)
Strength Available:
Category:
C
Indication & Dose
Indication:
For the treatment and specific prevention of
hypokalaemia
Dosage:
ADULT: 2 - 3 tablets daily. Severe deficiency: 9 - 12
tablets daily or according to the needs of the
patient
Indication:
As a diluent and vehicle for the administration of
medications
Contraindication
Adverse Effects
Acute
dehydration,
heat
cramps, Nausea,
vomiting,
hyperkalaemia, renal failure and in ulceration, ECG changes
conditions in which potassium retention is
present or where additives of potassium
and chloride could be clinically
detrimental
Not known
gastrointestinal
Not known
Dosage:
According to the needs of the patient
Indication:
Replacement of extracellular losses of fluid and
electrolytes, as an alkaliniser agent
Dosage:
100-1000 ml by IV or according to the needs of the
patient
Lactic
acidosis,
severe
acidosis, Anxiety, panic attacks, apprehension or
hypernatraemia and conditions where fear, paraesthesias, tremors, dizziness,
sodium
administration
would
be metabolic alkalosis, hypokalaemia
detrimental
Code
13.01.06
Drug
Generic Name:
Sodium Chloride,
Injection
Strength Available:
0.9 % in 500 ml
Category:
C+
13.01.07
Generic Name:
Modified Fluid Gelatin,
Injection
Strength Available:
4 % in 500 ml
13.01.08
Indication & Dose
Contraindication
Adverse Effects
Indication:
For replenishing fluid and for restoring/maintaining
the concentration of sodium and chloride ions
Hypernatraemia or fluid retention,
hypersensitivity (ophthalmic products),
sodium
chloride
solutions
with
preservatives in newborns, for injection or
flushing of intravenous lines or mixing
medications,
hypertonic
saline
abortifacient in pregnancies less than 15
weeks
Nausea, vomiting, diarrhoea, abdominal
cramps,
congestive
heart
failure,
hypertension,
tachycardia,
fluid
accumulation, irritability, restlessness,
weakness,
headache,
dizziness,
obtundation and convulsions
Not known
Hypersensitivity
anaphylactoid
Dosage:
100 - 1000 ml by IV or according to the needs of
the patient
Indication :
For primary volume replacement in hypovolaemia,
peri-operative stabilization of the circulation,
haemodilution, extracorporeal circulation
(haemodialysis and heart-lung machine)
Category:
B
Dosage:
ADULT 500 - 1500 ml given as IV infusion
Generic Name:
Sodium Chloride 0.9 %
with Dextrose 5 %,
Injection
Indication:
For replenishing fluid and energy and for restoring
or maintaining the concentration of sodium and
chloride ions
Strength Available:
In 500 ml
Category:
C+
Dosage:
According to the needs of the patient
reactions,
severe
Hypernatraemia or fluid retention, Thrombophlebitis,
rebound
hypersensitivity (ophthalmic products), hypoglycaemia, hypokalaemia, sodium
sodium
chloride
solutions
with accumulation and oedema
preservatives in newborns, for injection or
flushing of intravenous lines or mixing
medications,
hypertonic
saline
abortifacient in pregnancies less than 15
weeks
Code
13.01.09
Drug
Generic Name:
Dextrose,
Injection
Strength Available:
50 % in 10 ml
Category:
B
13.01.10
Generic Name:
Sodium Bicarbonate,
Injection
Strength Available:
8.4 % 10 ml
Category:
B
Indication & Dose
Indication:
For parenteral replenishment of fluid and minimal
carbohydrate calories as required by the clinical
condition of the patient
Dose:
According to the needs of the patient
Indication:
For acceleration of excretion in drug intoxication
(where excretion of the drug into the urine is
accelerated by elevated urine pH) and for acidosis
Dose:
According to the needs of the patient. In severe
shock due to cardiac arrest ; 50 ml IV
Contraindication
Adverse Effects
Do not use concentrated solutions of Thrombophlebitis, rebound hypoglycaemia,
dextrose in patients with anuria, diabetic hypokalaemia, pulmonary embolism, right
coma, hyperglycaemia, intracranial or atrial thrombosis, extravasation
intraspinal
haemorrhage,
delirium
tremens in dehydrated patients and
glucose-galactose
malabsorption
syndrome.
Do
not
administered
simultaneously with blood through the
same infusion set because of the
possibility that pseudoagglutination of red
cells may occur
Alkalosis, hypernatraemia, hypocalcaemia, Gastroinstestinal
hypochloraemia,
severe
pulmonary alkalosis
oedema, unknown abdominal pain
cramps,
flatulence,
13.2 MINERALS
Code
13.02.01
Drug
Generic Name:
Calcium Carbonate,
Tablet
Strength Available:
500 mg
Indication & Dose
Contraindication
Adverse Effects
Indication:
To be used only for elemental calcium supplementation and
phosphate binding activity in patients with chronic renal failure
Patients with calcium renal calculi
or history of renal calculi,
hypercalcaemia,
hypophosphataemia
Gastrointestinal
irritation,
constipation,
flatulence,
gastric
hypersecretion and acid rebound,
hypercalcaemia, alkalosis and renal
dysfunction
Dosage:
Initial 2.5 g daily and increased up to 17 g daily
Category:
A / KK
13.02.02
Generic Name:
Calcium Lactate,
Tablet
Strength Available:
300 mg
Indication:
For prophylaxis of calcium deficiency and treatment of chronic
hypocalcaemia
Ventricular
fibrillation
during Mild gastrointestinal disturbances,
cardiac
resuscitation, bradycardia, arrhythmias
hypercalcaemia,
hypercalciuria,
severe renal failure
Dosage:
ADULT 1-5 g daily in divided doses
Category:
C
13.02.03
Generic Name:
Calcium Gluconate,
Injection
Strength Available:
10 %
Category:
B
Indication:
i) Acute hypocalcaemia
ii) Hypocalcaemic tetany
iii) Cardiac resuscitation
Dosage:
i) 1-2 g (2.25-4.5 mmol). CHILD 50 mg/kg
ii) ADULT 1 g (2.2 mmol) by slow IV injection followed by
continuous infusion of 4 g (8.8 mmol) daily
iii) IV or intracardiac injection, 10 ml
Hypercalcaemia,
hypercalciurea, Sloughing or necrosis of the skin, soft
severe renal failure, patients tissue calcification. Hypercalcaemia
treated with digitalis
(excessive use)
13.3 VITAMINS
Code
13.03.01
Drug
Generic Name:
Cyanocobalamin
(Vitamin B12),
Tablet
Strength Available:
50 mcg
Indication & Dose
Indication:
Vitamin B12 deficiency of dietary origin
Contraindication
Adverse Effects
Hypersensitivity to any component of Diarrhoea, urticaria, pruritus, skin rash,
cyanocobalamin or hydroxycobalamin hypokalaemia, polycythemia vera, volume
formulations
overload
Dosage:
ADULT: 50-150 mcg daily
CHILD: 50-105 mcg daily in 1-3 divided doses
Category:
B
13.03.02
Generic Name:
Cyanocobalamin
(Vitamin B12),
Injection
Strength Available:
1000 mcg/ml
Category:
B
Indication:
i) Prophylaxis of anaemia associated with Vitamin
B12 deficiency
ii) Uncomplicated pernicious anaemia or Vitamin
B12 malabsorption
Dosage:
i) Prophylaxis of anaemia: 250-1000 mcg IM every
month.
ii) Uncomplicated pernicious anaemia or Vitamin
B12 malabsorption: Initial 100 mcg daily for 5-10
days followed by 100-200 mcg monthly until
complete remission is achieved. Maintenance: 100
mcg monthly. CHILD 30-50 mcg daily for 2 or more
weeks (to a total dose of 1-5mg). Maintenance:
100 mcg monthly to sustain remission
Hypersensitivity to any component of Diarrhoea, urticaria, pruritus, skin rash,
cyanocobalamin or hydroxycobalamin hypokalaemia, polycythemia vera, volume
formulations
overload
Code
13.03.03
Drug
Generic Name:
Ascorbic Acid
(Vitamin C),
Tablet
Strength Available:
100 mg
Indication & Dose
Indication:
Vitamin C deficiency
Contraindication
Adverse Effects
History of hyperoxaluria
In
large
doses,
gastrointestinal
disturbances, renal calcium oxalate calculi
formation
Patients treated with levodopa
Anorexia, nausea or diarrhoea, skin rash
and hypersensitivity
Dosage:
ADULT: 100-250 mg once or twice daily
CHILD: 100 mg three times daily for one week
followed by 100 mg daily until symptoms abate
Category:
C+
13.03.04
Generic Name:
Vitamin B1, B6, B12,
Tablet (Neurobion)
Strength Available:
-
Indication:
For deficiency or raised requirement of Vitamin B1,
B6, B12
Dosage:
1 - 3 tablets 3 times daily swallowed unchewed
Category:
B
13.03.05
Generic Name:
Vitamin B Complex,
Tablet
Indication:
Prophylaxis and treatment of vitamin B deficiency
Strength Available:
-
Dosage:
1-2 tablets daily
Category:
C+
Allergy to cobalamins,
anaemia of pregnancy
megaloblastic Peripheral neuropathies (long term
administration of large doses of pyridoxine)
Code
13.03.06
Drug
Generic Name:
Calcitriol,
Capsule
Strength Available:
0.25 mcg
Category:
A
Indication & Dose
Indication:
Treatment of:
i) Postmenopausal osteoporosis
ii) Renal osteodystrophy in patients on
haemodialysis
iii) Hypoparathyroidism and rickets
iv) Secondary hyperparathyroidism in renal failure
Contraindication
Adverse Effects
Hypercalcaemia, vitamin D toxicity, Hypercalcaemia,
nausea,
vomiting,
abnormal sensitivity to the effects of polydipsia, polyuria, weakness, headache,
vitamin D, malabsorption syndrome
somnolence, dry mouth, constipation,
muscle pain, bone pain, metallic taste
Dosage:
i) 0.25 mcg 2 times daily
ii) Initial dose 0.25 mcg. In patients with normal or
only slightly reduced serum calcium levels, doses
of 0.25 mcg every other day is sufficient
iii) 0.25 mcg/day given in the morning
iv) ADULT and CHILD 3 years and older : Initially
0.25 mcg/ml. CHILD less than 3 years : 10 to 15 ng/
kg/day
13.03.07
Generic Name:
Multivitamin,
Tablet
Strength Available:
Category:
B
Indication:
For prevention and treatment of vitamin
deficiencies
Dosage:
1 - 2 tablets daily or based on individual
requirements
Hypersensitivity to product components
Hypervitaminosis
Code
13.03.08
Drug
Generic Name:
Pyridoxine HCL
(Vitamin B6),
Tablet
Strength Available:
10 mg
Category:
B
Indication & Dose
Indication:
i) Pyridoxine-dependent convulsions in infancy
ii) Sideroblastic anaemia
iii) B6-deficient anaemia in adult
iv) Prophylaxis to peripheral neuritis in isoniazid
therapy
v) Nausea and vomiting of pregnancy and irradiation
sickness
Contraindication
Adverse Effects
Hypersensitivity to pyridoxine or any Peripheral
sensory
neuropathy,
component of preparation
hypotonia, respiratory difficulties, nausea
and other gastrointestinal complaints,
photosensitivity, vesicular lesions and
bullous lesions
Dosage:
i) INFANT 4 mg/kg daily for short periods
ii) 100 - 400 mg daily in divided doses
iii) ADULT 20 - 50 mg up to 3 times daily
iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times
daily
v) 20 - 100 mg daily
13.03.09
Generic Name:
Thiamine
Mononitrate
(Vitamin B1),
Tablet
Strength Available:
10 mg
Category:
C
Indication:
i) For the prevention or treatment of Vitamin B1
deficiency syndromes including beri-beri and
peripheral neuritis associated with
pellagra
ii) Wernicke-Korsakoff Syndrome
Dosage:
i) Mild to chronic deficiency: 10-25 mg daily. Severe
deficiency: 200- 300 mg daily
ii) 500 mg every 8 hours for 2 days, followed by 100 mg
2 times daily until patient can take oral dose
Hypersensitivity to thiamine or any Contact dermatitis, chronic pigmented
component
purpura, skin rash, itching
Code
13.03.10
Drug
Generic Name:
Pyridoxine HCl
(Vitamin B6),
Injection
Strength Available:
50 mg/2 ml
Category:
B
Indication & Dose
Indication:
i) Pyridoxine-dependent convulsions in infancy
ii) Sideroblastic anaemia
iii) B6-deficient anaemia in adult
iv) Prophylaxis to peripheral neuritis in isoniazid
therapy
v) Nausea and vomiting of pregnancy and
irradiation sickness
Dosage:
i) INFANT: 4 mg/kg daily for short periods
ii) 100 - 400 mg daily in divided doses
iii) ADULT: 20 - 50 mg up to 3 times daily
iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3
times daily
v) 20 - 100 mg daily
Contraindication
Adverse Effects
Hypersensitivity to pyridoxine or any Peripheral sensory neuropathy, hypotonia,
component of preparation
respiratory difficulties, nausea and other
gastrointestinal
complaints,
photosensitivity, vesicular lesions and
bullous lesions
13.4 MISCELLANEOUS NUTRITION AND BLOOD DISORDER
Code
13.04.01
Drug
Generic Name:
Folic Acid,
Tablet
Strength Available:
5 mg
13.04.02
Indication & Dose
Indications:
i) For the prevention and treatment of folate
deficiency states
ii) For the prevention of neural tube defect in the
foetus
Category:
C
Dosage:
i) ADULT: initially 5 mg daily for 4 months or until
haematopoietic response obtained. Maintenance:
5 mg every 1 - 7 days depending on underlying
disease
CHILD: up to 1 year, 500 mcg/kg daily; over 1 year,
as adult dose
ii) 5 mg daily starting before pregnancy and
continued through the first trimester
Generic Name:
Ferrous Fumarate,
Tablet
Indication:
Prevention and treatment of iron-deficiency
anaemias
Strength Available:
200 mg
Category:
C
Dosage:
Prophylactic 200 mg daily. Therapeutic 200 mg 2
times daily.
CHILD: up to 6 years 80-140 mg 2 times daily
Contraindication
Pernicious,
anaemias
aplastic
or
Adverse Effects
normocytic Gastrointestinal
pruritus
disturbances,
urticaria,
Haemochromatosis, haemolytic anaemia, Abdominal cramps, nausea, vomiting,
known hypersensitivity to iron salts
diarrhoea or constipation, dark stools,
heartburn, temporary teeth staining and
discolouration of urine
14.OBSTETRIC &
GYNAECOLOGY
14.1 Treatment of Vaginal and Vulva Conditions
14.1 TREATMENT OF VAGINAL & VULVA CONDITIONS
Code
14.01.01
Drug
Indication & Dose
Generic Name:
Clotrimazole Vaginal,
Tablet
Indications:
Vaginal candidiasis
Strength Available:
500 mg
Dosage:
500 mg as a single one-time dose
Category:
B
Contraindication
Hypersensitivity to clotrimazole
Adverse Effects
Local irritation or skin reaction and mild
burning, nausea, vomiting, troches,
increased liver enzymes
15.OPHTHALMOLOGY
15.1 Anti-Infective Eye Preparations
15.2 Miscellaneous Ophthalmology
15.1 ANTI-INFECTIVE EYE PREPARATIONS
Code
15.01.01
Drug
Generic Name:
Chloramphenicol,
Eye Drops
Strength Available:
0.5 %
Indication & Dosage
Indication:
Broad spectrum antibiotic in superficial eye
infections
Contraindication
Adverse Effects
Hypersensitivity
products
to
chloramphenicol Allergic reactions, superinfection, bone
marrow hypoplasia including aplastic
anaemia
Hypersensitivity
products
to
chloramphenicol Allergic reactions, superinfection, bone
marrow hypoplasia including aplastic
anaemia
Dosage:
1 - 2 drops every 3 - 4 hours
Category:
C
15.01.02
Generic Name:
Chloramphenicol,
Eye Ointment
Indication:
Conjunctivitis and other superficial eye infection
Strength Available:
1%
Dosage:
Apply 1/2 inch of ointment every 3 - 4 times into
the conjunctival sac
Category:
C
15.2 MISCELLANEOUS OPHTHALMOLOGY
Code
15.02.01
Drug
Generic Name:
Sodium Chloride,
Eye Drops (Normal
Saline Eye Drops)
Strength Available:
0.9 %
Indication & Dosage
Indication:
Irrigation of conjunctival sac
Contraindication
Hypersensitivity
Adverse Effects
Can cause temporary burning and irritation
Dosage:
1 - 2 drops every 3 - 4 hours
Category:
C
15.02.02
Generic Name:
Artificial Tears,
Eye Drops
Strength Available:
Category:
B
Indication:
Relief of various ocular irritation syndromes ( dry
eyes) & to promote corneal wetting
Dosage:
1 - 2 drops as frequently as required
Hypersensitivity
preparation
to
component
in Rare
16.PSYCHIATRY
16.1 Hypnotics and Anxiolytics
16.2 Antipsychotics
16.3 Antidepressant Drugs
16.4 Miscellaneous Psychiatric
16.1 HYPNOTICS AND ANXIOLYTICS
Code
16.01.01
Drug
Generic Name:
Alprazolam,
Tablet (Xanax®)
Indication:
Anxiety disorders
Strength Available:
0.5 mg
Dosage:
0.25 - 0.5 mg 3 times daily (elderly or deliberated
0.25 mg 2-3 times daily), increased if necessary to a
total dose of 3 mg/day.
Not recommended for children
Category:
A
16.01.02
Indication / Dose
Generic Name:
Bromazepam,
Tablet
Indication:
Anxiety disorders
Strength Available:
3 mg
Dosage:
3 - 18 mg daily in divided doses. 6 to 30 mg daily
(single or divided doses) in anxiety-neurosis.
Children not recommended
Category:
A
Contraindication
Adverse Effects
Hypersensitivity to benzodiazepines, acute
narrow angle glaucoma, concomitant use
of ketoconazole or itraconazole, CNS
depression
Drowsiness, blurred vision, coordination
disorder, gastrointestinal disturbance,
agitation, lightheadedness, dry mouth,
depression,
headache,
confusion,
hypotension,
syncope,
tachycardia,
seizures, respiratory depression, coma,
constipation, diarrhoea, nausea, vomiting,
insomnia, nasal congestion, rigidity,
increased salivation, dermatitis, sedation
Shock, severe psychosis, pregnancy and Fatigue, muscle weakness, drowsiness,
breastfeeding
hypotension, nausea and vomiting
Code
16.01.03
Drug
Generic Name:
Lorazepam,
Tablet
Strength Available:
1 mg
Category:
A / KK
16.01.04
Indication / Dose
Indication:
i) Severe anxiety
ii) Insomnia
Dosage:
i) 1 - 4 mg increase to 10 mg daily in divided doses.
ELDERLY (or delibitated) half adult dose
ii) 1 - 2 mg at bedtime
Not recommended in children
Generic Name:
Zolpidem Tartrate,
Tablet (Stilnox®)
Indication:
For treatment of insomnia
Strength Available:
10 mg
Dosage:
10 mg initially at bedtime.
In ELDERLY, 5 mg initially
Category:
A
Contraindication
Adverse Effects
Respiratory depression, acute pulmonary
insufficiency, sleep apnoea syndrome,
severe hepatic impairment, myasthenia
gravis, phobic or obsessional states,
depression or anxiety with depression,
acute
narrow-angle
glaucoma,
hypersensitivity to benzodiazepines
Fatigue, hypotension, ataxia, respiratory
depression,
sedation,
confusion,
depression, headache, nausea, tremor,
urinary retention, vertigo, withdrawal
syndrome, bradycardia, dependence or
abuse
Obstructive
sleep
apnoea,
acute
pulmonary
insufficiency,
respiratory
depression, myasthenia gravis, severe
hepatic impairment, psychotic illness,
pregnancy, breastfeeding, hypersensitivity
Nausea, dizziness, dependence, vertigo,
headache, drowsiness, myalgias, dyspepsia,
dry mouth, lethargy, flu-like symptoms,
depression,
constipation,
ataxia,
hallucinations
16.2 ANTIPSYCHOTICS
Code
16.02.01
Drug
Generic Name:
Amisulpride,
Tablet
Strength Available:
100 mg, 400 mg
Category:
A*
16.02.02
Generic Name:
Aripiprazole,
Tablet
Strength Available:
10 mg, 15 mg
Category:
A*
Indication / Dose
Indication:
Treatment of psychoses, particularly acute or chronic schizophrenia
disorders characterized by positive symptoms(e.g. delusion,
hallucinations, thought disorders) and/or negative symptoms(e.g.
blunted emotions, emotional and social withdrawal) including when
the negative symptoms predominate
Contraindication
Adverse Effects
Hypersensitivity to amisulpride,
pheochromocytoma,
prolactinomas
and
breast
cancer, pregnancy, lactation,
children under 15 years of age
Insomnia,
anxiety,
agitation,
extrapyramidal
symptoms,
galactorrhea,
gynecomastia,
amenorrhea,
breast
pain,
impotence,
gastrointestinal
disorder, weight gain
Dosage:
Predominantly negative episodes: 50-300 mg once daily adjusted
according to the patient’s response. Mixed episodes with positive and
negative symptoms: 400-800 mg/day in 2 divided doses adjusted
according to the patient’s response. Should be taken on an empty
stomach (Preferably taken before meals)
Indication:
i) Treatment of acute episodes of schizophrenia and for maintenance
of clinical improvement during continuation therapy
ii) Treatment of acute manic episodes associated with bipolar I
disorder
Dosage:
i) Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day
ii) Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment
should occur at intervals of not less than 24 hour
Patients who are hypersensitive Insomnia, restlessness, headache,
to aripiprazole or to any of the dizziness, akathisia, somnolence,
excipients
sedation, tremor, extrapyramidal
disorder,
blurred
vision,
tachycardia,
orthostatic
hypotension, nausea, vomiting,
constipation, dyspepsia, asthenia/
fatigue, weight gain, anxiety,
diabetic ketoacidosis , neuroleptic
malignant
syndrome,
seizure,
peripheral oedema
Code
16.02.03
Drug
Generic Name:
Chlorpromazine,
Tablet
Indication:
Psychosis mania and agitation
Strength Available:
25 mg, 100 mg
Dosage:
ADULT: Initial dose - 25 mg 3 times daily
according to response up to 1 g daily
PAEDIATRIC: Up to 5 years: 0.5 mg/kg body
weight every 4 - 6 hours (Maximum 40 mg
daily)
CHILD 6 - 12 years: A third to half adult dose
(Maximum 75 mg daily)
Category:
B
16.02.04
Indication / Dose
Generic Name:
Clozapine,
Tablet
Indication:
Treatment of resistant schizophrenia
Strength Available:
25 mg, 100 mg
Dosage:
Initial dose : 12.5 mg ( once or twice ) daily,
increase slowly in steps of 25 - 50 mg up to
300 mg daily within 2 - 3 weeks. Maximum
900 mg/day
Category:
A
Contraindication
Adverse Effects
Hypersensitivity
to
chlorpromazine
products,
phenothiazines,
myelosuppression, coma, severe CNS
depression, bone marrow depression
Postural
hypotension,
akathisia,
tardive
dyskinesia,
arrhythmias,
constipation,
haematologic effects, agranulocytosis, aplastic
anaemia,
thrombocytopenia,
neuroleptic
malignant syndrome, jaundice, agitation,
insomnia, parkinsonism symptoms, drowsiness,
convulsion and tachycardia, acute dystonia,
leukopenia,
angioedema,
bronchospasm,
urticaria, hyperprolactinemia, eye, cardiac, skin &
subcutanoues tissue disorders, dry mouth,
respiratory depression, neuroleptic malignant
syndrome. Rarely agranulocytosis, priapism
Severe hepatic and renal impairment,
myeloproliferative disorders, uncontrolled
epilepsy, pregnancy, lactation, coma,
hypersensitivity to clozapine products,
myocarditis with clozapine history,
agranulocytosis with clozapine history
(except due to previous chemotherapy),
WBC less than 3500, GI/GU obstruction,
narrow angle glaucoma, CNS depression
Hyperglycemia,
agranulocytosis,
sedation,
salivation, cardiovascular effects, dizziness /
vertigo, seizures, drowsiness, confusion, blurred
vision, dry mouth, jaundice, leucopenia,
neuroleptic malignant syndrome, anticholinergic
toxicity, hepatitis, hypotension, syncope,
constipation, tremor, weight gain, tachycardia,
hypersalivation.
Eosinophilia,
ketoacidosis,
hyperosmolar coma, convulsions, ECG changes,
circulatory collapse, arrhythmias, myocarditis,
cardiomyopathy, thromboembolism, aspiration
of ingested food, intestinal obstruction, ileus,
faecal
impaction,
hepatitis,
pancreatitis,
fulminant hepatic necrosis, interstitial nephritis,
neuroleptic malignant syndrome, unexplained
sudden death
Code
16.02.05
Drug
Generic Name:
Fluphenazine
Decanoate, Injection
(Modecate®)
Strength Available:
25 mg/ml
Category:
B
16.02.06
Generic Name:
Flupenthixol
Decanoate Depot,
Injection (Fluanxol®)
Strength Available:
20 mg/ml
Category:
B
Indication / Dose
Indication:
Long term management of psychotic disorders
Dosage:
By deep IM : Test dose 12.5 mg (6.25 mg in
ELDERLY), then after 4-7 days 12.5 mg-100 mg
repeated at intervals of 14-35 days, adjusted
according to response.
CHILD not recommended
Indication:
Chronic psychoses
Dosage:
By deep IM, initial test dose of 5-20 mg, then after
at least 7 days. 20 - 40 mg repeated at intervals of
2 - 4 weeks. Maximum 400 mg weekly. Usual
maintenance dose 50 mg every 4 weeks to 300 mg
every 2 weeks. ELDERLY, initially quarter to half
adult dose. CHILD not recommended. Deep IM
recommended. Not for IV use
Contraindication
Adverse Effects
Comatose or severely depressed patients,
blood
dyscrasias,
liver
damage,
hypersensitivity to fluphenazine products,
subcortical
brain
damage,
phaeochromocytoma, severe hypotension,
bone marrow depression
Weight gain, agranulocytosis, akathisia,
extrapyramidal effects, hepatotoxicity,
neuroleptic
malignant
syndrome,
hyperprolactinaemia, sedation, orthostatic
hypotension,
anticholinergic
effects,
seizures, aplastic anaemia, cholestatic
jaundice,
drowsiness,
dependence,
antimuscarinic
effects,
insomnia,
depression,
convulsions,
agitation,
tachycardia, postural hypotension, allergic
reactions,
agranulocytosis,
tardive
dyskinesia, depressive reactions
Hypersensitivity to flupenthixol. Extremely
excitable or overactive patients. Acute
alcohol, barbiturate or opiate poisoning.
Bone marrow depression, coma
Sedation,
restlesness,
extrapyramidal
symptoms, anticholinergic effects, weight
gain.
Insomnia,
drowsiness.
Rarely
extrapyramidal symptoms, if recommended
dose is exceeded. Occasionally tardive
dyskinesia in long-term therapy
Code
16.02.07
Drug
Generic Name:
Haloperidol,
Tablet
Indication:
Schizophrenia and other psychoses
Strength Available:
1.5 mg, 5 mg
Dosage:
ADULT : 1.5 - 5 mg 2 - 3 times daily up to 30 mg
daily.
Paed : Initial: 0.05 mg/kg/day or 0.25-0.5 mg/day
given in 2-3 divided doses; increase by 0.25-0.5 mg
every 5-7 days; maximum: 0.15 mg/kg/day.
Maximum 10 mg
Category:
B
16.02.08
Indication / Dose
Generic Name:
Haloperidol,
Injection
Strength Available:
5 mg/ml
Category:
B
Indication:
Acute psychoses and mania
Dosage:
ADULT: IM or IV , 2 mg - 10 mg then every 4 - 8
hours according to response to total maximum 18
mg daily.
Use in child is not recommended
Contraindication
Adverse Effects
Parkinson's
disease,
severe
CNS
depression, bone marrow suppression,
severe cardiac or hepatic disease,
comatose states, hypersensitivity to
haloperidol. Lactation
Extrapyramidal symptoms (EPS), tardive
dyskinesia,
sedation,
hypotension,
tachycardia, insomnia, anxiety, weight
changes,
anticholinergic
effects,
gynaecomastia, galactorrhoea, menstrual
irregularities,
neuroleptic
malignant
syndrome, arrhythmias, seizure, jaundice,
hyperpyrexia.
Anxiety,
depression,
anorexia, leukopaenia
Parkinson's
disease,
severe
CNS
depression, bone marrow suppression,
severe cardiac or hepatic disease,
comatose states, hypersensitivity to
haloperidol. Lactation
Extrapyramidal symptoms (EPS), tardive
dyskinesia,
sedation,
hypotension,
tachycardia, insomnia, anxiety, weight
changes,
anticholinergic
effects,
gynaecomastia, galactorrhoea, menstrual
irregularities,
neuroleptic
malignant
syndrome, arrhythmias, seizure, jaundice,
hyperpyrexia.
Anxiety,
depression,
anorexia, leukopaenia
Code
16.02.09
Drug
Generic Name:
Olanzapine,
Tablet
(Zyprexa®)
Strength Available:
5 mg, 10 mg
Category:
A*
16.02.10
Generic Name:
Olanzapine,
Disintegrating Tablet
(Zyprexa Zydis®)
Strength Available:
5 mg, 10 mg
Category:
A*
Indication / Dose
Indication:
i) Acute and maintenance treatment of schizophrenia and other
psychoses where positive and or negative symptoms are prominent
ii) Short-term use for acute mania episodes associated with Bipolar 1
disorder
Dosage:
i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days,
adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day
ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less
than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
Indication:
i) Acute and maintenance treatment of schizophrenia and other
psychoses where positive and or negative symptoms are prominent
ii) Short-term use for acute mania episodes associated with Bipolar 1
disorder
Dosage:
i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days,
adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day
ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less
than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
Contraindication
Adverse Effects
Hypersensitivity
to Somnolence,
agitation,
dizziness,
olanzapine products, narrow constipation, drowsiness, weight gain,
angle glaucoma, lactation
peripheral oedema, dry mouth,
postural hypotension, elevated liver
transaminases,
hyperglycaemia,
diabetic ketoacidosis . weight gain,
dizziness,
increased
appetite,
orthostatic hypotension, dry mouth,
constipation, tardive dyskinesia
Hypersensitivity
to Somnolence,
agitation,
dizziness,
olanzapine products, narrow constipation, drowsiness, weight gain,
angle glaucoma, lactation
peripheral oedema, dry mouth,
postural hypotension, elevated liver
transaminases,
hyperglycaemia,
diabetic ketoacidosis . weight gain,
dizziness,
increased
appetite,
orthostatic hypotension, dry mouth,
constipation, tardive dyskinesia
Code
16.02.11
Drug
Generic Name:
Perphenazine,
Tablet
Indication:
Strength Available:
4 mg
Dosage:
Category:
B
16.02.12
Indication / Dose
Generic Name:
Quetiapine Fumarate,
Extended Release
Tablet (Seroquel®)
Strength Available:
50 mg, 200 mg,
300 mg, 400 mg
Category:
A*
Schizophrenia and other psychoses
ADULT: Initially 4 mg 3 times daily adjusted according to
response, maximum 24 mg daily
ELDERLY: 1/4 to 1/2 adult dose
CHILD not recommended
Indication:
i) Schizophrenia
ii) Moderate to severe manic episodes in bipolar disorder
iii) Major depressive episodes in bipolar disorder
Dosage:
i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2.
Maintenance dose: 400 to 800 mg once daily. Maximum dose:
800 mg daily.
iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and
300 mg on Day 4. Recommended daily dose is 300 mg. May be
titrated up to 600 mg daily.
In elderly or hepatic impairment: Start with 50 mg/ day, may
be increased in increments of 50 mg /day to an effective dose
Contraindication
Adverse Effects
Blood dyscrasias, bone
marrow
suppression,
subcortical
brain
damage,
comatose/
obtunded
patients,
hypersensitivity
to
perphenazine products,
severe liver disease,
high doses of CNS
depressants,
hypersensitivity
to
perphenazine, lactation
CNS effects (extrapyramidal effects), drowsiness,
insomnia, convulsion, allergic reaction, tachycardia,
postural hypotension, dizziness, impaired glucose
tolerance, tardive dyskinesia, liver damage, nausea,
vomiting, cardiac arrest, agranulocytosis, haemolytic
anaemia,
hepatotoxicity,
alter
temperature
regulation, neuroleptic malignant syndrome, GI
disturbances, nasal congestion, antimuscarinic
symptoms, cardiovascular symptoms, ECG changes,
endocrine
effects,
blood
dyscrasias,
photosensitisation, contact sensitisation, rashes,
jaundice, corneal and lens opacities, purplish
pigmentation of the skin and eye
Hypersensitivity, severe
CNS depression, bone
marrow
suppression,
blood dyscrasias, severe
hepatic disease, coma
Headache, somnolence, weight gain, postural
hypotension, tachycardia, palpitations, dizziness,
rash, abdominal pain, constipation, dyspepsia,
anorexia, dry mouth, constipation, leucopenia,
dyspepsia, elevated serum transaminases (ALT, AST),
mild asthenia, peripheral oedema, weight gain,
syncope, rhinitis
Code
16.02.13
Drug
Generic Name:
Risperidone,
Oral Solution
Strength Available:
1 mg/ml
Category:
A
16.02.14
Generic Name:
Risperidone,
Tablet
Strength Available:
1 mg, 2 mg
Category:
B
Indication / Dose
Contraindication
Adverse Effects
Indication:
Hyperprolactinaemia, hypersensitivity to Somnolence,
dizziness,
hyperkinesia,
risperidone products, prolonged QT nausea,
extrapyramidal
effects,
interval
constipation, anxiety, headache, rhinitis,
Dosage:
rash, dyspepsia, tachycardia, dry mouth,
ADULT: 2 mg in 1 - 2 divided doses on 1st day then
weight
gain,
sexual
dysfunction,
4 mg in 1 - 2 divided doses on 2nd day then 6 mg in
hyperprolactinaemia,
menstrual
1 - 2 divided doses on 3rd day (slower titration
irregularities, severe hypotension, tardive
appropriate in some patients); usual range 4 - 8 mg
dyskinesia, neuroleptic malignant syndrome
daily; dose above 10 mg daily only if benefit
and hyperglycaemia, insomnia, agitation,
outweighs risk (maximum 16 mg daily)
depression, fatigue
Elderly (or in hepatic or renal impairment): initially
0.5 mg twice daily increased in steps of 0.5 mg
twice daily to 1-2 mg twice daily.
Not recommended in children under 15 years
Psychoses and schizophrenia
Indication:
Hyperprolactinaemia, hypersensitivity to Somnolence,
dizziness,
hyperkinesia,
risperidone products, prolonged QT nausea,
extrapyramidal
effects,
interval
constipation, anxiety, headache, rhinitis,
Dosage:
rash, dyspepsia, tachycardia, dry mouth,
ADULT: 2 mg in 1 - 2 divided doses on first day
weight
gain,
sexual
dysfunction,
then 4 mg in 1 - 2 divided doses on 2nd day then 6
hyperprolactinaemia,
menstrual
mg in 1 - 2 divided doses on 3rd day (slower
irregularities, severe hypotension, tardive
titration appropriate in some patients); usual range
dyskinesia, neuroleptic malignant syndrome
4 - 8 mg daily; dose above 10 mg daily only if
and hyperglycaemia
benefit outweigh risk (maximum 16 mg daily).
Elderly (or in hepatic or renal impairment): initially
0.5 mg twice daily increased in steps of 0.5 mg
twice daily to 1 - 2 mg twice daily.
Not recommended in children under 15 years
Psychoses and schizophrenia
Code
16.02.15
Drug
Generic Name:
Sulpiride,
Tablet
Indication:
Strength Available:
200 mg
Dosage:
Category:
B
16.02.16
Indication / Dose
Acute and chronic schizophrenia, chronic
delusional psychoses
200-400 mg twice daily; 800 mg daily in
predominantly negative symptoms and 2.4 g daily
in mainly positive symptoms. Elderly, lower initial
dose; increased gradually according to response.
Child under 14 years not recommended
Generic Name:
Trifluoperazine,
Tablet
Indication:
Strength Available:
5 mg
ADULT: Initially 5 mg twice daily, increase by 5 mg
after 1 week, then at 3-day intervals. Maximum 40
mg/day
CHILD up to 12 years: Initially up to 5 mg daily in
divided doses adjusted to response, age and body
weight
Category:
B
Psychotic disorder
Dosage:
Contraindication
Adverse Effects
Hypersensitivity
to
sulpiride,
phaeochromocytoma,
prolactin
dependent tumour, in combination with
sultopride and dopamine agonists apart
from in patients with Parkinson's disease,
lactation, levodopa, class Ia and III
antiarrhythmics, certain neuroleptics
(thioridazine,
chlorpromazine,
levomepromazine,
trifluoperazine,
cyamemazine,
amisulpride,
tiapride,
pimozide,
haloperidol,
droperidol),
bepridil,
cisapride,
diphemanil,
erythromycin, mizolastine, vincamine,
halofantrine, pentamidine, sparfloxacin,
moxifloxacin
Extrapyramidal syndrome, drowsiness, dry
mouth, urinary retention, tachycardia,
postural
hypotension,
dizziness,
galactorrhoea,
gynaecomastia,
amenorrhoea, sedation, somnolence. Early
dyskinesia, tardive dyskinesia, sedation or
drowsiness, transient hyperprolactinemia,
weight gain, QT interval prolongation,
orthostatic
hypotension,
neuroleptic
malignant syndrome
Coma,
bone
marrow
depression,
hypersensitivity
to
trifluoperazine
products and other phenothiazines, preexisting liver damage, central nervous
system depression
Seizures, extrapyramidal effects, blood
dyscrasias, agranulocytosis, neuroleptic
malignant
syndrome,
dry
mouth,
constipation, orthostatic hypotension,
blurred vision, tardive dyskinesia, urinary
retention, photosensitivity, rash, nausea,
tachycardia, dizziness, fatigue, headache,
weight gain, jaundice, dystonic reaction in
children,
sensitivity
reactions
eg
agranulocytosis, leucopenia, leucocytosis
and haemolytic anaemia
Code
16.02.17
Drug
Generic Name:
Zuclopenthixol,
Drops
(Clopixol Drop®)
Strength Available:
20 mg/ml
Category:
A*
16.02.18
Indication / Dose
Indication:
Only for psychoses with insight or compliance
Dosage:
Initial: 20-30 mg/day in 2-3 divided doses.
Maximum 150 mg daily. Usual maintenance dose
20 mg - 50 mg daily.
Elderly (or debilitated), initially quarter to half
adult dose
CHILD not recommended
Oral: Zuclopenthixol dihydrochloride: usual
maintenance dose: 20-40 mg/day; maximum daily
dose: 100 mg
Generic Name:
Zuclopenthixol
Acetate,
Injection (Clopixol
Acuphase®)
Indication:
Strength Available:
50 mg/ml
50 - 150 mg repeated after 2 - 3 days if necessary.
Additional dose may be needed 1 - 2 days after the
first injection. Maximum cumulative dose 400 mg
per course and maximum 4 injections; maximum
duration of treatment 2 weeks. Change to oral
dose 2 - 3 days after the last injection.
Child not recommended
Category:
A*
Only for treatment of agitated and violent patients
suffering from schizophrenia who are not
responding to the available standard drugs
Dosage:
Contraindication
Adverse Effects
Severe central nervous system depression,
coma,
blood
dyscrasias,
phaeocromocytoma.
Previous
hypersensitivity to zuclopenthixol or
clopenthixol. Comatose states, acute
alcohol,
barbiturate
and
opiate
intoxication. Pregnancy
Extrapyramidal
syndrome,
drowsines,
anticholinergic effect, tachycardia, postural
hypotension, dizziness, tardive dyskinesia,
urinary
retention,
disturbed
accommodation, tachycardia
Severe central nervous system depression,
coma,
blood
dyscrasias,
phaeocromocytoma.
Previous
hypersensitivity to zuclopenthixol or
clopenthixol. Comatose states, acute
alcohol,
barbiturate
and
opiate
intoxication. Pregnancy
Extrapyramidal
syndrome,
drowsines,
anticholinergic effect, tachycardia, postural
hypotension, dizziness, tardive dyskinesia,
urinary
retention,
disturbed
accommodation, tachycardia
Code
16.02.19
Drug
Contraindication
Adverse Effects
Only for treatment of agitated and violent patients
suffering from schizophrenia who are not
responding to the available standard drugs
Severe central nervous system depression,
blood dyscrasias, phaeocromocytoma.
Previous hypersensitivity to zuclopenthixol
or clopenthixol. Comatose states, acute
alcohol,
barbiturate
and
opiate
intoxication. Pregnancy
Extrapyramidal
syndrome,
drowsines,
anticholinergic effect, tachycardia, postural
hypotension, dizziness, tardive dyskinesia,
urinary
retention,
disturbed
accommodation
Generic Name:
Zuclopenthixol
Decanoate,
Injection (Clopixol
Depot®)
Indication:
Strength Available:
200 mg/ml
By deep IM injection test dose 100 mg followed
after 7 - 28 days by 100 - 200 mg or more followed
by 200 - 400 mg at intervals of 2 - 4 weeks adjusted
according to response. Maximum 600 mg weekly.
Child not recommended
Category:
A*
16.02.20
Indication / Dose
Generic Name:
Paliperidone,
Extended Released
Tablet
(Invega®)
Strength Available:
6 mg, 9 mg
Category:
A*
Dosage:
Indication:
Second or third line treatment of schizophrenia
Dosage:
ADULT 6 mg once daily in the morning, adjusted if
necessary; usual range 3 -12 mg daily. Renal
impairment (creatinine clearance between 10-50
mL/min) 3 mg once daily. Avoid if creatinine
clearance less than 10 ml/min
Lactation, hypersensitivity to Paliperidone, Headache, tachycardia, akathisia, sinus
Risperidone or to any product component tachycardia,
extrapyramidal
disorder,
somnolence, dizziness, sedation, tremor,
hypertonia,
dystonia,
orthostatic
hypotension & dry mouth. Menstrual
disturbances,
erectile
dysfunction,
galactorrhoea and gynaecomastia
Code
16.02.21
Drug
Generic Name:
Paliperidone,
Prolonged Release
Injection (Invega
Sustenna®)
Strength Available:
100 mg, 150 mg
Category:
A*
16.02.22
Generic Name:
Lithium Carbonate,
Tablet
Strength Available:
300 mg
Category:
A
Indication / Dose
Indication:
Second or third line treatment of acute and
maintenance treatment of schizophrenia in adults
Dosage:
Initiation: Deltoid IM 150 mg eq on Day 1, followed
by deltoid IM 100 mg eq on one week later.
Maintenance: Monthly dose of 75 mg eq (this can be
increased or decreased based on individual patient’s
tolerability and/or efficacy). These monthly
maintenace dose can be administered in either the
deltoid or gluteal muscle
Indication:
i) Prophylaxis and treatment of acute mania and
hypomania episodes
ii) Prophylaxis of manic depression in bipolar illness
or bipolar depression and recurrent depression
Dosage:
1800 mg/day in 2-3 divided doses, desired serum
lithium level ranging between 0.4-1 mmol/litre.
Maintenance 900-1200 mg/day in 2-3 divided doses
Contraindication
Adverse Effects
Moderate to severe renal impairment, Insomnia, headache, agitation, somnolence,
dementia-related psychosis, lactation sedation, dizziness, injection site pain,
akathisia,
extrapyrimidal
disorder,
constipation,
nausea,
vomiting,
nasopharyngitis, bradycardia, bundle branch
block, postural orthostatic tachycardia
syndrome, tachycardia, blood cholesterol
increased,
blood
glucose
increased,
convulsion, dizziness postural, drooling,
dysarthria, dyskinesia, dystonia, hypertonia,
lethargy, neuroleptic malignant syndrome,
oromandibular
dystonia,
parkinsonism,
psychomotor
hyperactivity,
syncope,
oculogyric crisis, eye rolling, vision blurred,
amenorrhea,
erectile
dysfunction,
galactorrhea, gynecomastia, menstruation
irregular, sexual dysfunction
Renal insufficiency, Addison's disease,
untreated hypothyrodism, lactation,
delibated or dehydrated patient,
pregnancy,
disturbed electrolyte
balance, major surgery
Gastrointestinal effect, vertigo, dazed feeling,
fine hand tremor, polyuria, drowsiness,
muscle weakness, anorexia, dry mouth,
fatigue, seizures, leucocytosis, goitre, coma.
Exacerbation of psoriasis, acne, rash, nausea,
diarrhoea, vertigo,loss of concentration,
tremors, hypothyroidism, weight gain, cardiac
arrhythmias; exophthalmos, restlessness
16.3 ANTIDEPRESSANT DRUGS
Code
16.03.01
Drug
Generic Name:
Agomelatine,
Tablet
Indication:
Strength Available:
25 mg
Dosage:
Category:
A*
16.03.02
Indication & Dose
For the treatment of major depressive episodes in
adult
Adverse Effects
History of previous hypersensitivity to the
active ingredient or any of the excipients.
Hepatic impairment (i.e. cirrhosis or active
liver disease). Taking potent CYP1A2
inhibitors (e.g. fluvoxamine, ciprofloxacin)
Headache, dizziness, somnolence, insomnia,
migraine; anxiety; nausea, diarrhea,
constipation, upper abdominal pain;
hyperhidrosis; back pain; fatigue; increased
ALAT &/or ASAT
The recommended dose is 25mg once daily at
bedtime. If there is no improvement of symptoms,
the dose maybe increased to 50mg once daily, i.e.
2 (two) of 25mg tablet, taken together at bedtime.
Generic Name:
Dothiepin HCl,
Tablet
Indication:
Strength Available:
25 mg, 75 mg
Initially 75 mg (ELDERLY 50-75 mg) daily in divided
doses or single dose at bedtime, increased
gradually as necessary to 150 mg daily (ELDERLY 75
mg may be sufficient), up to 225 mg daily in some
circumstances.
CHILD is not recommended
Category:
A
Contraindication
Depression of any aetiology
Dosage:
Concomitant use of MAOIs, recovery Drowsiness, extrapyramidal symptoms,
phase of myocardial infarction, hepatic tremor, confusional state, disorientation,
failure, epilepsy
dizziness,
anticholinergic
effects,
paraesthesia, hypotension, tachycardia,
palpitations,
arrhythmias,
conduction
defects, libido changes, nausea, vomiting,
constipation, rash, pharyngitis, impotence,
anemia
Code
16.03.03
Drug
Generic Name:
Fluvoxamine,
Tablet (Luvox®)
Indication:
Strength Available:
50 mg, 100 mg
For depression, initially 50 - 100 mg daily in the
evening, increased if necessary to 300 mg daily
(over 150 mg in divided doses); usual maintenance
dose 100 mg daily.
CHILD and ADOLESCENT under 18 years not
recommended
Category:
B
16.03.04
Indication & Dose
Depressive disorder
Dosage:
Generic Name:
Fluoxetine HCl,
Capsule
Indication:
Strength Available:
20 mg
Dosage:
Category:
A
i) Depressive illness
ii) Obsessive-compulsive disorder
i) 20 mg once daily increased after 3 weeks if
necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40
mg) once daily max 80 mg once daily (ELDERLY max
60 mg once daily)
ii) Initially 20 mg once daily increased after 2 weeks
if necessary, usual dose 20 - 60 mg (ELDERLY 20 40 mg) once daily, max 80 mg (ELDERLY max 60
mg) once daily, discontinue if no improvement
within 10 weeks.
CHILD and ADOLESCENT under 18 years are not
recommended
Contraindication
Adverse Effects
Use of MAOI within 14 days,
coadministration
of
terfenadine,
astemizole or cisapride, may cause
increased plasma concentrations of these
drugs and an increased incidence of side
effects, hypersensitivity to fluvoxamine
Blurred vision, dry mouth, tremor,
gastrointestinal disturbances, somnolence,
constipation, headache, insomnia, vomiting,
dizziness, agitation, extrapyramidal effects,
bradycardia,
seizures,
hepatotoxicity,
withdrawal syndrome, Steven Johnson
Syndrome, anphylactic reaction, abnormal
ejaculation, hepatitis, asthenia, abnormal
bleeding, hyponatremia, seizure, serotonin
syndrome,
worsening
depression,
hypomania, mania (rare), suicidal thoughts
Present or recent treatment with MAOIs, Tremor, asthenia, gastrointestinal disorder,
hypersensitivity to fluoxetine
inappropriate secretion of adrenocortical
hormone,
nervousness,
insomnia,
headache, anorexia, anxiety, dry mouth,
decreased libido, delayed ejaculation,
anorgasmia, sweating and serotonin
syndrome
Code
16.03.05
Drug
Generic Name:
Escitalopram,
Tablet (Lexapro®)
Strength Available:
10 mg
16.03.06
Indication & Dose
Indication:
i) Treatment of major depressive episodes
ii) Treatment of panic disorder with or without
agoraphobia
Dosage:
Category:
A*
i) 10 mg once daily; may be increased to max 20
mg daily.
ii) Panic disorder with or without
agoraphobia :Initially 5 mg for the first week,
thereafter increased to 10 mg daily. May be further
increased up to max 20 mg daily, dependent on
individual patient response.
ELDERLY initially half adult dose, lower
maintenance dose may be sufficient.
CHILD and ADOLESCENT under 18 years not
recommended
Generic Name:
Sertraline HCI,
Tablet
Indication:
Strength Available:
50 mg
Dosage:
Category:
B
Major depression, obsessive-compulsive disorder
(OCD), panic disorder
Depression, obsessive-compulsive disorder: 50 mg/
day. Panic disorder: Initially 25 mg/day. After 1
week, increase dose to 50 mg/day
All dose changes should be made at intervals of
more than 1 week, max: 200 mg/day
Contraindication
Adverse Effects
Concurrent use of MAOIs or within 14 Dizziness, headache, nausea, sweating,
days of discontinuing MAOS treatment
somnolence,
insomnia,
constipation,
diarrhoea, decreased appetite, sexual
dysfunction, fatigue, pyrexia, sinusitis,
yawning, rash, Steven Johnson Syndrome,
rhinitis, blurred vision, nasal congestion,
prolactinemia, dry mouth, decrease
prothrombin, hepatic failure, hypoglycemia,
hypokalemia, suicidal ideation, diaphoresis,
Syndrome of inappropriate antidiuretic
hormone secretion(SIADH)
Concurrent use or recent use of MAOIs, Male sexual dysfunction, gastrointestinal
hypersensitivity to sertraline products
complain, tremor, dizziness, insomnia,
headache, dry mouth, somnolence,
ejaculatory
dysfunction,
dyspepsia,
decreased libido, sweating, anorexia,
agitation, visual disturbances, serotonin
syndrome, withdrawal syndrome, rash,
pharyngitis,
purpura,
agranulocytosis,
elevated liver enzyme, antidepressants
increase the risk of suicidal
Code
16.03.07
Drug
Generic Name:
Imipramine HCI,
Tablet
Indication:
Strength Available:
25 mg
Initially up to 75 mg daily in divided doses
increased gradually to 150 - 200 mg (up to 300 mg
in hospital patients); up to 150 mg may be given as
a single dose at bedtime.
ELDERLY initially 10 mg daily; increased gradually
to 30 - 50 mg daily.
CHILD is not recommended
Category:
B
16.03.08
Indication & Dose
Generic Name:
Mirtazapine,
Orodispersible Tablet
(Remeron®)
Strength Available:
15 mg, 30 mg
Category:
A*
Depression.
Dosage:
Indication:
Episodes of major depression.
Dosage:
Initially 15 mg daily at bedtime increased according
to response up to 45 mg daily as a single dose at
bedtime or in 2 divided doses.
CHILD and ADOLESCENT under 18 years not
recommended
Contraindication
Adverse Effects
MAOIs use within 14 days, first trimester
of
pregnancy,
hypersensitivity
to
imipramine products, during acute
recovery phase of myocardial infarction,
arrhythmias (particularly heart block), not
indicated in manic phase, severe liver
disease
Anticholinergic,
drowsiness,
dizziness,
tinitus, palpitation and tachycardia, seizure,
weight gain, constipation, urinary retention,
increased
appetite,
confusion,
agranulocytosis, thrombocytopenia, blood
dyscrasias
Hypersensitivity to mirtazapine or Agranulocytopenia, neutropenia, mania,
component of formulation, MAOIs, dizziness, increase appetite, constipation,
procarbazine, selegiline
somnolence. Patients should be advised to
report any fever, sore throat, stomatitis or
other signs of infection during treatment.
Blood count should be performed and the
drug stopped immediately if blood
dyscrasia suspected, increased appetite,
raised serum cholesterol and serum
triglycerides, raised ALT (SGPT) level,
asthenia, dizziness, dream disorder,
agranulocytosis,
neutropenia, seizure,
worsening depression, suicidal ideation
Code
16.03.09
Drug
Generic Name:
Moclobemide,
Tablet
Indication:
Strength Available:
150 mg
Initially 300 mg daily in divided doses. Gradually to
increase up to 600 mg daily in divided doses
depending on response. Usual range 150 - 600 mg
daily.
Not recommended in children
Category:
A*
16.03.10
Indication & Dose
Generic Name:
Venlafaxine HCl,
Extended Release
Capsule (Efexor XR®)
Strength Available:
75 mg, 150 mg
Category:
A*
Treatment of depressive syndrome
Dosage:
Indication:
i) Depression
ii) Generalized anxiety disorder
iii) Social anxiety disorder (social phobia)
iv) Panic disorder
Dosage:
i), ii) & iii) ADULT: 75 mg once daily. May increase
dose by 75 mg/day every 4 days to a maximum
dose of 225 mg/day
iv) 37.5 mg/day for the first 4-7 days after which
the dose should be increased to 75 mg once daily.
CHILD and ADOLESCENT under 18 years not
recommended
Contraindication
Adverse Effects
Acute confusional state, hypersensitivity
to moclobemide, concomitant use with
selective serotonin reuptake inhibitors,
conventional
MAOIs
or
tricyclic
antidepressants, concomitant use of
narcotics
Sleep
disturbance,
dizziness,
gastrointestinal disturbance, restlessness,
agitation, blurred vision, dry mouth,
headache,
constipation,
possible
hyponatraemia, diaphoresis, rash, increase
libido, abdominal pain, hepatotoxicity,
oedema, orthostatic hypotension, tremor
Recent or concomitant use of MAOIs, risk
of potentially life-threatening serotonin
syndrome hypersensitivity to venlafaxine
hydrochloride or any other component of
the product
Abnormal
ejaculation,
anorgasmia,
impotence, anorexia, constipation, weight
loss,
diarrhoea,
dyspepsia,
anxiety,
dizziness,
insomnia,
nervousness,
somnolence, tremor, asthenia, abnormal
bleeding, activation of mania, suicide
ideation,
hepatitis,
hypertension,
hyponatraemia,
seizures,
sweating
symptom, nausea,
dream
disorder,
headache, blurred vision
Code
16.03.11
Drug
Generic Name:
Amitriptyline HCl,
Tablet
Indication:
Strength Available:
25 mg
Initially 75 mg. ADULT and ELDERLY : 30 - 75 mg daily
in divided doses or as a single dose at bedtime,
increase gradually as necessary to 150 - 200 mg.
CHILD under 16 years are not recommended
Category:
B
16.03.12
Depression
Dosage:
Generic Name:
Duloxetine,
Capsule
Indication:
Strength Available:
30 mg, 60 mg
Dosage:
Category:
A*
16.03.13
Indication & Dose
Major depressive disorder, diabetic peripheral
neuropathic pain
ADULT: 60 mg once daily up to a maximum dose of
120mg/day (in divided doses).
CHILD and ADOLESCENT under 18 years not
recommended
Generic Name:
Clomipramine HCI,
Tablet
Indication:
Strength Available:
25 mg
Initially 10 mg daily, increased gradually as necessary
to 30 - 150 mg daily in divided doses or as a single dose
at bedtime; max 250 mg daily.
ELDERLY initially 10 mg daily increased carefully over
approximately 10 days to 30 - 75 mg daily.
CHILD not recommended
Category:
A
Depressive illness, obsessive-compulsive disorder
Dosage:
Contraindication
Adverse Effects
Hypersensitivity to drug/class. Immediate
recovery
phase
after
myocardial
infarction, heart block, mania. MAOI use
within the last 14 days
Dry mouth, constipation, nausea,
vomiting, urinary retention, blurred
vision, drowsiness, dizziness, tachycardia,
increased appetite, confusion, seizures,
myocardial
infarction,
stroke,
agranulocytosis, thrombocytopenia, rash
and hypersensitivity reactions, blood
sugar changes, endocrine side effects,
impotence, menstrual irregularities, bone
marrow depression
Concomitant use with MAOIs, potent
CYP1A2 inhibitors, hepatic or severe
renal impairment, uncontrolled narrowangle glaucoma, hypersensitivity to
duloxetine or any other component of
the product
Gastrointestinal disorders, excessive
sweating, CNS disorders (eg dizziness,
fatigue, insomnia, somnolence, blurred
vision, dysuria), hepatotoxicity, suicidal
thought, increased urinary frequency,
increased libido, palpitation
Hypersensitivity to drug, concomitant/
recent use of MAOIs, recent myocardial
infarction, urinary retention, glaucoma,
phaeochromocytoma
Anticholinergic reactions, cardiovascular
effects, insomnia, increase anxiety, skin
rashes, dizziness, somnolence, headache,
constipation, fatigue, nausea, sweating,
dyspepsia, libido changes, seizures
17.RESPIRATORY
17.1 Bronchodilators
17.2 Corticosteroids
17.1 BRONCHODILATORS
Code
17.01.01
Drug
Generic Name:
Aminophylline,
Injection
Indication:
Reversible airways obstruction, acute severe
asthma
Strength Available:
25 mg/ml
Dosage:
Category:
B
17.01.02
Indication & Dose
Deteriorating acute asthma not previously treated
with theophylline, by slow IV injection over 20
minutes 250 - 500 mg (5 mg/kg), then as for acute
severe asthma. Acute severe asthma by IV
infusion : 500 mcg/kg/hour, adjusted according to
plasma-theophylline concentration.
CHILD : 6 month - 9 years : 1 mg/kg/hour, 10 - 16
years : 800 mcg/kg/hour
Generic Name:
Ipratropium Bromide
20 mcg and Fenoterol
50 mcg/dose,
Inhalation (Berodual)
Indication:
Management of symptoms in chronic obstructive
airway disorders with reversible bronchospasm
such as bronchial asthma and chronic bronchitis
with or without emphysema
Strength Available:
-
Dosage:
Category:
B
ADULT & CHILD more than 6 years; Acute asthma 2
puffs. Severe cases: if breathing has not noticeably
improved after 5 mins, 2 further puffs may be
taken. Intermittent and long-term treatment 1-2
puffs for each administration, up to max 8 puffs/
day (average: 1-2 puffs three times daily)
Contraindication
Hypersensitivity to theophylline
derivatives,
hypersensitivity
ethylenediamine
Adverse Effects
or Tachycardia, palpitations, nausea and other
to gastrointestinal disturbances, headache,
CNS stimulation, insomnia, arrythmias, also
allergy to ethylenediamine which can cause
urticaria, erythema, and exfoliative
dermatitis
Hypertrophic obstructive cardiomyopathy,
tachyarrhythmias. Hypersensitivity to
atropine-like
substances
&
sympathomimetic amines
Fine
tremor of
skeletal
muscles,
nervousness, dry mouth, headache,
dizziness, tachycardia and palpitations,
hypokalaemia, cough, nausea, vomiting,
sweating,
weakness,
myalgia/muscle
cramps
Code
Drug
17.01.03
Generic Name:
Ipratropium Bromide
0.0125 % , Inhalation
Solution (125 mcg/ml)
Strength Available:
0.0125 %
Category:
B
Indication & Dose
Contraindication
Indication:
Hypersensitivity to ipratropium products,
Only for treatment of :
atropine, soya lecithin or related food
i) Patients with ischaemic heart disease who
products
develop extrasystole with salbutamol or
terbutaline
ii) Patients with chronic bronchitis who have airway
obstruction and who do not respond to salbutamol
or terbutaline. Reversible airways obstruction,
particularly in chronic obstructive pulmonary
disease
Adverse Effects
Headache, nausea, dry mouth, rare and
reversible anticholinergic side effects,
ocular side effects if substances enters eyes,
cough
Dosage:
ADULT : 500 mcg up to 4 times daily. CHILD 5 - 12
years : 125 - 250 mcg up to 4 times daily, 12 years :
250 - 500 mcg up to 4 times daily
17.01.04
Generic Name:
Ipratropium Bromide
0.5 mg and
Salbutamol 2.5 mg per
UDV
Strength Available:
Category:
B
Indication:
Management of reversible bronchospasm
associated with obstructive airway diseases
Dosage:
Acute attacks : 1 unit dose vial. In severe cases not
relieved by 1 unit dose vial, 2 unit dose vials may
require, patient should consult a doctor
immediately. Maintenance : 1 unit dose vial 3 - 4
times daily
Hypersensitivity to atropine or its
derivatives or to any other component.
Hypertrophic obstructive cardiomyopathy
or tachyarrythmia
Headache,
dizziness,
nervousness,
tachycardia, fine tremor, palpitations.
Potentially serious hypokalaemia may result
from beta2-agonist therapy, dryness of
mouth, dysphonia, ocular complications,
allergic type reactions
Code
17.01.05
17.01.06
17.01.07
Drug
Indication & Dose
Generic Name:
Salbutamol,
Tablet
Indication:
Asthma and other conditions associated with
reversible airways obstruction
Strength Available:
2 mg
Dosage:
Category:
B
CHILD: 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12
years : 2 mg 3 - 4 times daily
CHILD over 12 years and ADULT : 2 - 4 mg 3 - 4
times daily
Generic Name:
Salbutamol,
Inhalation Solution
Indication:
Asthma and other conditions associated with
reversible airways obstruction
Strength Available:
0.5 %
Dosage:
Category:
B
2 ml may be inhaled up to 4 times daily over a
period of 3 minutes per inhalation (0.5 ml diluted
in 2.5 ml of normal saline by inhalation over 5 to
15 minutes)
Generic Name:
Salbutamol,
Inhalation (Ventolin®)
Indication:
Asthma and other conditions associated with
reversible airways obstruction
Strength Available:
100 mcg/dose
Dosage:
Category:
B
ADULT: 100 - 200 mcg up to 3 - 4 times daily.
CHILD: 100 mcg increased to 200 mcg if necessary
Contraindication
Adverse Effects
Hypersensitivity to any of their
components. Premature labour e.g.
placenta
praevia,
associated
with
toxaemia of pregnancy or antepartum
haemorrhage from whatever cause
Fine tremor (particularly in the hands),
nervous tension, headache, peripheral
dilatation and palpitations, tachycardia,
arrhythmias, disturbances of sleep and
behaviour in children
Hypersensitivity
components
to
any
of
their Slight tremor (particularly in the hands),
nervous tension, headache, peripheral
dilatation and palpitations, tachycardia,
arrhythmias, disturbances of sleep and
behaviour in children, muscle cramps,
hypersensitivity
reactions
including
paradoxical
bronchospasm,
urticaria,
angioedema, hypotension, pulmonary
oedema, erythema multiforme
Hypersensitivity
components
to
any
of
their Slight tremor (particularly in the hands),
nervous tension, headache, peripheral
dilatation and palpitations, tachycardia,
arrhythmias, disturbances of sleep and
behaviour in children, muscle cramps,
hypersensitivity
reactions
including
paradoxical
bronchospasm,
urticaria,
angioedema, hypotension, pulmonary
oedema, erythema multiforme
Code
Drug
17.01.08
Generic Name:
Terbutaline Sulphate,
Tablet
Indication:
Asthma and other conditions associated with
reversible airways obstruction
Strength Available:
2.5 mg
Dosage:
Category:
B
17.01.09
Indication & Dose
ADULT: Initially 2.5 mg 3 times daily for 1 - 2 week,
then up to 5 mg 3 times daily.
CHILD less than 7 years: 75 mcg/kg 3 times daily, 7
- 15 years: 2.5 mg 2 - 3 times daily
Generic Name:
Theophylline, Long
Acting Tablet
(Neulin ®)
Indication:
Reversible airways obstruction and acute severe
asthma
Strength Available:
250 mg
ADULT: 250 mg 2 times daily.
CHILD under 12 years: Up to 10 mg/kg body weight
2 times daily
Category:
B
Dosage:
Contraindication
Adverse Effects
Hypersensitivity to terbutaline and other Palpitations, tachycardia, increases in
sympathomimetic amines
ejection fraction, increases in cardiac
output have been reported following
subcutaneous terbutaline, tremor and tonic
cramp
Hypersensitivity to theophylline
Tachycardia, palpitations, nausea and other
gastrointestinal disturbances, headache,
central nervous system stimulation,
insomnia, arrythmias
17.2 CORTICOSTEROIDS
Code
17.02.01
Drug
Generic Name:
Beclomethasone
Dipropionate 100
mcg/dose, Inhalation
Indication:
Prophylaxis of asthma especially if not fully
controlled by bronchodilators
Strength Available:
100 mcg/dose
ADULT: 100 mcg 3 - 4 times daily or 200 mcg twice
daily.
CHILD more than 6 years: 50 - 100 mcg 2 - 4 times
daily
Category:
B
17.02.02
Indication & Dose
Generic Name:
Budesonide,
Inhalation
Strength Available:
200 mcg/dose
Category:
B
Dosage:
Indication:
Maintenance treatment of asthma as prophylactic
therapy especially if not fully controlled by
bronchodilators
Dosage:
ADULT: 200 - 1600 mcg daily in 2 - 4 divided doses.
Maintenance with twice daily dosing.
CHILD more than 7 years: 200 - 800 mcg, 2 - 7 years
200 - 400 mcg. To be taken orally in 2 - 4 divided
doses
Contraindication
Adverse Effects
Hypersensitivity
to
beclomethasone
dipropionate, acute asthma exacerbations,
status asthmaticus. Special care is
necessary in patients with active or
quiescent pulmonary tuberculosis
Candidiasis of the mouth and throat,
hoarseness or throat irritation, headache,
secondary hypocortisolism, osteoporosis,
cataract,
glaucoma,
paradoxical
bronchospasm (discontinue immediately).
Patients are advised to gargle after using
the medication
Hypersensitivity to budesonide. Moderate Mild irritation of the throat, coughing, and
to severe bronchiectasis
generally reversible hoarseness of the
voice. Bad taste, dryness of the throat.
Candidiasis of the mouth and throat,
paradoxical bronchoconstriction, headache,
nausea, tiredness, thirst, diarrhoea, skin
reaction
18.RHEUMATOLOGY
18.1 Anti Rheumatic
18.2 Gout
18.3 Drugs For The Relief of
Soft Tissue Inflammation
18.1 ANTI RHEUMATIC
Code
18.01.01
Drug
Generic Name:
Meloxicam,
Tablet
Strength Available:
7.5 mg
Category:
A / KK
Indication / Dose
Indication:
Only for patients not responding to other NSAIDs in the
treatment of
i) painful osteoarthritis
ii) rheumatoid arthritis
Dose:
i) initially 7.5 mg daily. May be increased to 15 mg daily
ii) initially 15 mg daily. May be reduced to 7.5 mg daily
Maximum 15 mg daily.
Child under 12 years not recommended
Contraindication
Adverse Effects
Active
peptic
ulceration,
pregnancy,
lactation,
hypersensitivity to NSAIDs or
aspirin,
severe
hepatic
insufficiency, non-dialysed severe
renal insufficiency. Children less
than 15 year
Dyspepsia, nausea, abdominal pain,
pruritis, skin rash, constipation.
Vomiting,
flatulence,
diarrhoea,
anaemia, pruritus, lightheadedness,
headache, oedema
18.2 GOUT
Code
18.02.01
Drug
Generic Name:
Allopurinol,
Tablet
Strength Available:
300 mg
Category:
A / KK
Indication / Dose
Contraindication
Adverse Effects
Indication:
i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year)
ii) Clinical or radiographic signs of erosive gouty arthritis
iii) The presence of tophaceous deposits
iv) Urate nephrolithiasis
v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or
leukaemia
Hypersensitivity
to
allopurinol, pregnancy,
lactation, acute gout,
asymptomatic
hyperuricaemia
Skin rash, maculopapular, pruritic,
Stevens-Johnson
Syndrome,
peripheral neuritis, alopecia, GI upset,
toxic epidermal necrolysis. Acute
attack of gouty arthritis in early stages
of therapy. Skin reactions (discontinue
immediately at first sign of rash). Very
rarely,
granulomatous
hepatitis.
Occasionally;
thrombocytopenia,
agranulocytosis, & aplastic anaemia in
patients with impaired renal function
Dose:
Initial dose : 100-300 mg daily. Maintenance : 300-600 mg daily. Maximum:
900 mg daily
18.3 DRUGS FOR THE RELIEF OF SOFT-TISSUE INFLAMMATION
Code
18.03.01
Drug
Generic Name:
Prolase,
Tablet (Papase)
Strength Available:
Category:
B
Indication / Dose
Indication:
Oedema and inflammation in conjunction with
other physical or chemotherapeutic measures
Dose:
2 tablet 4 times daily
Contraindication
Blood clotting disease
Adverse Effects
Skin rash, vertigo and gastrointesinal upsets
19.DIAGNOSTIC
19.1 Diagnostic Aids and Test Preparation
19.1 DIAGNOSTIC AIDS & TEST PREPARATION
Code
19.01.01
Drug
Indication / Dose
Generic Name:
Indication:
Hydroxyethyl Cellulose For lubricating purpose
Jelly (KY Jelly)
Strength Available:
Category:
B
Dose:
Apply sufficiently for lubricating purpose
Contraindication
Not known
Adverse Effects
Not known
20.MISCELLANEOUS
20.1 General Disinfectant
20.2 Miscellaneous
20.1 GENERAL DISINFECTANT
Code
20.01.01
Drug
Generic Name:
Sodium
Dichloroisocyanurate
Tablet
(Germisep)
Indication / Dose
Indication:
Low and medium level disinfectant
Contraindication
Adverse Effects
Avoid contact between solid and acid, Irritation on eyes, dermatitis, lung damage,
ammonia, urea and reducing agents
skin burns, ulceration, itching
Dose:
50 - 10,000 ppm av chlorine
Strength Available:
5 gm
Category:
C
20.2 MISCELLANEOUS
Code
20.02.01
Drug
Indication / Dose
Generic Name:
Ether,
Solvent
Indication:
To remove adhesive plaster from the skin
Strength Available:
-
Dose:
Dose depending on the route and procedure
Category:
C
Contraindication
Hypersensitivity to iohexol/iopromide Not known
products, intrathecal corticosteroids,
immediate repeat myelography, local or
systemic infection
Adverse Effects
20.02.02
20.02.03
20.02.04
20.02.05
20.02.06
20.02.07
20.02.08
20.02.09
20.02.10
20.02.11
Aeroplast Plastic Surgical Spray
Opsite Spray
Cathejell with Lidocaine
Chloroform
Effervescent Chlorine Disinfectant Tablet (Dichlosep)
Moisturizing Hand Solution
Sodium Chloride 1g/10ml 200ml, Mixture
Sodium Chloride 0.9% for irrigation
Sodium Chloride Powder Pulv
Spirit Industrial Methylated
INDEX (GENERIC NAMES)
Acarbose 50 mg, Tablet
08.01.01
Amoxicillin 250 mg, Capsule
04.01.01
Acetylsalicylic Acid 100 mg, Glycine 45 mg, Tablet
05.09.01
Amoxicillin 500 mg &Clavulanate 125 mg, Tablet
04.01.03
Acetylsalicylic Acid Soluble 300 mg, Tablet
03.01.01
Amoxicillin 500 mg, Capsule
04.01.01
Acriflavine 0.1 %, Lotion
06.08.01
Amoxicillin Trihydrate 125 mg/5 ml, Syrup
04.01.02
Activated charcoal 250 mg, Tablet
01.01.03
Ampicillin Sodium &Sulbactam Sodium 375 mg, Tablet
04.01.04
Acyclovir 800 mg, Tablet
04.03.01
Ampicillin Sodium 1 g & Sulbactam Sodium 500 mg, Injection
04.01.05
Adenosine 3 mg/ml, Injection
05.03.01
Antivenene Malaysian Pit Viper, Injection
01.01.04
Adrenaline 1 mg/ml, Injection
05.07.01
Antivenene Serum (Cobra), Injection 0
1.01.05
Aeroplast Plastic Surgical Spray
20.02.02
Aqueous 100 gm, Cream
06.01.01
Agomelatine 25 mg, Tablet
16.03.01
Aqueous 30 gm, Cream
06.01.01
Albendazole 200 mg, Tablet
04.04.01
Aripiprazole 10 mg, Tablet
16.02.02
Albendazole 200 mg/ml,Suspension
04.04.02
Aripiprazole 15 mg, Tablet
16.02.02
Allopurinol 300 mg, Tablet
18.02.01
Artificial Tears, Eye Drops
15.02.02
Alprazolam 0.5 mg, Tablet
16.01.01
Ascorbic Acid (Vitamin C) 100 mg, Tablet
13.03.03
Aminophylline 25 mg/ml, Injection
17.01.01
Atenolol 100 mg, Tablet
05.04.02
Amisulpride 100 mg, Tablet
16.02.01
Atenolol 50 mg, Tablet
05.04.02
Amisulpride 400 mg, Tablet
16.02.01
Atropine Sulphate 1 mg/ml, Injection
02.05.01
Amitriptyline HCl 25 mg, Tablet
16.03.11
Bacampicillin 400 mg, Tablet
04.01.06
Amlodipine 10 mg, Tablet
05.06.05
Beclomethasone Dipropionate 100 mcg/dose, Inhalation
17.02.01
Benzhexol 2 mg, Tablet
12.04.01
Calcium Gluconate 10%, Injection
13.02.03
Benzoic Acid Compound 30 gm, Ointment
06.07.01
Calcium Lactate 300 mg, Tablet
13.02.02
Benzyl Benzoate 25 %, Emulsion
06.07.02
Captopril 25 mg, Tablet
05.05.03
Benzylpenicillin 5 MU, Injection
04.01.07
Carbamazepine 200 mg, Tablet
12.02.01
Betamethasone 17-Valerate 0.1%, Cream
06.03.01
Carbamazepine CR 400 mg, Tablet
12.02.02
Bisacodyl 10 mg, Suppository
09.05.02
Carbimazole 5 mg, Tablet
08.02.01
Bisacodyl 5 mg, Tablet
09.05.01
Cathejell with Lidocaine
20.02.04
Bismuth Subgallate and Benzyl Benzoate, Suppository
09.04.01
Ceftriaxone 1 g, Injection
04.01.08
Bisoprolol Fumarate 2.5 mg, Tablet
05.04.04
Cefuroxime Axetil 250 mg, Tablet
04.01.09
Bisoprolol Fumarate 5 mg, Tablet
05.04.04
Cetirizine HCl 10 mg, Tablet
07.03.01
Bromazepam 3 mg, Tablet
16.01.02
Chloramphenicol 0.5 %, Eye Drops
15.01.01
Bromhexine HCl 4 mg/5 ml, Elixir
07.03.09
Chloramphenicol 1 %, Eye Ointment
15.01.02
Bromhexine HCl 8 mg, Tablet
07.03.08
Chloramphenicol 5 %, Ear Drops
07.01.01
Bromocriptine Mesilate 2.5 mg, Tablet
08.04.01
Chlorhexidine Gluconate 0.2 %, Mouthwash
07.02.03
Budesonide, Inhalation
17.02.02
Chlorhexidine Gluconate 5%, Solution
06.08.02
Bupivacaine 0.5%, Injection
02.04.01
Chloroform
20.02.05
Calamine 120 ml, Lotion
06.02.01
Chlorpheniramine Maleate 10 mg/ml, Injection
07.03.02
Calamine 25 gm, Cream
06.01.02
Chlorpheniramine Maleate 2 mg/5 ml, Syrup
07.03.03
Calcitriol 0.25 mcg, Capsule
13.03.06
Chlorpheniramine Maleate 4 mg, Tablet
07.03.04
Calcium Carbonate 500 mg, Tablet
13.02.01
Chlorpromazine 100 mg, Tablet
16.02.03
Diclofenac 1%, Emulgel
03.03.03
Diclofenac Sodium 50 mg, Tablet
03.03.01
Diclofenac Sodium 75 mg/3 ml, Injection
03.03.02
Digoxin 0.25 mg, Tablet
05.01.01
Digoxin 0.625 mg, Tablet
05.01.01
Digoxin 250 mcg/ml, Injection
05.01.02
Diltiazem HCL 30 mg, Tablet
05.06.01
Diosmin 450 mg and Hesperidin 50 mg, Tablet
09.08.04
04.01.12
Diphenhydramine HCl 14 mg/5 ml and
Ammonium Chloride 135 mg/5 ml Expectorant
07.03.12
Clozapine 100 mg, Tablet
16.02.04
Diphenoxylate with Atropine Sulphate, Tablet
09.03.01
Clozapine 25 mg, Tablet
16.02.04
Donepezil HCl 10 mg, Tablet
12.03.01
Colchicine 0.5 mg, Tablet
06.09.02
Donepezil HCl 5 mg, Tablet
12.03.01
Cyanocobalamin (Vitamin B12) 0.5 mg, Tablet
13.03.01
Dopamine 40 mg/ml, Injection
05.01.03
Cyanocobalamin (Vitamin B12) 1000 mcg/ml, Injection
13.03.02
Dothiepin HCl 25 mg, Tablet
16.03.02
Dextrose 50%, Injection
13.01.09
Dothiepin HCl 75 mg, Tablet
16.03.02
Dextrose, Powder
08.01.02
Doxycycline 100 mg, Capsule
04.01.13
Diazepam 10 mg/2 ml, Injection
12.05.01
Duloxetine 30 mg, Capsule
16.03.12
Diazepam 5 mg, Rectal Solution
12.05.03
Duloxetine 60 mg, Capsule
16.03.12
Diazepam 5 mg, Tablet
12.05.02
Effervescent Chlorine Disinfectant Tablet
20.02.06
Choline Salicylate 8.7%, Cetylkonium
Chloride 0.01%, Dental Gel
07.02.02
Cinnarizine 25 mg, Tablet
07.03.11
Clomipramine HCI 25 mg, Tablet
16.03.13
Clonazepam 2 mg, Tablet
12.02.11
Clotrimazole Vaginal, Tablet
14.01.01
Cloxacillin Sodium 125 mg/5 ml, Suspension
04.01.10
Cloxacillin Sodium 250 mg, Capsule
04.01.11
Cloxacillin Sodium 500 mg, Capsule
04.01.11
Cloxacillin Sodium 500 mg, Injection
Enalapril 5 mg, Tablet
05.05.01
Frusemide 40 mg, Tablet
05.02.02
EphedrineHCl 30 mg/ml, Injection
05.07.02
Fusidic Acid 2 %, Cream
06.07.03
ErythromycinEthylsuccinate 200 mg/5 ml, Suspension
04.01.14
Gamma Benzene Hexachloride 0.1 %, Lotion
06.07.04
ErythromycinEthylsuccinate 400 mg, Tablet
04.01.15
Gemfibrozil 300 mg, Capsule
05.11.01
Escitalopram 10 mg, Tablet
16.03.05
Glibenclamide 5 mg, Tablet
08.01.03
Essential Phospholipids, Capsule
09.08.01
Gliclazide 80 mg, Tablet
08.01.04
Ethambutol HCL 400 mg, Tablet
04.01.16
Gliclazide 30 mg, Modified Release Tablet
08.01.09
Ether Solvent
20.02.01
Glycerin 25% and Sodium Chloride 15%, Enema
09.05.03
Ethyl Chloride, Spray
02.03.02
Glyceryl Trinitrate 0.5 mg, Tablet
05.06.03
Felodipine 5 mg, Tablet
05.06.02
Griseofulvin 125 mg, Tablet
04.02.01
Ferrous Fumarate 200 mg, Tablet
13.04.02
Haloperidol 1.5 mg, Tablet
16.02.07
Flumazenil 0.1 mg/ml, Injection
01.01.01
Haloperidol 5 mg, Tablet
16.02.07
Fluoxetine HCl 20 mg, Capsule
16.03.04
Haloperidol 5 mg/ml, Injection
16.02.08
Flupenthixol Decanoate Depot 20 mg/ml, Injection
16.02.06
Heparin Sodium in Sodium Chloride, Injection
05.08.02
Fluphenazine Decanoate 25 mg/ml, Injection
16.02.05
Hepatitis B Vaccine, Injection
11.01.02
Fluvoxamine 100 mg, Tablet
16.03.03
Hydrochlorothiazide 25 mg, Tablet
05.02.04
Fluvoxamine 50 mg, Tablet
16.03.03
Hydrochlorothiazide 50 mg, Tablet
05.02.05
Folic Acid 5 mg, Tablet
13.04.01
Hydrocortisone 1%, Cream
06.03.02
Framycetin Sulphate 0.5%, Dexamethasone 0.05%
and Gramicidin 0.005%, Ear Drops
Hydrocortisone Sodium Succinate 100 mg, Injection
08.03.01
07.01.03
Hydrogen Peroxide 20 volume, Solution
06.08.04
Frusemide 10 mg/ml, Injection
05.02.01
Hydroxyethyl Cellulose Jelly
19.01.01
Lignocaine 2%, Injection
02.04.02
Hydroxyzine HCl 25 mg, Tablet
07.03.05
Lignocaine 2%, Jelly
02.03.01
Hyoscine N-Butylbromide 10 mg, Tablet
09.02.01
Lignocaine HCl 2%,Injection
05.03.02
Hyoscine N-Butylbromide 20 mg/ml, Injection
09.02.02
Lithium Carbonate 300 mg, Tablet
16.02.22
Imipramine HCI 25 mg, Tablet
16.03.07
Loratadine 10 mg, Tablet
07.03.06
Insulin Recombinant Synthetic Human intermediate-acting
08.01.06
Insulin Recombinant Synthetic Human pre-mixed
08.01.07
Loratadine 5 mg and Pseudoephedrine
Sulphate 120 mg, Tablet
07.03.07
Insulin Recombinant Synthetic Human short-acting
08.01.05
Lorazepam 1 mg, Tablet
16.01.03
Ipratropium Bromide 0.0125%, Inhalation Solution
17.01.03
Magnesium Trisilicate & Aluminium Hydroxide, Tablet
09.01.02
Magnesium Trisilicate, Mixture
09.01.01
Mannitol 20%, Injection
05.02.03
Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg per UDV 17.01.04
Ipratropium Bromide 20 mcg and
Fenoterol 50 mcg/dose, Inhalation
17.01.02
Mefenamic Acid 250 mg, Tablet
03.03.04
Isoniazid 100 mg, Tablet
04.01.17
Meloxicam 7.5 mg, Tablet
18.01.01
IsosorbideDinitrate 10 mg, Tablet
05.06.06
Memantine HCI 10 mg, Tablet
12.03.03
Ketoconazole 200 mg, Tablet
04.02.02
Metformin HCl, Tablet
08.01.08
Ketoprofen 2.5%, Gel
03.03.05
Methyl Salicylate 25%, Ointment
03.04.01
Lactulose 3.35 gm/5 ml, Liquid
09.05.04
Metoclopramide HCl 10 mg, Tablet
09.06.01
Lamotrigine 50 mg, Tablet
12.02.03
Metoclopramide HCl 10 mg/2 ml, Injection
09.06.02
Levetiracetam 500 mg, Tablet
12.02.04
Metoprolol 100 mg, Tablet
05.04.01
Levodopa 200 mg and Benserazide 50 mg, Tablet
12.04.03
Metronidazole 200 mg, Tablet
04.01.18
Levothyroxine Sodium 100 mcg, Tablet
08.02.02
Metronidazole 500 mg/100 ml,Injection
04.01.19
Miconazole 2%, Cream
06.02.02
Opsite Spray
20.02.03
Midazolam 5 mg/ml, Injection
02.01.01
Oral Rehydration Salt
13.01.01
Midazolam 7.5 mg, Tablet
02.01.02
Orphenadrine 60 mg/ 2ml, Injection
12.04.02
Mirtazapine 15 mg, Orodispersible Tablet
16.03.08
Paliperidone 100 mg, Prolonged Release Injection
16.02.21
Mirtazapine 30 mg, Orodispersible Tablet
16.03.08
Paliperidone 150 mg, Prolonged Release Injection
16.02.21
Moclobemide 150 mg, Tablet
16.03.09
Paliperidone 6 mg, Extended Released Tablet
16.02.20
Modified Fluid Gelatin, Injection
13.01.07
Paliperidone 75 mg, Prolonged Release Injection
16.02.21
Moisturizing Hand Solution
20.02.07
Paliperidone 9 mg, Extended Released Tablet
16.02.20
Monobasic Sodium Phosphate 48%,
Dibasic Sodium Phosphate 18%
Papase, Tablet
18.03.01
09.08.02
Paracetamol 120 mg/5 ml, Syrup
03.01.03
Morphine Sulphate 10 mg/ml, Injection
03.02.03
Paracetamol 500 mg, Tablet
03.01.02
Multivitamin, Tablet
13.03.07
Naloxone HCl 0.4 mg/ml, Injection
01.01.02
Paradichlorobenzene, Turpentine Oil
and Chlorbutol, Ear Drops
07.01.02
Neomycin 0.5 %, Cream
06.07.05
Paraffin Yellow Soft 30 gm, Cream
06.01.03
Nifedipine 10 mg, Tablet
05.06.04
Paraffin, Liquid
09.05.05
Noradrenaline Acid Tartrate, Injection
05.07.03
Perindopril 4 mg, Tablet
05.05.04
Olanzapine 10 mg, Disintegrating Tablet
16.02.10
Perphenazine 4 mg, Tablet
16.02.11
Olanzapine 10 mg, Tablet
16.02.09
PethidineHCl 50 mg/ml, Injection
03.02.01
Olanzapine 5 mg, Disintegrating Tablet
16.02.10
Phenobarbitone 30 mg, Tablet
12.02.05
Olanzapine 5 mg, Tablet
16.02.09
Phenoxymethyl Penicillin, Tablet
04.01.20
Omeprazole 20 mg, Tablet
09.07.03
Phenytoin Sodium 100 mg, Capsule
12.02.06
Phenytoin Sodium 250 mg/5 ml, Injection
12.02.07
Pyrazinamide, Tablet
04.01.21
Phenytoin Sodium 30 mg, Capsule
12.02.06
Pyridoxine HCL (Vitamin B6) 10 mg, Tablet
13.03.08
Pizotifen 0.5 mg, Tablet
12.01.01
Pyridoxine HCl (Vitamin B6) 50 mg/2 ml, Injection
13.03.10
Potassium Chloride 10 % w/v, Injection
13.01.02
Quetiapine Fumarate 200 mg, Extended Release Tablet
16.02.12
Potassium Chloride 600 mg, Tablet
13.01.03
Quetiapine Fumarate 300 mg, Extended Release Tablet
16.02.12
Potassium Citrate and Citric Acid, Mixture
10.01.01
Quetiapine Fumarate 400 mg, Extended Release Tablet
16.02.12
Potassium Permanganate 1:10,000, Solution
06.08.03
Quetiapine Fumarate 50 mg, Extended Release Tablet
16.02.12
Povidone Iodine 10%, Solution
06.08.05
Ranitidine 150 mg, Tablet
09.07.01
Prazosin HCL 1 mg, Tablet
05.05.02
Ranitidine 25mg/ml, Injection
09.07.02
Prazosin HCL 2 mg, Tablet
05.05.02
Prazosin HCL 5 mg, Tablet
05.05.02
Rifampicin 150 mg, Isoniazid 75 mg,
Pyrazinamide 400 mg & Ethambutol HCl 275 mg, Tablet
04.01.23
Prednisolone 5 mg, Tablet
08.03.02
Rifampicin, Capsule
04.01.22
Primidone 250 mg, Tablet
12.02.12
Risperidone 1 mg, Tablet
16.02.14
Prochlorperazine Maleate 5 mg, Tablet
09.06.04
Risperidone 1 mg/ml, Oral Solution
16.02.13
Prochlorperazine Mesylate 12.5 mg/ml, Injection
09.06.03
Risperidone 2 mg, Tablet
16.02.14
Procyclidine HCl 10 mg/2 ml, Injection
12.04.04
Rivastigmine Transdermal 4.6 mg, Patch
12.03.02
Promethazine HCl 5 mg/5 ml, Syrup
07.03.13
Rivastigmine Transdermal 9.5 mg, Patch
12.03.02
Propanolol HCL 40 mg, Tablet
05.04.03
Salbutamol 0.5 %, Inhalation Solution
17.01.06
Propofol, Injection
02.01.03
Salbutamol 2 mg, Tablet
17.01.05
Protein Free Haemodialysate, Jelly
06.09.01
Salbutamol, Inhalation
17.01.07
Salicylic Acid 2%, Cream
06.04.01
Spirit Industrial Methylated
20.02.11
Salicylic Acid, Lactic Acid & Oxypolyethoxydodicane, Solution
06.05.01
Spironolactone 25 mg, Tablet
05.02.03
Selenium Sulphide, Shampoo
06.06.01
Streptomycin Sulphate 1 gm, Injection
04.01.24
Sertraline HCI 50 mg, Tablet
16.03.06
Sulphamethoxazole 400 mg & Trimethoprim 80 mg, Tablet
04.01.25
Silver Sulfadiazine 1 %, Cream
06.07.06
Sulpiride 200 mg, Tablet
16.02.15
Simvastatin 20 mg, Tablet
05.11.02
Suxamethonium Chloride 100mg/2 ml, lnjection
02.02.01
Simvastatin 40 mg, Tablet
05.11.02
Terbutaline Sulphate 2.5 mg, Tablet
17.01.08
Sodium Bicarbonate 8.4 %, Injection
13.01.10
Tetanus Toxoid, Injection
11.01.01
Sodium Bicarbonate, Magnesium Carbonate,
Tincture Cardamom Compound, Mixture
Theophylline 250 mg, Long Acting Tablet
17.01.09
09.01.03
Thiamine Mononitrate (Vitamin B1) 10 mg, Tablet
13.03.09
Sodium Biphosphate 16% & Sodium Phosphate 6% Enema
09.08.03
Thymol Compound, Gargle
07.02.01
Sodium Chloride 0.9 % with Dextrose 5 %, Injection
13.01.08
TIclopidine HCL 250 mg, Tablet
05.09.02
Sodium Chloride 0.9 %, Injection
13.01.06
Tramadol HCl 50mg, Capsule
03.02.02
Sodium Chloride 0.9% for irrigation
20.02.09
Tranexamic Acid 250 mg, Capsule
05.10.01
Sodium Chloride 1g/10ml 200ml, Mixture
20.02.08
Trifluoperazine 5 mg, Tablet
16.02.16
Sodium Chloride Powder Pulv
20.02.10
Trimetazidine 20 mg, Tablet
05.12.01
Sodium Chloride, Eye Drops
15.02.01
Sodium Dichloroisocyanurate, Tablet
20.01.01
Triprolidine HCl 2.5 mg and Pseudoephedrine
HCl 60 mg, Tablet
07.03.10
Sodium Lactate Compound (Hartmanns Solution)
13.01.05
Typhoid Vaccine, Injection
11.01.03
Sodium Valproate 200 mg, Tablet
12.02.08
Valproic Acid and Sodium Valproate (ER) 500 mg, Tablet
12.02.10
Sodium Valproate 200 mg/5 ml, Syrup
12.02.09
Venlafaxine HCl 150 mg, Extended Release Capsule
16.03.10
Venlafaxine HCl 75 mg, Extended Release Capsule
16.03.10
Vitamin B Complex, Tablet
13.03.05
Vitamin B1, B6, B12, Tablet
13.03.04
Warfarin 1 mg, Tablet
05.08.01
Warfarin 2 mg, Tablet
05.08.01
Warfarin 3 mg, Tablet
05.08.01
Warfarin 4 mg, Tablet
05.08.01
Water for Injection
13.01.04
Zinc Oxide 15 gm, Cream
06.04.02
Zolpidem Tartrate 10 mg, Tablet
16.01.04
Zuclopenthixol 20 mg/ml, Drops
16.02.17
Zuclopenthixol Acetate 50 mg/ml, Injection
16.02.18
Zuclopenthixol Decanoate 200 mg/ml, Injection
16.02.19